Microscale Approaches to the Design and Optimisation of Equilibrium Controlled Bioconversions by Halim, MB
  
  
 
 
 
 
MICROSCALE APPROACHES TO THE 
DESIGN AND OPTIMISATION OF 
EQUILIBRIUM CONTROLLED 
BIOCONVERSIONS 
 
 
 
Murni Binti Halim 
 
 
A thesis submitted for the degree of  
Doctor of Philosophy 
to  
University College London 
 
 
 
 
Department of Biochemical Engineering 
University College London 
Torrington Place 
London 
WC1E 7JE 
2012 
  
 2 
 
‘I, Murni Binti Halim, confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis.’ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 3 
 
ABSTRACT 
 
 
 
 
 
The widespread use of biocatalysis in industry will require conversions to achieve 
high space-time yields. For many next generation bioconversions the low 
thermodynamic equilibrium constant of reactions currently limits their industrial 
implementation. This thesis aims to establish a series of generic microscale methods 
for the rapid evaluation of process options to enhance the yield of such equilibrium-
controlled bioconversions. These are evaluated based on the asymmetric synthesis of 
chiral amino alcohols by the CV2025 ω-transaminase (ω-TAm) from C. violaceum 
DSM30191. Using 50 mM each of L-Erythrulose (Ery) as substrate and S-α-
methylbenzylamine (MBA) as amino donor the standard yield of the product 
2−amino−1,3,4−butanetriol (ABT) is just 26 % (mol.mol-1). This reaction produces 
acetophenone (AP) as a by-product which is also inhibitory to the CV2025 ω-TAm. 
 
Microscale methods to evaluate four process options for increasing the bioconversion 
yield were established each operating at 300 µL volume. The first option involves 
screening of alternative amino donors to the widely-used MBA. The second couples 
ω-TAm with an alcohol dehydrogenase (ADH) to convert the inhibitory AP by-
product into the non-inhibitory (R)-1-phenylethanol (a glucose dehydrogenase (GDH) 
is also present to facilitate co-factor recycling). The third approach involves physical 
in-situ product removal (ISPR) of the volatile AP by operation at reduced pressure in 
a 96-well vacuum manifold. The final approach involves ISPR using polymeric resins, 
such as the Amberlite
TM
 XAD series, for selective adsorption of AP from the 
bioconversion medium. For the particular reaction studied here, use of alternative 
amino donors such as isopropylamine (IPA) enabled a 2.8-fold increase in the reaction 
yield to 72 % (mol.mol
-1
) while the second enzyme system, though more expensive to 
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implement, achieved a 3.8-fold increase in yield and almost quantitative conversion 
(98 % (mol.mol
-1
)). 
 
Each of the microscale methods was subsequently implemented as process options in 
an automated micro-scale process sequence linking biocatalyst production, 
bioconversion and product analysis. The high throughput potential of the methods was 
then illustrated using a focused library of ten novel ω-TAms from various strains. The 
bioconversion rates and yields of each enzyme were evaluated using a range of 
alternative amino donors. This highlight one novel ω-TAm, able to utilise L-α-serine 
as amino donor at improved yield than the CV2025 ω-TAm. This opens up the 
possibility of engineering whole cell TAm biocatalysts where the normally expensive 
amino donors are synthesised in vivo by normal amino acid metabolism starting from 
simple, cheap substrates. The microscale methods also enabled rapid optimisation of 
bioconversion conditions using the second enzyme system. This identified the 
possibility of reducing by 40-fold the standard concentrations of the co-factor 
recycling enzymes thus reducing the contribution of the enzymes to the overall Costs 
of Goods (CoG). 
 
Overall, this work has established an efficient and generic microscale approach to aid 
bioprocess design and specifically to help increase the yield of equilibrium-controlled 
bioconversions. The bioconversion rates and yields for the optimised reaction systems 
were subsequently verified for preparative scale bioconversions. 
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NOMENCLATURE AND 
ABBREVIATIONS 
 
 
 
 
 
 
 
ABT (2S,3R)-2-amino-1,3,4-butanetriol 
ADH Alcohol dehydrogenase 
ADH-TB Alcohol dehydrogenase from Thermoanaerobium brockii   
AP Acetophenone 
AQC 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
BSA Bovine serum albumin 
C liquid phase concentration at equilibrium (g.l
-1
) 
Ci initial liquid phase concentration(g.l
-1
) 
Cl Chloride 
CV20205 Chromacterium Violaceum 20205 
C. violaceum Chromacterium Violaceum 
dB Width of baffle (mm) 
DCW Dry cell weight 
di Diameter of impeller (mm) 
DiTi Tecan disposable tip 
DOT Dissolved oxygen tension (%) 
dT Diameter of vessel (mm) 
ε Extinction coefficient 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
E-PLP Transaminase –PLP complex 
E-PMP Transaminase –PMP complex 
Ery L-erythrulose 
λ Path length equal to 1 cm 
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g Gram 
ggads
-1
 Equilibrium solid phase concentration of the solute in solution 
gdcw Grams of dry cell weight 
GDH Glucose dehydrogenase 
H3PO4 Phosphoric acid 
HCl Hydrogen cloride 
HEPES N−2−hydroxyethylpiperazine−N’−ethanesulphonic acid 
His6-tag 6x histidine- tagged 
HPA Hydroxypyruvate 
HPLC High pressure liquid chromatography 
hr hour 
IMAC Immobilized metal-ion affinity chromatography 
IPA Isopropylalcohol 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
ISPR In situ product removal 
K Thermodynamic equilibrium constant 
kDa Kilo Dalton 
kg Kilogram 
Ki Inhibition concentration 
L Litre 
l Liquid phase 
LB Luria Bertani 
LiHa Tecan handling arm / liquid handler 
M Molar 
M mass of wetted adsorbent in the experiment (g) 
m meter 
MBA (S)-α-Methybenzylamine 
mbar milibar 
MeOH Methanol 
Mg
2+
 Magnesium ion 
MgCl2 Magnesium chloride 
mg Milligram 
min Minute 
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mL Millilitre 
mM Millimolar 
mm Milimeter 
mmol Millimol 
n Nano 
N Nitrogen 
NaCl Sodium Cloride 
NADP
+
 Nicotinamide adenine dinucleotide phosphate 
NADPH Reduced form of nicotinamide adenine dinucleotide phosphate 
NaOH Sodium Hydroxide 
NH3 Ammonia 
NH4OH Ammonium Hydroxide 
OD600 Optical density at 600 nm 
PLP Pyridoxal 5´phospahte 
PMP Pyridoxamine phosphate 
PPG Polypropylene glycol 
PTFE Polytetrafluoroethylene 
q Equilibrium solid phase concentration of the solute (ggads
-1
) 
RO Reverse osmosis 
RoMa Tecan manipulator arm 
rpm Revolutions per minute 
SA Static surface area 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TAm Transaminase 
TAm BSU09260_1971 ω-Trasaminase from Bacillus subtillis 
TFA Trifluoroacetic acid 
Te-VacS Tecan vacuum manifold 
TLC Thin Layer Chromatography 
U Units of enzyme activity (molmin-1) 
µL Microlitre 
µm Micrometer 
µmol Micromole 
UV/Vis Ultra violet / visible 
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V Volume (L) 
V.fluvialis Vibrio Fluvialis 
v/v Volume by volume 
VW Total well volume 
W Watt 
Wt Wilde type 
w/v Weight by volume 
XAD 7 Synthetic polymeric resins 
XAD 16 Synthetic polymeric resins 
XAD 1180 Synthetic polymeric resins 
ω-TAm ω-transaminase 
ºC Degree Celsius 
ΔG Gibbs free energy 
2xTY E. coli rich media 
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1. INTRODUCTION AND AIMS OF 
THE PROJECT 
 
 
 
 
 
1.1. DEVELOPMENT OF CHIRAL PHARMACEUTICALS 
 
In pharmacology, chirality is an important factor in drug efficacy. Therefore, attaining 
enantiomerically pure intermediates and products efficiently and economically is of 
immense importance in industry (Sanchez and Demain, 2011).  Pharmaceuticals with 
an asymmetric carbon (chiral centre) are termed chiral drugs which often present as 
the racemate (mixture of equal amounts of left and right-handed enantiomers). In an 
achiral environment, two enantiomers in a racemate show identical physical and 
chemical properties but in a chiral environment (i.e in vivo), they demonstrate 
different chemical, biochemical, and pharmacologic behaviours. In the past decades, 
single-enantiomer drugs have been thought to be preferable to racemates due to the 
lack of technologies for single-enantiomers synthesis. Nevertheless, after the 
recognition that two enantiomers of the same compound can have different 
pharmacological activities and the emergence of new technologies of asymmetric 
synthesis and chiral separation, it has made it possible for pharmaceutical companies 
to develop single-enantiomer drug (Shimazawa et al., 2008). Furthermore, it is now an 
obligatory by the regulatory bodies that characterisation of the single optical isomers 
of a chiral drug compound is carried out before licensing a drug for the marketplace 
(FDA, 1992).   
 
Subsequently, many single-enantiomers drugs have been approved and marketed with 
the worldwide market share of these drugs increased from 27 % in 1996 to 39 % in 
2002 (Shimazawa et al., 2008). For example, Verapamil is a drug where the (S)-
enantiomer is used to alleviate high blood pressure, whilst the (R)-enantiomer is used 
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to inhibit the resistance of cancer cells to chemotherapy agents (Wainer, 1993).  Other 
examples are (S)-Ibruprofen and (S)-Ketoprofen which are the chiral switch drugs of 
the popular racemates (Figure 1.1).  These drugs are the most numerous classes of 
non-steroidal anti-inflammatory drugs that are widely used for the treatment of 
inflammatory diseases, such as rheumatoid arthritis, as both analgesics and 
antipyretics. However, the racemates are responsible for many adverse reactions such 
as reactions affecting a range of organs, including the gastrointestinal tract, kidney, 
bone marrow, and liver systems. Therefore, with the combination of the 
stereospecificity of action with the configurationally inversion reaction have provided 
drug companies a rationale for the use of the (S)-enantiomers of these drugs in 
therapy, as this reduces the total dose and reduces the toxicity that is associated with 
the (R)-enantiomer (Leffingwell, 2003; Kelley et al., 1992).   
 
Figure 1.2 further shows the importance of chiral drugs. Of the top five selling 
cardiovascular drugs, four are sold as single enantiomers (Lipitor®, Zocor®, 
Pravacol® and Vasotec®) while the fifth (Norvasc®) is a racemate which potentially 
may be important as the single (R)-(+)-enantiomer (Leffingwell, 2003; Zhang et al., 
2002). An overall look at the 20 year period from 1983–2002 of worldwide approved 
drugs, according to chirality (Figure 1.3) indicates that single-enantiomers surpassed 
achirals whereas racemates represented the minority category at 23 % of worldwide 
approved drugs (Caner et al., 2004). 
 
All these examples provide an insight into a number of chiral chemicals with 
significant pharmacological activity. A single enantiomer formulation would have 
higher potency and thus require lower dosages, subsequently reducing the potential 
side effects of the drug (Stinson, 1994).  Similarly, in the agro-chemical industry, 
single enantiomer compounds may reduce application volumes thus reducing cost and 
lessening the environmental impact (Breuer et al., 2004). 
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Figure 1.1. The chemical structures of (S)-ibuprofen and (S)-ketoprofen drugs. Image 
reproduced from Leffingwell (2003). 
 
 
 
 
 
Figure 1.2. Top 5 cardiovascular drugs in 2002. Sources: Nat. Rev. Drug Disc. 2(4), 344 (2003); 
Chem. & Eng. News 81(18), 48 (2003). Image reproduced from Leffingwell (2003).  
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Figure 1.3. Distribution of worldwide-approved drugs according to chirality in the period 
1983–2002. *Including diastereomeric mixtures. Image reproduced from Caner et al. (2004). 
 
 
It is estimated that pharmaceutical companies spend approximately  $ 0.8 to 1.3 
billion US for drug discovery per new compound (Schmidt and Blaser, 2003), which 
consequently putting an enormous economic pressure.  The technology harnessed, to 
both develop and manufacture a drug, therefore, needs to be cost effective, rapid and 
sustainable. Additionally the competition from the drug candidates of other companies 
requires the timely development of a drug to minimise the time to market. 
Nevertheless, the emphasis of either time or cost depends on the phase of 
development of a candidate drug (Yazbeck et al., 2004).   
 
Primarily, during the discovery phase of a candidate compound, when small amounts 
of material, i.e 10 mg – 100 g are required, it is the time taken to produce material for 
further investigation and characterisation of pharmacological properties that are vital.  
Later on, when process development is being carried out, and production at the 
kilogram and potentially the ton-scale, is required, process cost and sustainability 
become the defining parameters.  A cost effective process requires conversion at the 
highest possible yield with the minimum of side products utilising materials that are 
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affordable and available from reliable sources.  The cost of goods is impacted by the 
value of process reagents.  This includes both the starting materials and reagents used 
in each processing step, thus the number of processing steps can significantly increase 
overall costs.  Productivity includes the output for time spent in the factory, which 
defines how many processing cycles can be completed in a given time, as well as the 
overall process yield. Overall product yield is also impacted on by the number of 
processing steps since yield losses will be incurred at each stage.  The process 
developed is further limited by the sustainability of supply of materials, the 
availability of suitable facilities for operating the process, and in an age where the 
environmental issues are an important factor, the production and disposal of waste 
streams must be accounted for.  Additionally, intellectual property issues may prevent 
the use of certain technologies in a commercial process.  
 
The synthesis of optically pure products is often multi-step, employing complex 
chemistry and producing low product yields. The increase in complexity and 
subsequent cost of the production of homochiral compounds, versus racemates, has 
led to the development of several ’toolboxes’ for asymmetric synthesis (Yazbeck et 
al., 2004).  The approaches include asymmetric chemocatalysis, use of a precursor 
from a chiral pool, crystallisation of diastereomeric salts, biocatalysis, and 
chromatographic separation.  The use of asymmetric chemocatalysis is an attractive 
option, particularly for hydrogenation reactions, although the scope of this technique 
may be limited by the commercial availability of catalyst, patent restrictions and the 
rarity of broad spectrum catalysts.  Resolutions of racemic mixtures may be carried 
out by direct crystallisation, diastereomeric crystallisation, chromatography or 
enzyme kinetic resolution. These techniques, however, usually result in at least a 50 
% yield loss, but higher yields may be possible by the introduction of a re-
racemisation step, of the unwanted isomer, into the process (Park et al., 2002). 
Crystallisation faces limitations due to the lack of development of efficient high 
throughput screening methods.  However, the generation of homochiral salts does 
result in ease of downstream processing.  Chromatography faces high costs due to 
large waste streams and high cost of resins and scalability.  Another approach to the 
synthesis of complex chiral compounds is the use of chiral synthons at the beginning 
of the synthesis. These are relatively simple enantiomerically pure starting compounds 
which provide the desired chirality in the reactions that follow.  The selection of a 
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chiral precursor from an existing chiral pool of compounds may be limited by the 
chemicals available, with the majority of commercial chiral molecules (being both 
cost effective as a precursor molecule and available at suitable quantities) being 
amino acids and simple carbohydrates.   
 
Additionally, the trend for new chiral pharmaceutical reagents is constantly 
developing due to the fact that the human body functions using chiral catalysis 
(Pollard and Woodley, 2006). Nature itself has demonstrated biological catalysts to 
have a role in the production of chiral molecules.  For example, simple carbohydrates 
can serve as chiral starting materials for the synthesis of more complex molecules 
(Draths et al., 1992) which can be carried out by plants and microbes where the 
simple carbohydrate D-glucose is used as a starting material for the synthesis of 
amino acids and related metabolites.  Biocatalysts may perform a synthetic or 
resolution role depending upon the reaction and was further described in the following 
Section 1.2.   
 
1.2. BIOCATALYSIS  
 
 
1.2.1. Industrial Biocatalysis 
 
The increasing size and complexity of the molecules of chiral pharmaceutical reagents 
normally results in multiple chiral centres (Pollard and Woodley, 2006). Therefore, 
the major reason of using biocatalysis for a synthesis step is to exploit the region and 
streoselectivity properties of biocatalyst to obtain high purity compounds whilst 
avoiding the need for difficult synthesis. Biocatalysis have turned out to be 
competitive compared with classic chemical as well as chemocatalytic synthetic 
approaches (Drauz et al., 2012). Some of remarkable advantages of biocatalysis in 
over chemocatalysis are biodegradability, sustainably produced, non-toxic, highly 
specific catalysts and mild reaction conditions (Lin et al., 2011). Figure 1.4 shows an 
aldol reaction for the asymmetric preparation of β-hydroxy α-amino acids that 
demonstrated an advantage of biocatalysis with the possibility of using substrates 
without the need for protecting groups due to the high selectivity of enzymes for 
speciﬁc functional groups. Whereas in the biocatalytic step, glycine can be used 
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directly as a donor, in a chemocatalytic reaction totally protected glycine is required. 
Therefore, biocatalysis offers a straightforward access, requiring only one synthetic 
step compared to ﬁve steps in the chemical approach (Drauz et al., 2012). 
Nevertheless the effective application of biocatalytic processes in the chemical 
industry depends mainly on cost competitiveness with the existing, and well 
established chemical processes (Sanchez and Demain, 2011).  
 
 
Figure 1.4. (a) Multistep chemical and (b) protecting group-free biocatalytic strategies in an 
aldo reaction. Image reproduced from Drauz et al. (2012). 
 
 
Furthermore, the principal driving forces for present and future research and 
development in industrial biocatalysis are including (Ghisalba et al., 2010):  
 
 The continued demand for chiral building blocks and enantiomerically pure 
compounds, in general. 
 A growing interest in areas of synthesis where biocatalysts offer clear 
advantages over purely chemical strategies (further described in the next 
Section 1.2.2).  
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 The multi functionality of the products, calling for sophisticated and laborious 
protection group strategies, has immense potential for selective and direct 
biocatalytic synthetic methodologies. 
 International efforts to promote sustainable development and environmentally 
friendly technologies. 
 
A significant increase in the use of biocatalysts for chemical synthesis has been 
observed within recent years (Sanchez and Demain, 2011). Despite a comparatively 
lower start, the implementation of biocatalysis processes at an industrial scale which 
is reflected by products commercialized at a scale over 100 kg on an annual basis, is 
almost doubling every decade and the market for enzymes has increased in an almost 
exponential manner from the 1960s to 2000 (Fernandes, 2010). Processes including 
biocatalytic steps are extensively reviewed (Pollard and Woodley, 2006; Breuer et al., 
2004; Panke et al., 2004; Patel, 2001; Schmid et al., 2001; Schoemaker et al., 2003)  
 
Some examples of the successful application of biocatalysis in  industry are the use of 
acylases in the production of β-lactam antibiotics (De Vroom, 1999), the production 
of acrylamide from acetonitrile employing nitrile hyratase (Nagasawa and Yamada, 
1990) and the industrial scale synthesis of chiral cyanohydrin (S)-meta-
phenoxybenaldehyde, an intermediate in the synthesis of pyrethroid insecticide using 
recombinant (S)-hydroxynitrilase lyase (Griengl et al., 1998). Further examples of 
complex drug compounds and the biocatalytic steps involved in their process 
developments are shown in Figure 1.5. These examples show the extensive influence 
of biocatalysis on the development of important pharmaceutically active compounds. 
 
Alongside the increasing number of large-scale processes, is the development of 
process technology to overcome some of the limitations of processes involving 
biological systems thus enhancing the viability of a biocatalytic step.  This technology 
includes the use of continuous reaction and separation bioreactors (De Roode et al, 
2001), the use of packed bed reactors (Jeong et al., 2000) which can improve 
volumetric productivity as well as alleviate product inhibition, microscale high 
throughput techniques (Section 1.5) and many possible strategies for improving 
bioconversion performances (Section 1.4.10). 
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Figure 1.5. Complex drug compounds with multiple chiral centres and the biocatalytic step(s) 
associated with the development of each synthetic route. Image reproduced from Pollard and 
Woodley (2006). 
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1.2.2. Biocatalysis Processes   
 
Bioconversion is becoming essential to the fine chemical industry in that their 
customers demand single isomer intermediates (Sanchez and Demain, 2011; Rogers, 
1999). In many cases, biocatalysis has replaced chemical catalysis because of 
(Sanchez and Demain, 2011; Tao and Xu, 2009; Buchholz et al., 2005):  
 
 Higher enantioselectivity and higher regioselectivity in aqueous solution.  
 Do not require protection and deprotection of functional groups.  
 Better stability. 
 Operates under milder conditions, i.e avoidance of high and low temperatures, 
under mild pH values. 
 Greater efficiency. 
 Low energy consumption. 
 Fewer by-products. 
 Non-toxic when correctly used. 
 Can be reused (immobilized). 
 Can be degraded biologically. 
 Can be produced in unlimited quantities. 
 
 
Figures 1.6 shows comparisons of the traditional chemical and the new enzyme 
processes for the hydrolysis of penicillin G. (Buchholz et al., 2005). The chemical 
synthesis procedure used for the production was environmentally problematic solvents 
and toxic compounds, leading to toxic wastes that are difficult to recycle and therefore 
is not a sustainable process. In contrast, the enzyme process is more sustainable and 
leads to a considerable reduction in waste which in turn reduces the processing costs. 
Also, in this process the product yield could also be increased to > 95 %. 
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Figure 1.6. Comparison of the chemical and the enzymatic processes for the hydrolysis of 
penicillin G. The product, 6-aminopenicillinanic acid (6-APA), is used for the synthesis of 
semisynthetic penicillins with side chains other than phenylacetic acid. In the enzyme process, the 
by-product phenylacetic acid can be recycled in the production of penicillin by fermentation. 
Image reproduced from Buchholz et al. (2005). 
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Furthermore, although biocatalytic processes are now widely used in industry, there 
remain fundamental barriers to their widespread use which include (Lye and 
Woodley, 1999): 
 
 Cheap and stable enzyme catalyst must become more easily available. 
 Systematic design methods are needed to speed up the development process 
sequences. The design must also enable rational choices to be made between 
chemical and biocatalytic routes to the same end product. 
 The low productivities that are often observed with biocatalytic systems, 
relative to the chemical equivalent must be enhanced in order to develop more 
economic processes. 
 
 
Enzyme processes, as with all catalysed chemical processes can be divided into two 
categories (Buchholz et al., 2005):  
 
1. Equilibrium-controlled processes: the desired product concentration or property has 
a maximum at the end-point of the process, the chemical equilibrium is independent 
of the properties of the enzyme, but is dependent upon on pH and temperature. 
 
2. Kinetically controlled processes: the desired product concentration or property 
reaches a maximum, the concentration or properties of which depend on the properties 
of the enzyme, pH, and temperature. The process must be stopped when the maximum 
is reached. 
 
As displayed in Figure 1.7, in both cases the time to reach the maximum product 
concentration or property depends on the properties and amount of enzyme used, and 
of the catalysed process (i.e endo- or exothermal, pH- and temperature dependence of 
equilibrium constants, solubility and stability of substrates, products) and therefore 
must be deliberated in the rational design of enzyme processes. Furthermore, other 
differences to consider are substrate concentrations and the formation of undesired by-
products in un-catalysed bimolecular reactions (Buchholz et al., 2005). 
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Figure 1.7. Time-dependence (progress curves) of equilibrium- (solid line) and kinetically 
(broken line) controlled processes catalyzed by enzymes. The suitable end-points of these 
processes are those where the maximum product concentration or property is achieved – that is, 
A for the kinetically and B for the equilibrium controlled process. Such processes are illustrated 
with the hydrolysis of lactose in milk or whey, where mainly protein and fats are precipitated in 
the milk by addition of a ‘coagulating’ enzyme. The enzyme β-glucosidase that catalyzes the 
hydrolysis of lactose also catalyzes the kinetically controlled synthesis of tri- and tetra-
saccharides. When lactose is consumed, these oligosaccharides are hydrolyzed. This also 
illustrates the formation of undesired by-products in enzyme-catalyzed processes. The 
oligosaccharides are by-products in the equilibrium controlled hydrolysis of lactose. On the other 
hand, in the kinetically controlled synthesis of the oligosaccharide that can be used as prebiotics, 
by-product formation is due to the hydrolysis to monosaccharides. The formation of the by-
products must be minimized by selecting suitable process conditions and biocatalysts. Image 
reproduced from Buchholz et al. (2005). 
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The catalyst part of the biological system can thereby consist of whole cells, cellular 
extracts, or an isolated enzyme. For economic reasons, the whole cell biocatalysis is 
often primarily be considered over the use of cellular extract, isolated enzymes or 
permeabilized cells to perform biotransformations. This is possible when the 
following criteria are met: (i) no diffusion limitations for substrate(s) and/or 
product(s) and (ii) no side or follow-up reactions due to the presence ofother cellular 
enzymes (Ghisalba et al., 2010). The further factors that can influence the decision of 
using each biological system for various bioconversions have been extensively 
reviewed (Sanchez and Demain, 2011; Chartrain et al., 2004). Biotechnological 
processes use one or more enzymes with or without co-factors or co-substrates as 
biocatalysts as illustrated and described in Figure 1.8. 
 
 
 
Figure 1.8. Classification of biocatalytic processes with enzymes as biocatalysts. I and II must 
be performed with enzymes in living cells, III can be performed with enzymes in dead cells or as 
IV with isolated enzymes. Image reproduced from Buchholz et al. (2005). 
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Biocatalysis reactions can be operated under various process conditions (Ghisalba et 
al., 2010):  
 
 Batch or fed-batch application of whole cells in free or immobilized form in an 
aqueous environment. 
 Continuous application of whole cells in immobilized form in an aqueous 
environment. 
 Application of whole cells in two-liquid phase, multiphase systems, or in 
micelles. 
 Use of acetone-dried or permeabilized cells. 
 Batch or fed-batch application of free crude or purified enzymes in aqueous or 
organic environment. 
 Use of polyethyleneglycol (PEG)-modified enzymes in organic solvents. 
 Continuous application of immobilized enzymes. 
 Use of enzyme membrane reactors, the method of choice for systems with co-
factor recycling or reactions with expensive enzymes. 
 
 
1.3. CHIRAL AMINES  
 
Chiral amines exist in more than one form, called enantiomers, and often only one of 
them has pharmacologic properties and is suitable for production in optically active 
drugs. Enantiomerically pure chiral amines are of increasing commercial value and 
widely used in the fine chemical and  pharmaceutical areas in view of their 
application such as a resolving agent (Nieuwenhuijzen et al., 2002), chiral auxiliaries / 
chiral bases (Henderson et al., 2000), and pharmaceuticals intermediates to produce 
various drug molecules (Berger et al., 2001). Some examples of chiral amines used in 
commercial molecules include L-tert-leucine (Kempf et al., 1991) in an HIV protease 
inhibitor used in AIDS therapy (Figure 1.9 (A)), S-(+)-clopidogrel (Gawronski, 2006) 
which targets thrombin to provide treatment for thrombosis (Figure 1.9 (B)) (Bajusz, 
et al, 1990) and L-6-hydroxynorleucine (Patel, 2001) which is an intermediate for 
antihypertensive Omapatrilat (Figure 1.9 (C)). 
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Figure 1.9. Examples of peptidomimetic drugs. (A) L-tert-leucine used in peptidomimetic HIV 
protease inhibitor (B) S-(+)-clopidogrel used in a drug for thrombosis therapy (C) L-6-
hydroxynorleucine used as an intermediate in the synthesis of Omapatrilat, an antihypertensive 
drug. 
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Chiral amines can be produced by either chemical or biocatalytic synthetic routes 
(Breuer et al., 2004). The current methods used to prepare these compounds are 
mostly based upon the resolution of racemates either by recrystallization of 
diastereomeric salts (Jacques et al., 1980), or by enzyme-catalysed kinetic resolution 
of racemic substrates. In chemical kinetic resolution, two enantiomers show different 
reaction rates in a chemical reaction, thereby creating an excess of the less reactive 
enantiomer. However, taking the reaction to 100 % completion will again produce 
equal amounts of both enantiomers.. Meanwhile, the enzymatic kinetic resolution only 
converts one enantiomer depending on the stereoselectivity of the enzyme, and thus a 
50 : 50 mixture of converted enantiomer product is obtained and the unreacted 
enantiomer remains intact. Biocatalytic kinetic resolutions using hydrolytic enzymes 
such as protease, lipase, esterase and transaminase have been studied extensively for 
preparing optically pure enantiomers (Shin and Kim, 1998; Gutman et al., 1992; 
Jackson et al., 1995; Tsai and Wei, 1994). Examples of both chemical and enzymatic 
kinetic resolution mechanisms are shown in Figures 1.10 and 1.11. 
 
 
Figure 1.10. Kinetic resolution in the esterification reaction of racemic mandelic acid with 
optically active (-)-menthol to a pair of diastereomeric esters. The (R)-enantiomer of mandelic 
acid displays the higher reaction rate and with incomplete conversion, the reaction mixture 
becomes enriched in (S)-mandelic acid. Full hydrolysis of the incomplete esterification mixture 
gives an excess of (S)-mandelic acid. Taking the reaction to 100 % completion will again produce 
equal amounts of both esters. Image reproduced from Marckwald and McKenzie (1899). 
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Figure 1.11. Reaction scheme of the kinetic resolution via ω-TAm starting with racemic (rac) 
amines is limited by 50% maximum yield. For example, due to (S)-stereoselectivity of the ω-
TAm, only (S)-amine is converted into ketone. Image reproduced from Koszelewski et al. (2010). 
 
 
However, it is extremely difficult to produce the required enantiomer of many chiral 
amines by the standard chemical techniques (Nugent and El-Shazly, 2010) whilst the 
kinetic resolution method is also viewed as un-economic and non-competitive due to 
its disadvantage of producing only 50 % maximum of the desired enantiomer. 
Therefore, these approaches have been surpassed by other methods and attentions are 
recently turning towards enzyme-catalysed asymmetric synthesis approach with the 
use of ω-TAm (Figure 1.12) to generate chiral amines has received increasing 
attention (Koszelewski et al., 2010; Koszelewski et al., 2008; Shin and Kim, 1997) 
due to its emphasized characteristics as detailed in Section 1.2. For instance, out of 38 
major asymmetric synthetic processes of the chemical industry, 22 use biocatalysis 
(Blaser and Schmidt, 2003). 
 
 
Figure 1.12. Reaction scheme of the asymmetric synthesis of prochiral ketones via ω-TAm with 
theoretically a 100 % yield if the equilibrium can be shifted appropriately. Image reproduced 
from Koszelewski et al. (2010). 
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1.4. TRANSAMINASES (TAms) 
 
1.4.1. Introduction to TAm 
 
Recently, TAms (also known as aminotransferases) have received increased interest 
due to their great potential for the production of natural and non-natural amino acids 
as well as chiral amines, which are in demand by the pharmaceutical industry 
(Christen and Metzler, 1985; Sheldon, 1996; Shin and Kim, 1997; Stirling, 1992; Shin 
and Kim, 2001). Optically active amines and amino acids are required for the 
preparation of a broad range of biologically active compounds showing various 
pharmacological properties (Sutin et al., 2007; Dominik et al., 2008) such as building 
blocks in the synthesis of neurological, immunological, anti-hypertensive and anti-
infective drugs. For example, biocatalytic transamination of L- Erythrulose (Ery) for 
synthesis of chirally pure 2-amino-1,3,4-butanetriol (ABT) is established to illustrate 
the importance of this compound as a chiral synthon for  use as building blocks in the 
synthesis of protease inhibitors (Kwon and Ko, 2002), such as in the synthesis of 
Nelfinavir
TM
 (Figure 1.13), an HIV-protease inhibitor (Kaldor et al., 1997) 
Furthermore, it is estimated that 70 % of drugs involve an amino group reaction 
during their synthesis. In most cases, the pharmacological activities of these 
compounds are related to the configuration of the stereogenic center such as, between 
(S) and (R)-enantiomers.  
 
Figure 1.13. Structure of the protease inhibitor drug NelfinavirTM.  Highlighted section shows 
the use of ABT at the core of the molecule. Image reproduced from Ingram et al. (2007). 
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Compared to other enzymes such as amino acid dehydrogenase and amine 
dehydrogenases, and chemical methods for production of amino acids and chiral 
amines, the TAm have some superior features such as relaxed substrate specificity, 
rapid reaction rates and no requirement for external cofactor regeneration (Kaulmann 
et al., 2007). TAm can be divided into four subgroups, with groups I, III, and IV 
comprised of -aminotransferases, whilst group II consists of -TAm. -TAm 
enzymes have the potential to access a range of substrates not accepted by -
aminotransferases. 
 
Enantioenriched amines and amino acids can be produced via two methods (Section 
1.5.4), which are asymmetric synthesis (Shin and Kim, 1999) using a chiral ketone 
(i.e amination of the ketone) and kinetic resolution (Shin and Kim, 1997) of racemic 
amine (i.e deamination of the amine). The strict enantioselectivity of -TAm is 
beneficial to achieving the high yield of unreacted (R)-enantiomer by kinetic 
resolution and to obtaining highly enantiopure (S)-enantiomer by asymmetric 
synthesis (Shin and Kim, 1999; 2001). In the asymmetric synthesis of chiral amines 
with -TAm, the choice of amino donor is of considerable importance. For instance, 
it is impractical to use some chiral amines as an amino donor in synthesizing other 
chiral amines due to their high cost, despite their high reactivity.  
 
 
1.4.2. Classification of TAms 
 
TAms can be divided into four subgroups based on their amino-acid sequence (Mehta 
et at., 1993, Sayer et al., 2007). All TAms known to date use the same co-enzyme to 
catalyze the same type of reaction and, as catalysts, are distinguished only by their 
substrate specificities. Their structural differences reflect their substrate specificities 
(Mehta et al., 1993). Subgroup I appears to be the most versatile, which their 
members accepting alanine, dicarboxylic and aromatic amino acids as substrates. In 
subgroup II, the substrates possess as a unique feature a distal amino group that 
undergoes the transamination reaction, and its functional homogeneity is reflected by 
a high degree of sequence similarity among its members. Subgroup III has two 
members, while their amino acids substrates are of different chirality but both share 
the same oxo acids substrate. Finally, subgroup IV also consisting only two members, 
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that acts on structurally and biosynthetically related substrates. Subgroup II, regarded 
as collectively -TAm, contains ornithine (EC 2.6.1.13), 4-aminobutyrate (EC 
2.6.1.19), acetylornithine (EC 2.6.1.11), diaminopelargonate (EC 2.6.1.62) and -
amino acid:pyruvate TAm (EC 2.6.1.18).  
 
Since diamine-ketoglutaric TAms or ‘amine TAms’ (Kim, 1964; Samsonova et al., 
2003) were reported capable of utilizing a substrate without a carboxylic acid group 
several other -TAms were also founded to show catalytic activity towards primary 
amines and aliphatic amines without carboxyl group (Yohana et al., 1987; Shin and 
Kim, 1999; Shin et al., 2003; Sayer et al., 2007, Kaulmann et al., 2007). Protein 
sequence of these characterized enzymes are not yet available, but they belong to -
amino acid:pyruvate TAm that prefer pyruvate, as the amine acceptor rather than -
ketoglutarate (Kaulmann et al., 2007). 
 
1.4.3. Structure of ω-TAm 
 
Figure 1.14 shows the ribbon structure of the homodimeric ω-TAm from Vibrio 
Fluvialis, where each subunit had a molecular weight of 50 kDA. An active site 
model of the ω-TAm has been constructed (Figure 1.15) (Shin and Kim, 2002). This 
resulted in a two-binding site model, which contained two pockets, one large and one 
smaller, the latter one presenting a strong repulsion for a carboxlate, playing a vital 
role in the substrate specificity and stereoselectivity. The large pocket showed a dual 
recognition mode for both hydrophobic and carboxyl groups, and corresponded to a 
carboxylate trap, while the small pocket played the role of a side chain recognition 
site (Shin and Kim, 2002).  
 
1.4.4. ω-TAm for Investigation 
 
Transaminases are ubiquitously present in microorganisms and higher organisms and 
play an important role in amino-acid metabolism (Christen and Metzler, 1985). To 
date, general properties of -TAm were extensively studied using three different 
microorganisms, Vibrio fluvialis JS17, Klebsiella pneumoniae JS2F, and Bacillus 
thuringiensis JS64 (Shin and Kim, 2001). 
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Figure 1.14. Ribbon structure of homodimeric ω-TAm from V. fluvialis JS17. Figure created 
from the PDB structure file 1qgd using PyMOL Molecular Graphics System (DeLano, 2002) on 
World Wide Web http://www.pymol.org. 
 
 
 
Figure 1.15. Two-Binding Site Model of ω-TAm from V. fluvialis showing (a) binding of the 
amino donor and (b) the binding of the amino acceptor. L and S denote large and small binding 
pockets respectively. Image reproduced from Shin and Kim (2002). 
 
 
 
  
 49 
 
The -TAm from these three enzymes showed high enantioselectivity for certain 
enantiomers of chiral amines such as (S)--methylbenzylamine (Shin and Kim, 1998; 
Shin and Kim, 2001; Sayer et al., 2007) and demonstrated the highest amino acceptor 
reactivity for pyruvate (Shin and Kim, 2001). Among these strains, Vibrio fluvialis 
JS17, was found to be one of the most promising strains for both kinetic resolution 
and asymmetric synthesis. This makes -TAm from Vibrio fluvialis JS17 and other 
related enzymes suitable and good candidates as biocatalyst for the production of 
chiral amino alcohols. 
 
However, since the Vibrio fluvialis JS17 strain was isolated from soil as reported by 
Shin and Kim (2001), it is not publicly available. Kaulmann et al. (2007) have 
searched for a new strain, which is Vibrio fluvialis-like amine transaminase family.  
By using BLASTP search, they have successfully recruited a novel -TAm from 
Chromobacterium violaceum DSM30191 (CV2025 -TAm). The gene from C. 
violaceum strain was cloned into the expression vector pET29a and expressed in 
Escherichia coli BL21 (Kaulmann et al., 2007). The -amino acid:pyruvate 
transaminases from C. violaceum shows 38 % sequence similarity to the -TAm from 
Vibrio fluvialis JS17 and also favour the transamination reaction in the forward 
direction. The CV2025 -TAm was thus extensively used here to achieve the research 
aim and objectives (Section 1.5). Also, a library of novel -TAms from various 
strains (Table 2.3) (made available by the Institute of Structural and Molecular 
Biology, University College London) was studied as described in Chapters 5 and 6. 
 
1.4.5. ω-TAm Bioconversions 
 
 
Since it was discovered over 60 years ago, few processes using this enzyme have been 
commercialized due to the low equilibrium constant of the transaminases reaction that 
result in a low yield of product conversion. Figure 1.16 shows the general reaction 
scheme of a TAm reaction. However, the unfavourable equilibrium position is not a 
problem for transamination using -TAm, for example, the reaction between chiral 
amines and pyruvate (Shin and Kim, 1998). The conversion of (S)--
methylbenzylamine (MBA) and pyruvate to acetophenone (AP) and L-alanine (Figure 
1.17) using -TAm from V. fluvialis is almost quantitative since the equilibrium 
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entirely favours product formation in the forward direction, which is towards L-
alanine (Shin and Kim, 1998; Kaulmann et al., 2007). 
 
 
 
 
 
Figure 1.16. General reaction scheme of a TAm reaction where an amino group is transferred 
to a carbonyl group. 
 
 
 
 
 
 
Figure 1.17. Reaction scheme of the ω-transamination (ω-TAm) bioconversion between (S)--
methylbenzylamine (MBA) and pyruvate to acetophenone (AP) and L-Alanine in the presence of 
co-factor pyridoxal 5’-phosphate (PLP). 
 
 
Investigation into stability  of the purified TAm showed loss in enzyme activity over a 
long fermentation period (i.e 70 hours), and this suggests this enzyme is more stable 
in the environment of the lysate form (Ingram et al., 2007). Proteins in lysate are often 
subject to attack by endogenous proteases. However, by using E.coli BL21 gold 
(DE23) strain, lacking both the La and OmpT protease, reduces such degradation 
(Studier and Moffatt, 1986; Ingram et al., 2007). The lower instability of transaminase 
as observed by Ingram and co-workers (2007) may be due to the loss of the tetrameric 
conformation that is comprised of two loosely associated dimmers during purification. 
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In addition, it would be also appealing to compare the reactions using recombinant 
whole cells expressing -TAm with lysed cells, since whole cell biocatalyst represent 
the cheapest and often most efficient solution in industrial single and multi-step 
bioconversions. Moreover, immobilization techniques of the cells or enzymes can 
furthermore be used to improve the stability while adding the benefit of allowing the 
catalyst to be recycled for multiple batches.  
 
Immobilization of enzymes can provide several advantages compared to free 
enzymes, including easy recovery and reuse of enzyme, improved operational and 
storage stability of the enzyme, the possibility for continuous operation in packed bed 
reactors, and minimizing protein contamination in the product (Sheldon, 2007). 
Immobilization of whole cell ω-TAm by entrapment in calcium alginate beads has 
been applied for the kinetic resolution of chiral amines in a packed bed reactor (Shin 
et al., 2001). 
 
1.4.6. Reaction Mechanism of ω-TAm 
 
ω-TAm is a well-characterized pyridoxal 5’-phosphate (PLP) dependent enzyme. As 
shown in schematic Figure 1.18, ω-TAm catalyses the enzymatic amino transfer by 
ping-pong bi-bi mechanism (Christen and Metzler, 1985). The mechanisms by which 
ω-TAm enzymes act can be divided into two half-reactions (Figure 1.19). 
 
 In the first half-reaction, the amino acid (amino donor) donates its amino group to the 
PLP form of the enzyme (E-PLP) to produce enzyme bound pyridoxamine 5’-
phosphate (E-PMP), and the respective keto product is released. During the second-
half reaction, the keto acid (amino acceptor) accepts the amino group from E-PMP to 
produce the corresponding amino acid and regeneratesE-PLP, thus completes the 
transaminase cycle (Christen and Metzler, 1985). The fully regenerated ω-TAm’s co-
factor within the same two substrates reaction, hence avoid co-factor regeneration 
problems in oxidation / reduction reaction mechanisms of ω-TAm (Hwang et al., 
2005; Pannuri et al., 2003). 
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Figure 1.18. Schematic representation of the ping pong bi-bi ordered reaction mechanism used 
of ω-TAm. 
 
 
 
 
Figure 1.19. Schematic diagram of -transamination. E-PLP and E-PMP represent a complex 
between -transaminase and pyridoxal 5-phosphate and a complex between -transamination 
and pyridoxamine phosphate respectively.  
 
 
 
 
 
1.4.7. Range of Potential of Amino Donors and Amino Acceptors 
 
The substrate spectrum for C. Violaceum CV2025 ω-TAm as published by Kaulmann 
et al. (2007) was mainly obtained with a cell extract. As with the Vibrio fluvialis 
enzyme, CV2025 -TAm showed high activities towards amino donors of aromatic 
(S)-amines such as (S)--MBA and (S)-aminoindane with little or no reactivity 
towards (R)--MBA (Kaulmann et al., 2007).  The high selectivity for (S)-amines 
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could lead to a useful asymmetric strategy for the preparation of enantiopure amines 
and amino alcohols (Shin et al., 2001; Yun et al., 2003; Yun et al., 2005; Kaulmann et 
al., 2007). In comparison to Vibrio fluvialis enzyme, CV2025 -TAm showed slightly 
lower reactivity for reactions with (S)-enatiomers and the reasons are remains to be 
elucidated.  
 
Besides (S)--MBA and (S)-aminoindane, 1-methyl-3-phenylpropylamine and 
benzylamine were also can be considered as efficient candidates as an amino donor 
for transamination reaction by CV2025 -TAm (Table 1.1). Aminodiols (2-amino-1-
phenylpropane-1,3-diol and 3-amino-1,2-propanediols), aliphatic amines and amino 
acid tested were also tested as amino donor but no significant activities were detected 
except for 1-methyl and 1,5-dimethylhexylamine (amines) and L-alanine (-amino 
acids) which are in agreement with data obtained for Vibrio fluvialis enzyme 
(Kaulmann et al., 2007).  
 
As for amino acceptor candidates, besides keto acids, such as pyruvate and 
hydropyruvate (HPA), several aliphatic and aromatic aldehydes showed significant 
reactivity (Table 1.2). Distinctly from Vibrio fluvialis enzyme (Shin and Kim, 2001), 
higher conversions were observed for hydroxypyruvate (HPA) and glyoxylate 
(aliphatic aldehyde) for CV2025 -TAm reactions. Among the amine acceptors 
tested, only pyruvate, glyoxylate and benzylaldehyde allowed conversion of  90 % 
(Kaulmann et al., 2007). The incomplete transamination might be due to chemical 
equilibrium, acceptor reactivity and poor substrate/ products solubility and inhibitions 
effects.  
 
The low molecular weight aldehydes such as propanal and butanal showed good 
amino acceptor reactivity as pyruvate (Shin and Kim, 1997; Stirling, 1992) and due to 
their low costs such aldehydes are favoured over relatively expensive pyruvate. 
However, when considering both reactivity and enzyme stability, pyruvate offered a 
better option (Shin and Kim, 2001).   
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Table 1.1. Specificity of CV2025 -transaminase towards various amino donors. Image 
reproduced from Kaulmann et al. (2007). 
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Table 1.2. Specificity of CV2025 -transaminase towards various amino acceptors. Image 
reproduced from Kaulmann et al. (2007). 
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1.4.8. Asymmetric Synthesis and Kinetic Resolution 
 
-TAm catalyzed production of targeted chiral amine compounds are either by direct 
asymmetric synthesis from pro-chiral ketones or kinetic resolution of racemic amines. 
The choice of reaction methods between asymmetric synthesis from prochiral 
compounds and kinetic resolution from racemic compounds depends on the 
enantioselectivity of the enzyme and the economics of the reaction process. The strict 
enantioselectivity of the enzyme is beneficial to achieve high yield of either unreacted 
(R)-enantiomer by kinetic resolution or (S)-enantiomer by asymmetric synthesis (Shin 
et al., 2001; Shin and Kim, 1999). As described earlier in Section 1.4.8, the kinetic 
resolution method is, however, always hampered by a maximum of 50 % theoretical 
yield. -TAm which has sufficiently high enatioselectivity, could lead to a useful 
asymmetric synthesis method permitting the production of high enantiopure 
homochiral amines. 
 
Asymmetric synthesis has been one of the central themes in biotransformation 
(Klibanov, 1990; Shin and Kim, 1999) as well as in modern organic chemistry (Chan, 
1993; Sonawane et al., 1992; Shin and Kim, 1999). The asymmetric synthesis of 
chiral amines with -TAm may offer many potential advantages over kinetic 
resolution. These advantages include: the lack of need for reductive amination to 
prepare racemic amines from ketone precursors, chiral precursors are usually less 
expensive than racemic mixtures (Sheldon, 1996; Shin and Kim, 1999) and two fold 
higher theoretical yield (Shin and Kim, 1999). However, the challenges of using this 
method are to shift the equilibrium to the product side, especially when using amino 
acid as an amino donor, stereoselectivity of the enzyme has to be perfect, which is not 
always the case for -transaminase (Dominik et al., 2008), and much more severe 
product inhibition than the kinetic resolution method (Shin and Kim, 1998; Shin and 
Kim, 1999).  
 
1.4.9. ω-TAm Bioconversion Process Challenges  
 
Despite many advantages, such as broad substrate specificity (Section 1.4.7), high 
turnover rate, and high stability (Taylor et al., 1998), the industrial use of ω-TAm  has 
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been limited, mainly due to the low equilibrium constant of the bioconversion 
reaction. Also, severe product inhibition will prevent from using high concentrations 
of amine substrate (Shin and Kim, 1998). As described earlier in Section 1.4.8, the 
best approach to the pure chiral amine would be asymmetric synthesis, if possible 
(Shin and Kim, 1998), however, proved to be difficult due to these limitations. 
Therefore, recent work has started focusing on overcoming tackle these issues for a 
higher reaction yield. 
 
1.4.9.1. ω-TAm Thermodynamic Equilibrium 
 
The low equilibrium constant of the ω-TAm reaction is the main problem that inhibits 
high bioconversion. The transamination reaction (Section 1.3.1) is reversible, and the 
optimum bioconversion rate is determined by the initial concentrations and the 
thermodynamic equilibrium constant (K) of the reaction (Tufvesson et al., 2011). 
Meanwhile, K is determined by the change in Gibbs free energy (ΔG) for the reaction 
given by the difference in ΔG between the products and the reactants. For instance, 
the amine transfer from an amino acid to an alpha keto acid to form another amino 
acid, the change in ΔG is small and in turn the equilibrium constant of the reaction is 
around one (Tufvesson et al., 2011; Taylor et al., 1998). The equilibrium constant of 
the reaction determines how low a concentration of product or co-product is required 
to achieve the desired yields. Therefore, the knowledge of the reaction equilibrium 
constant and / or ΔG (Jankowski et al., 2008) is important in determining of the 
process strategy needed to meet the requirements in terms of yield and product 
concentration (Tufvesson et al., 2011; Seo et al., 2011).  
 
Kaulmann et al. (2007) reported on transamination of a range of amino acceptors of 
keto acids and aldehydes with MBA, and the results showed only a few acceptors 
allowed conversion of more than 70 % (Table 1.2) after the equilibrium was reached. 
These observations were due to the equilibrium being strongly in favor of the MBA 
(amine donor). The kinetic study for ω-TAm from Bacilus thuringiensis JS64 
demonstrated by kinetic resolution of α-methylbenzylamine, reported a K of about 
10
−3
 (Shin and Kim, 1998). When 2-propyl amine was used as the amine donor, the 
equilibrium becomes more favorable, but still the equilibrium lies strongly in favor of 
the reactants (Truppo et al.,2009). 
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1.4.9.2. Substrate and Product Inhibitions 
 
Inhibition by substrate and / or product is another significant problem that needs to be 
overcome for an efficient industrial transamination process. Substrate inhibition is a 
common phenomenon in enzyme chemistry, which is virtually always observed with a 
fast reacting substrate enantiomer for enzyme processing a defined stereoselectivity 
(Shin and Kim, 2002; Wang et al., 1999; Kaiser, 1980). Accurate understanding of 
substrate inhibition is critical to determine the optimal substrate concentration to be 
used for the reaction.  
 
Substrate inhibition of -TAm result from the formation of abortive dead-end 
complexes, such as between the amino donor and E-PMP and / or amino acceptor and 
E-PLP (Shin and Kim, 1998), which restrain them from undergoing further reaction 
and inhibits the formation of the right Michaelis complexes. This phenomenon is due 
to the presumably similar active site structures and recognition mechanisms of both E-
PLP and E-PMP, thus each enzyme form can facilitate non-productive binding.  
 
For   instance, it was reported that substrate inhibition as observed when either keto 
acid (i.e pyruvate) or other reactive aldehyde (i.e. butryraldehyde) was used in the ω-
TAm bioconversions (Shin and Kim, 2002). They also found that (R)-enatiomers of 
amines severely inhibit the enzyme activity even though the (R)-amines are nearly 
non-reactive due to high-enatioselectivity of -transaminase.  The high propensity for 
this non-productive binding indicates that binding pockets of -transaminase have not 
evolved to precisely control enatioselectivity and substrate preference during the 
binding step (Shin and Kim, 2002). The substrate inhibition problem can be overcome 
by controlling the substrate concentration in the medium (Shin and Kim, 2002). 
 
Meanwhile, product inhibition phenomena (Shin and Kim, 1996) result from the right 
formation of Michaelis complex between product and transaminase enzyme. This is 
due to the reversibility of enzyme reaction, which product can bind to the enzyme and 
thus reduces the chances of substrate binding to the enzyme active site.   
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1.4.10. Possible Strategies for Improving Reaction Performances 
 
Systematic design methods are hence necessary to overcome the thermodynamic 
equilibrium and inhibition limitations to enhance productivity of the ω-TAm 
biocatalytic process prior industrial application. Recently, a number of methods have 
been demonstrated to (at least) partly overcome these challenges, such as: 
 
1.4.10.1. In situ product removal (ISPR) methods 
 
In situ product removal (ISPR) methods can be used to address both thermodynamic 
and inhibition limitations by selectively removing the product from the reaction 
solution as soon as it is formed which can also further benefit subsequent downstream 
processing (Lye and Woodley, 1999; Jauregi and Varley, 1998; Jauregi et al., 1997). 
Besides, ISPR method is also used to increase the productivity or yield of biocatalytic 
processes by minimizing product losses owing to degradation or un-controlled release 
and reducing the total number of downstream-processing steps (Lye and Woodley, 
1999). 
 
The best strategy for ISPR will depend on the properties of the product amine as well 
as other components in the reaction mixture. In general, a strategy is considered 
favorable when it produces a huge driving force for separating the product from the 
other components (Tufvesson et al., 2011). The physico-chemical properties that are 
most commonly exploited for ISPR are volatility, solubility, charge, hydrophobicity, 
and molecular size (Tufvesson et al., 2011; Lye and Woodley, 1999). One of the 
example of an effective ISPR application is the removal of an enzyme that inihibit L-
erythrulose from the reaction medium of transketolase catalysed condensation of 
glycoaldehyde with hydroxypyruvate (Figure 1.20) using an immobilized 
phenylboronate resin (Affigel 60) (Lye and Woodley, 1999). 
 
 
 
 
 
 
  
 60 
 
 
 
 
Figure 1.20. Transketolase catalysed condensation of glycolaldehyde with β-hydroxypyruvate 
to yield L-erythrulose with the evolution of carbon dioxide. 
 
 
 
Industrial examples of research into ISPR techniques have shown some impressive 
results, and most of the cases involve the implementation to overcome inhibitory or 
toxic effects of the product on the biocatalyst. The stereoselective reduction of 3,4-
methylene dioxyphenyl acetone to S-3,4-methylene-dioxyphenyl isopropanol by a 
whole cell Zygosaccharomyces rouxii biocatalyst with XAD-7 resin application for 
simultaneous in situ substrate supply has been demonstrated up to a scale of 300 L 
with the final product increased from 6 g.L
-1
 to 40 g.L
-1
 (Vicenzi et al., 1997).  
Likewise, XAD-2 was used for ISPR substrate supply of geraniol that inhibits 
Ceratocystic variospora biocatalyst at 20 L scale and managed to increased 
production of monoterpenes from 0.04 g.L
-1
 to 1.9 g.L
-1
 (Schindler, 1982).  Both of 
these examples were operated in batch mode operation of ISPR techniques.  
 
An example of an industrial continuous ISPR process has been described for the 
conversion of niacin to 6-hydroxynicotinic acid by whole cells of Achromabacter 
xylosoxidans to overcome the magnesium salt of the product which is insoluble at 
neutral pH (Kulla, 1991). The continuous ISPR process allowed a productivity of 1.5 
g.L
-1
.hr
-1
 to be obtained. These examples have clearly highlighting the role of the 
application of ISPR techniques in improving the yield and productivity of biocatalysts 
processes, and these three impressive industrial ISPR examples are summarised in 
Table 1.3 (Lye and Woodley, 1999).  
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Table 1.3. Examples of industrial in situ product removal research. Image reproduced from 
Lye and Woodley (1999).  
 
 
 
 
A biphasic extractive system was verified as one of the keys to the success of 
enzymatic resolution reaction at high substrate concentration (Shin and Kim, 1997). 
Furthermore, the two-liquid-phase system (Wubbolts et al., 1996; Van Sonsbeek et 
al., 1993; Shin and Kim, 1999) has proved versatile in biotransformation, permitting 
high concentrations of substrate of low solubility to be used in aqueous media, the 
shifting of equilibrium positions, and the removal of product inhibition (Shin and 
Kim, 1999).  
 
The  possible drawbacks of this system are phase and/or solvent toxicity to enzyme 
and mass transfer limitations attributable to a restricted interfacial area. A biphasic 
reaction system (Figure 1.21) was successfully introduced to keep the concentration 
of inhibitory products low at the reaction site (i.e aqueous phase) despite the difficulty 
in constructing a continuous process, and a serious problem of interfacial enzyme 
inactivation in emulsion state (Shin et al., 2001) in kinetic resolution with -
transaminase (Shin and Kim, 1999; Shin and Kim, 1998).  Also, in order to overcome 
the problems encountered in the two-liquid-phase system, an enzyme membrane 
reactor (EMR) with a membrane contractor can be used to facilitate emulsion-free 
extraction (Shin and Kim, 2001).  
 
Furthermore, evaporation of a volatile product (or by-product) may also be an option 
for shifting the equilibrium towards the product and overcoming inhibition. Yun et al. 
(2004) have previously reported a great achievement with reduced pressure method 
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that significantly enhance the yield of ω-TAm bioconversion of (R,S) sec-butylamine 
by greatly remove an inhibitory product, 2-butanone. For volatile amines, distillation 
could also be a possible route for product recovery in kinetic synthesis. For example 
(R)-sec-butylamine (boiling point 63 °C) was recovered by distillation of the product 
mixture under basic conditions (Hanson et al., 2008). Also, it was later reported, a 
small enhancement in yield by sweeping the reactor with nitrogen gas to remove the  
acetone formed (Savile et al., 2010). 
 
Nevertheless, there are limitations with all ISPR strategies which are commonly 
related to the selectivity of separation and the relative concentrations of the reaction 
components, including the solvent. For instance, in using resin adsorption it was 
observed that the ketones or amines have similar distribution behaviour and, therefore, 
will co-extract into the solvent or resin unless another driving forces are in place such 
as ionization (Tufvesson et al., 2011). 
 
Figure 1.21. Reaction scheme of -transamination in biphasic system. Image reproduced from 
Shin and Kim (1997). 
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1.4.10.2. Alternative Amino Donor  
 
Low equilibrium constant is a common problem in ω-TAm bioconversion, however, 
depending on substrate combinations, some of them have equilibrium constants that 
are high enough not to limit the reaction (Shin and Kim, 1997; 1998) such as ω-amino 
acid: pyruvate ω-TAm shown catalytic activity toward aliphatic amines not bearing a 
carboxyl group (Yohana et al., 1987; Christen and Metzler, 1985). Therefore, the 
simplest and most straightforward approach is the screening of ω-TAm for amine 
donor specificity in search for a combination with suitable amine acceptors bearing 
high equilibrium constant toward the desired product. 
 
1.4.10.3. Addition of Excess  Substrate 
Another simple option for shifting the equilibrium towards a high yield of the product 
would in principle be to use an excess of either amine donor or amine acceptor. This 
strategy was applied by Savile et al. (2010) for the production of Sitagliptin at high 
substrate concentrations using an approximately 10-fold excess of 2-propylamine. 
However, the use of this strategy is limited to those cases when the equilibrium is 
only slightly unfavourable (Tufvesson et al., 2011). 
1.4.10.4. Auto-Degradation of By-product 
Another convenient approach is the use of self-degrading by-product or products. For 
instances, the spontaneously cyclized of the amino-keto acid formed when using 
ornithine or lysine as amine donor has thus favoured the reaction in the direction of 
the amine (Ager et al., 2001; Li et al., 2002). The similar approach was used recently 
to shift the equilibrium of the transaminase reaction (Truppo et al., 2010).  
1.4.10.5. Enzymatic Cascade / Second Enzyme Reactions 
The transamination reaction can be coupled to other enzymatic steps that convert the 
by-product into a non-reactive compound or back to the original substrate hence 
increase yield of the desired product. Recently, a multitude of different coupling 
reactions have been proposed and reported (Truppo and Turner, 2010; Koszelewski et 
al., 2008; Koszelewski et al., 2009; Yun et al., 2003).  Nevertheless, for the greatest 
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feasibility, the interactions and compatibility of the enzymes and associated reagents  
first need to be considered.  
 
1.5. MICROSCALE HIGH-THROUGHPUT EXPERIMENTATION 
 
1.5.1. Conventional Microwell Plate Platform 
 
The need to improve the efficiency of biocatalyst process development is a constant 
challenge as efforts to continue to reduce the overall timeline of pharmaceuticals from 
design to market and reduce overall development costs (Pollard and Woodley, 2006). 
The development of industrial biocatalytic bioconversion is usually a slow process 
compared with the traditional chemical routes  (Pollard and Woodley, 2006; Yazbeck 
et al., 2004). This is due to the necessity to screen a large set of biocatalyst libraries in 
order to identify the appropriate enzymes, followed by a large amount of data that 
need to be collected at each stage of the process development (Lye et al., 2003; 
Fernandes, 2010). Therefore, the need to develop new methods that could handle large 
quantities of biocatalysis experiments is become crucial.  
 
Parallel experimentation on miniaturised platforms is gaining increasing attention 
mainly for shortening  bioprocess development,  and offers a cost-effective method of 
process optimization (Micheletti and Lye, 2006). Additional key advantages of 
microscale techniques include (Lye et al., 2002; Lye et al., 2003): 
 
 Rapid evaluation of large enzyme libraries. 
 Reduction in the quantity of materials including expensive enzymes and 
substrates required for process development.  
 Rapid generation of early data for process design and model establishment 
predictive of larger scale operations. 
 Early identification of the optimum reaction conditions and reactor 
configurations. 
 Promotion of a rapid and efficient translation from discovery to pilot plant scale. 
 Capacity to automate the complete bioprocess as will be discussed further in the 
following Section 1.5.2. 
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A majority of the microscale bioprocess studies have been developed on miniaturized 
reactors mostly using multi-well plates (Fernandes, 2010). The microwell systems are 
commercially available in different geometries and sizes with scales ranging from 20 
to 2000 µL  (Micheletti and Lye, 2006; Doig et al., 2002). Figure 1.22 shows the 
dimensions of 3 standard size microwell bioreactors.   
 
Figure 1.22.   Diagram representation of individual microwell formats: (a) 96-deep square well 
format; (b) 24-round well format; (c) 96-round well format. VW represents the total well volume; 
SA represents the static surface area available for gas–liquid mass transfer. Image reproduced 
from Lye et al. (2003). 
 
 
 
Although the use of microscale techniques has been comprehensively used during the 
past decade for screening purposes, it is only recently that studies on fundamental 
engineering aspects have been performed, including mass and heat transfer 
phenomena and scaling up techniques (Zhang et al., 2008; Marques et al., 2009; 
Barrett et al., 2010).   
 
Of special interest is the liquid mixing in such small reactors, which behave 
differently from larger scale processes in terms of the importance of diffusion and 
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convection (Matosevic et al., 2008). Orbital shaking of microwell plates has been 
found to be the most efficient way to promote mixing, and several studies have been 
conducted to determine the critical speed to assure an uniform mixing (Micheletti et 
al., 2006). These studies have led to a better understanding of the reaction conditions 
and engineering principles of the microscale tools, and will provide excellent 
guidance toward successful scale translation (Zhang et al., 2008; Islam et al., 2008).   
 
Recent studies have also focused on the quantification of enzyme kinetics using 
microscale tools (Lye et al., 2002). Doig et al. (2002) have   performed a microscale 
study of a whole cell cyclohexanone monooxygenase performing the oxidation of 
bicyclic ketones to synthesize chiral lactones. They were able to characterize the 
oxygen mass transfer behaviour under different reaction conditions and microwell 
geometries, as well as accurately determined the substrate inhibition parameters. 
Furthermore, the use of microscale techniques integrated with analytical tools such as 
HPLC (high-performance liquid chromatography) for the reliable determination of 
kinetic parameters has been established using cellular extracts, pure and immobilized 
enzymes (Chen et al., 2008; Matosevic et al., 2011).  
 
Due to the high level of parallelization and reduced requirements of materials 
involved, intensive screening of biocatalysts and process variables has, therefore, 
become more feasible whilst the reproducibility of bioconversion processes have been 
substantially improved (Fernandes, 2010). Therefore, microscale bioprocessing 
techniques have emerged as an ideal tool that can be used to study and evaluate the 
different components in the process development, characterization and ultimately 
implementation of bioconversion processes to production scale. 
 
1.5.2. Automation Microscale Platform 
 
The benefits of miniaturization of bioprocessing will further arise from the adoption 
of automated operation of whole bioprocess sequences that facilitate the parallel 
evaluation of whole bioprocess performance at the earliest product development. The 
established microwell formats can be easily adopted with ready automation processes 
as numbers of commercially available laboratory robotic platforms are recently started 
to receive a great attention. 
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The applications of microtitre plate with integration of automation robots of 
bioprocess development will greatly help to reduce the labour requirement, increases 
the operational and analytical accuracy and minimizes the number of expensive large-
scale trials required which in turn reduce the total cost to market of new 
biopharmaceuticals (Zhang et al., 2008). Recently, the use of automated shaken 
microtitre plates have been become widely explored for studies of wide range 
bioprocess operations that include complex bioprocess developments such as stem 
cell expansion, mammalian cell culture, bacterial fermentation, biotransformation and 
downstream processing. The factors influence the industrial uptake of microscale 
bioprocess technologies is summarizes in Figure 1.23. 
 
Automated microscale approaches have been studied expansively for the rapid and 
quantitative collection of bioprocess design data (Lye et al., 2003; Micheletti and Lye, 
2006). Of special interest is a study reported on the robotic application that linked 
fermentation, induction and bioconversion steps using a Packard Multiprobe II robot 
for investigation of trade-offs between recombinant production and specific 
cyclohexance monooxygenase (CHMO) activity and bioconversion (Ferreira-Torres et 
al., 2005) and the same approach was later had been repeated for a tranketolase (TK)-
expressing E.coli biocalyst using a Tecan robotic platform (Micheletti et al., 2006).  
 
Furthermore, a commercial robotic liquid handling workstation (Freedom EVO) was 
successfully modified for parallel microscale chromatography application to 
accelerates automated high-throughput separations by microscale biochromatography 
(Britsch et al., 2008). The robot also helps to overcome sample preparation and 
separation bottlenecks in numerous applications where multiple samples are to be 
processed or analysed. The applications include, screening of cell culture supernatants 
for recombinant monoclonal antibodies, rapid two-dimensional parameter 
optimization in the development of individual process chromatography steps, and a 
variety of new diagnostic applications for medical purposes (Britsch et al., 2008). 
 
Jackson et al. (2006) have reported an automated microscale Normal Flow Filtration 
(NFF) technique that is able to quantitatively evaluate the influence of upstream 
processing conditions on the microfiltration behaviour of E. coli fermentation broths 
based on the use of a Tecan VacS two-position vacuum filtration manifold with Tecan 
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Genesis Freedom liquid handling robot.  The technique used in this work alongside 
microwell fermentation studies allows the integrated parallel quantification and 
optimisation of upstream and downstream operations. Chen et al. (2008),  recently 
published work where a full kinetic model was established using automated 
microscale tools, evaluating key parameters such as substrate and product inhibition. 
 
 
 
 
Figure 1.23. Capabilities framework for the industrial adoption of high-throughput 
technologies. This illustration is based on the implementation of high-throughput screening 
programmes in the pharmaceutical sector. Arrows represent the progression of microwell and 
microfluidic systems, respectively. Image reproduced from Micheletti and Lye (2006). 
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1.6. AIM AND OBJECTIVES OF THE PROJECT 
 
Recently bioconversion processes have received increased interest as replacements for 
conventional chemical syntheses, especially those for chiral and environmentally 
unfriendly syntheses (Section 1.2).  The advantage of biocatalysis lies (Section 1.2.2) 
in the ability to operate at near neutral pH, ambient temperatures, pressures and in an 
aqueous environment. More importantly, biocatalysts are highly reaction specific, 
enantiomer-specific and regio-specific (Illanes, 2008). However, the widespread use 
of biocatalysis in industry requires conversions to achieve higher space-time yields 
than is currently possible (Pollard and Woodley, 2006). As described in Section 1.4.9, 
an issue generic to many types of bioconversions is the need to overcome 
unfavourable reaction equilibrium. 
 
ω-TAms converts a carbonyl group to an amino group, and is an industrially relevant 
example of a biocatalyst featuring unfavourable equilibrium positions which are a 
problem in a range of asymmetric syntheses (Section 1.4). ω-TAms have received 
increased interest due to their great potential for the production of natural and non-
natural amino acids as well as other chiral amines, which are in demand by the 
pharmaceutical industry (Christen and Metzler, 1985; Sheldon, 1996; Shin and Kim, 
1997; Stirling, 1992; Shin and Kim, 2001). Optically active amines are required for 
the preparation of a broad range of biologically active compounds (Section 1.1) 
showing various pharmacological properties (Sutin, 2007; Koszelewski et al., 2008) 
such as building blocks in the synthesis of neurological, immunological, anti-
hypertensive and anti-infective drugs. The challenges for industry are (i) how to select 
a suitable transaminase for a particular bioconversion, (ii)_ need to be able to explore 
early bioprocess solutions to overcoming equilibrium control of reaction and increase 
product yield, (iii) need to evaluate both substrates and products for inhibitory effects 
(iv) need to rapidly identify cheap and ready sources of amine donors for each 
TAm/substrate combination and (v) how to evaluate different process options for 
increasing space-time yields quickly and cost effectively. 
 
The aim of this research is, therefore, to create and demonstrate microscale process 
methodologies for overcoming the major factors limiting bioconversion production 
rate and yield. For ω-TAms there are typically low equilibrium constants and product 
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inhibition as described in Section 1.4.9. In particular, generic solutions for shifting the 
reaction equilibrium towards product formation for ω-TAm bioconversions will be 
highlighted with the application of high-throughput microscale methods that are 
predictive of larger scale operating conditions. In order to achieve this aim, the 
primary objectives of the project are summarized below. 
 
 The first objective is to develop techniques for the evaluation of the basic 
kinetic properties and parameters of the ω-TAm enzyme at the mirco-scale (< 
1mL). ω-TAm activity was initially studied with MBA and pyruvate as model 
substrates known to have rapid reaction rates and high yields. The validated 
methods obtained from microwell scale were then used for further 
investigation of mechanisms to overcome the reaction equilibrium problem. 
The results of this work are presented and discussed in Chapter 3. 
 
 The second objective was then to establish novel microscale methods to enable 
evaluation of different process solutions to overcome product inhibition and 
equilibrium control of reactions and hence increase product formation. Four 
approaches were demonstrated for the CV2025 ω-TAm asymmetric synthesis 
of chiral amines. The first option examined ω-TAm bioconversions with 
different types of amino donors as alternatives to MBA. The second option 
couples ω-TAm with alcohol dehydrogenase (ADH) and glucose 
dehydrogenase (GDH) for removing the inhibitory AP by conversion to non-
inhibitory (R)-1-Phenylethanol. The third and fourth approaches are based on 
physical in situ product removal (ISPR) methods of applying reduced pressure 
conditions for evaporation of the volatile AP and utilizing synthetic polymeric 
resins for adsorption of AP to eliminate it from the reaction system.  The 
results of this work are presented and discussed in Chapter 4. 
 
 The third objective was to integrate the methods established in Chapter 4 into 
an efficient automated microscale process sequence. The research here was 
mainly focussed on comparison of both conventional and automated 
microscale processes techniques and the potential benefits of increased 
processing speed and reduced experimental costs attained with the automation 
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platform. The automated microscale process sequences were also applied to 
the evaluation of ω-TAm libraries. The results of this work are presented and 
discussed in Chapter 5. 
 
 The fourth objective was to illustrate successful scale-up of selected ω-TAm 
reactions identified in Chapter 5. The scale-up of CV2025 ω-TAm 
bioconversions with optimised second enzyme reaction conditions and using a 
novel BSU09260_1971 ω-TAm from Bacillus subtillis capable of using L-α-
Serine as amino donor were performed at µL and preparative scales to 
demonstrate the capacity of the microscale automation tools to speed up 
bioprocess design and optimisation and evaluation of a broad range of 
biocatalyst and process options. The results of this work are presented and 
discussed in Chapter 6. 
 
 Finally, in Chapter 7, the generic outcomes of this work are highlighted and 
suggestions for future work are presented. 
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2. MATERIALS AND METHODS 
 
 
 
 
 
2.1. MATERIALS 
 
2.1.1. Reagents and Suppliers 
 
Nutrient broth and nutrient agar were obtained from Fisher Scientific (Leicestershire, 
UK). All other reagents were obtained from Sigma-Aldrich (Gillingham, UK) unless 
otherwise stated and were of the highest purity available. Reverse osmosis (RO) water 
was used in all experimental work. 
 
2.1.2. Media Preparation 
 
E. coli BL21 fermentations for expression of CV2025 ω-TAm obtained from plasmids 
pQR800 and pQR801 were performed using LB-glycerol (Luria-Bertani media) 
medium, the contents of which are described in Table 2.1. E. coli fermentations for 
expression of ω-transaminases obtained from plasmids pQR426, pQR813, pQR956, 
pQR960, pQR978, pQR985, pQR1010, pQR1014, pQR1017, pQR1019 were 
performed using 2xTY (E. coli rich media) medium the contents of which are 
described in Table 2.2.   
 
The different components of both media were weighed out and dissolved in RO water 
to a final volume of 1 L. The pH of the media was adjusted to pH 7 with a solution of 
1 M NaOH when necessary. The medium were then autoclaved at 121 
o
C for 15 min.    
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Table 2.1. Composition of the LB-glycerol medium used in E. coli fermentations for expression 
of CV2025 ω-transaminases obtained from plasmids pQR800 and pQR801. 
 
Component Concentration (g.L
-1
) 
Yeast extract 5.0 
Tryptone 10.0 
NaCl 10.0 
Glycerol 10.0 
 
 
 
 
Table 2.2. Composition of the 2xTY medium used in E. coli fermentations for expressions of ω-
transaminases obtained from plasmids pQR426, pQR813, pQR956, pQR960, pQR978, pQR985, 
pQR1010, pQR1014, pQR1017, pQR1019. 
 
Component Concentration (g.L
-1
) 
Yeast extract 10.0 
Tryptone 16.0 
NaCl 5.0 
 
 
2.1.3. Agar Plate Preparation 
 
LB agar and 2xTY agar were prepared by adding 15 g.L
-1
 of agar to LB-glycerol 
medium and 2xTY medium as described in Tables 2.1 and 2.2, respectively. The agars 
prepared were then autoclaved at 121 
o
C for 15 min. Once cooled down to a 
temperature between 40 - 50 °C, 30 mL of media were poured into each standard size 
Petri dish (Fisher Scientific, UK) under aseptic conditions. The agars were then 
allowed to solidify before use. 
 
2.1.4. Antibiotic Solution 
 
The antibiotic kanamycin was dissolved in RO water to a concentration of 150 g.L
-1
. 
The solution was then sterilized by passing it slowly through a 0.2 µm filter (Fisher 
Scientific, UK) and aseptically transferred into previously sterilized 1.5 mL 
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Eppendorf tubes and stored at -20 °C. The antibiotic was added to all LB glycerol 
medium, 2xTY medium, LB agar and 2xTY agar before the start of any culture.  
 
2.1.5. Glycerol Stocks 
 
To prepare master stock cultures, a single colony was picked from the plate 
containing the desired enzyme (Section 2.2.1). This was then inoculated into a sterile 
250 mL shake flask containing 25 mL of culture medium with the corresponding 
antibiotic. When the culture reached an OD of 0.5 at 600 nm (Section 2.6.3), 400 µL 
aliquots of cell broth were mixed aseptically in sterilized 1.5 mL Eppendorf tubes 
with 200 µL of a 50 % (v/v) filter sterilized glycerol solution. The aliquots were then 
frozen and stored at -80 
o
C and were used throughout the rest of this project.  
 
2.1.6. Transaminase plasmids 
 
ω-TAm from plasmids pQR800 and pQR801(with an N-Terminal His6-tag) contained 
the complete CV2025 ω-TAm gene and were constructed in previous work 
(Kaulmann et al., 2007). The other ten novel transaminases used in this work came 
from different microorganisms as listed in Table 2.3.  The genes were selected after 
an exhaustive bioinformatics analysis. Using as a query pQR801 sequence, sequences 
were collected and aligned. A phylogenetic tree was constructed using MEGA 5.0 and 
sequences closely related to pQR801 were selected. The selected sequences were 
pulled out and producing microorganisms were identified. Microorganisms were 
obtained either from Professor  John Ward (Institute of Structural and Molecular 
Biology, UCL) personal collection or from DSMZ (Germany). The genomic DNA 
were then purified. The primers were designed containing the NdI and Xho I 
restriction sites. TAms were amplified by PCR and ligated into pET29a vector (Merk, 
USA), which contained inducible T7 promoter, the Lac repressor and codes for 
resistance to kanamycin. All TAms constructed were fully sequenced to check they 
were in the right orientation and to verify that there were no mutations were inlcuded 
during amplification. The  E.coli BL21 BL21gold (DE3) transformed with each 
plasmid constructed were kindly provided by Professor John Ward. 
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Table 2.3. List of ω-TAm novel library. 
Microorganism Construct 
Gene ID 
Plasmid 
Chromobacterium violaceum DSM30191 CV2025 pQR801 
Pseudomonas putida KT 2440 PP2799 pQR811 
Pseudomonas aeruginosa PAO2 PAO0221 pQR813 
Bacillus licheniformis BLi00474 pQR985 
Klebsiella pneumoniae KPN_03745 pQR1011 
Bacillus subtillis BSU09260_1971 pQR960 
Deinococcus geothermalis Dgeo_1177 pQR978 
Kineococcus radiotolerans Krad_4078 pQR956 
Microccocus luteus Mlut_00920 pQR1014 
Rhodospirillum rubrum Rru_A1254 pQR1017 
Rhodobacter sphaeroides Rsph17025_2835 pQR1019 
 
 
2.2. FERMENTATIONS  
 
2.2.1. Shake Flask Fermentations Using LB Media 
 
Glycerol stocks of E.coli BL21 contained plasmids of each of the ω-TAms were 
grown in LB agar plate in the presence of kanamycin (150 µg.mL
-1
). Using a single 
colony from the agar plate, an overnight culture of the cell was then inoculated in a 
200 mL shake flask (20 mL working volume) containing LB glycerol broth as 
described in Table 2.1 again with the addition of a similar concentration of 
kanamycin. Growth was performed at 37 C with orbital shaking at 250 rpm using an 
SI 50 orbital shaker (Stuart Scientific, Redhill, UK). The total volume of this culture 
was then used to inoculate a 2 L shake flask (200 mL working volume). When the 
OD600 reached a value of 1.8 - 2.0, Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
was added to a final concentration of 0.2 mM. After 5 hours of induction, the cells 
were harvested, and 2 mM co-factor, pyridoxal-5-phosphate (PLP) was added prior to 
storage at -20 C following removal of the broth by centrifugation (Hettich Universal 
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320 Benchtop Centrifuge, GMI Inc, USA), or immediate use for whole cell 
bioconversions (Section 2.3.1). 
 
2.2.2. Shake Flask Fermentations Using 2xTY Media 
 
Cells grown in 2xTY media were cultured as described in Section 2.2.1, except they 
were first cultured at 37 C but following IPTG induction (when OD600 reached a 
value of 1.8 - 2.0) the temperature was lowered to 30 C prior to harvest after a further 
5 hours. 
 
2.2.3. 7.5 L New Brunswick Fed-batch Fermentation  
 
Batch fermentation was carried out in a 7.5 L fermentor (BioFlo 110, New 
Brunswick, Hertfordshire, UK) with a working volume of 5.0 L. The fermentor had an 
aspect ratio of 1.79:1 and was comprised of two six-bladed dual Rushton-type 
impellers (di = 59 mm, di/dt = 0.25) and four equally spaced baffles. The temperature 
was monitored by a thermocouple and automatically controlled at 37 
o
C via cold 
water circulation in the external jacket of the fermentor or a heating jacket. The pH 
was measured using an Ingold gel filled pH probe (Ingold Messtechnik, Urdorf, 
Switzerland), and was controlled with the addition of 85 % v/v H3PO4 (acid) and 28 
% v/v NH4OH (base). DOT was monitored using a polarographic oxygen electrode 
(Ingold Messtechnik, Urdorf, Switzerland) and was set to be maintained at 80 % 
through a cascade control of the impeller speed. Ingoing air was sterilized by passage 
through a 0.2 µm membrane filter and dispersed in the vessel at the base of the lower 
turbine with a ring sparger at a constant of flow rate was 5 L.min
-1
 (1 vvm).  
 
The vessel was filled with 4.5 L of LB glycerol media, and all the probe calibrations 
and pre-sterilization procedures were performed following the manufacturer 
instructions. The fermentor was then sterilized as a complete unit in an autoclave at 
121 
o
C for 20 min, and after the media was cooled down, the corresponding antibiotic 
(Section 2.1.4) and sterilized antifoam PPG, was added to a final concentration of 0.2 
g.L
-1
. The fermentor was then inoculated aseptically with five 100 mL shake flasks 
cultures previously grown overnight as described in Section 2.2.1. The fermentor was 
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initially contained LB glycerol media of 3 g.L
-1
 of glycerol. After the glycerol was 
consumed, and thus the glycerol becoming limiting, the culture was supplemented 
with two shots addition of pre-sterilized 5 g.L
-1
 of glycerol at two time intervals. Data 
was logged by on-line measurements of DOT, pH, temperature and impeller speed 
impeller using the BioCommand software (BioFlo 110, New Brunswick, 
Hertfordshire, UK) as well as by taking regular OD600 measurements as described in 
Section 2.6.2. 
 
 
2.3. BIOCATALYST PREPARATION 
 
2.3.1. Whole Cell and Lysate Forms  
 
Fresh E.coli BL21 cells containing the required ω-transaminase used for whole cell 
bioconversions were usually obtained as described in Sections 2.2.1 and 2.2.2. When 
a cell-free lysate was needed, upon thawing, the cell pellet was resuspended in 50 mM 
HEPES buffer (pH 7.5) with additional  2 mM PLP and were sonicated with a 
Soniprep 150 sonicator (MSE, Sanyo, Japan) using 10 seconds on / off at 10 µm 
amplitude for 10 cycles. Cells were placed on ice to stop overheating during the 
sonication. The sonicated lysate was then centrifuged at 5000 rpm in Falcon tubes for 
5 min (Hettich Universal 320 Benchtop Centrifuge, GMI Inc, USA) to remove cell 
debris. The resulting supernatant was then filtered through a 0.2 µm filter (Paradisc
TM 
25 AS, Whatman, UK) to obtain clarified extract. The clarified supernatant was 
finally aliquoted into 1.5 mL Eppendorf tubes to be stored at -20 
o
C. Prior to the 
initiation of a bioconversion, the frozen lysates (300 µL) were thawed in a water bath 
at 30 
o
C for typically 10 min and then immediately incubated with co-factors PLP. 
 
2.3.2. Purified Enzymes (His6-tag Purification) 
 
The transaminases expressed from all plasmids except pQR800 have an N-terminal 
His6-tag to facilitate rapid single-step purification using His-Select Nickel Affinity 
Gel which is an immobilized metal-ion affinity chromatography (IMAC) product. The 
His-Select Nickel Affinity Gel was stored in 30 % (v/v) ethanol and removed just 
prior to use. The affinity gel was thoroughly resuspended with gentle inversion, and 
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an appropriate aliquot was removed for use (3 - 4 mL affinity gel was used for 5 mL 
of clarified recombinant protein prepared as described in Section 2.3.1). The affinity 
gel was then poured into a spin column (Spin Column Pierce Zeba empty, Thermo 
Scientific Pierce, Fisher Scientific UK Ltd, Loughborough, UK). The composition of 
all buffers used for the enzyme purification procedure is shown in Table 2.4, the pH 
of all buffers was 7.5 and all steps were performed at room temperature. All 
separations steps were performed by using spin protocol, which an additional gravity 
force was added by spinning the column in a centrifuge for 2 min at 1000 rpm. 
 
The affinity gel was first washed with 1 - 2 volumes of deionized water to remove the 
ethanol. After equilibration with 1 column volume of equilibration buffer, the 
purification was commenced by loading the lysate solution. The spin column was then 
left for 15 - 30 min on an orbital shaker (~175 rpm) to gently mix the affinity gel and 
the lysate solution. Following removal of the supernatant, the affinity gel was washed 
with 3 - 4 column volumes of washing buffer. The affinity gel suspension was then 
again mixed gently on an orbital shaker for 4 min prior removing the supernatant. 
Elution was carried by gently mixing the affinity gel with a volume of 2.5 - 5 mL of 
elution buffer for 30 - 60 min on an orbital shaker prior to collection of the 
supernatant of histidine containing protein. 
 
Table 2.4. His6-tag enzyme purification buffers used for affinity purification (Section 2.3.2). 
Buffer   Components 
Equilibration       
50 mM HEPES buffer (pH 7.5), 0.4 mM PLP, 0.5 M NaCl, 15 
mM Imidazole. 
 
Wash 
50 mM HEPES buffer (pH 7.5), 0.4 mM PLP, 0.3 M NaCl, 20 
mM Imidazole. 
 
 
Elution 
50 mM HEPES buffer (pH 7.5), 0.4 mM PLP, 0.3 M NaCl, 250 
mM Imidazole. 
 
 
 
The affinity gel was cleaned after each run. The affinity gel was washed with 2 
column volumes of deionized water followed by a cleaning step which was performed 
by passing through 5 column volumes of 6.0 M guanidine HCl (Fisher Fisher 
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Scientific UK Ltd, Loughborough, UK), pH 7.5. The guanidine HCl solution was then 
removed by washing with 2 - 3 column volumes of deionized water. The affinity gel 
was then re-equilibrated with 2 - 3 column volumes of equilibration buffer for 
immediate use or was washed with 1 - 2 column volumes of 30 % (v/v) ethanol and 
finally resuspended in 30 % (v/v) ethanol and stored at 2 - 8 ºC. 
 
Following recovery of a fraction of his-tagged protein, in order to remove free EDTA 
and EDTA-nickel complexes from the elution buffer, the enzyme solution was 
desalted using a PD-10 desalting column (GE Heathcare UK Ltd, Buckinghamshire, 
UK) containing 8.3 mL of Sephadex
TM
 G-25 medium with a size exclusion limit of 
5000 Mr. The column storage solution was removed just prior use. All the separation 
steps were performed under gravity. The column was first equilibrated with 25 mL of 
50 mM HEPES buffer containing 4 mM PLP. A Labmate PD-10 Buffer Reservoir 
(GE Heathcare UK Ltd, Buckinghamshire, UK) was employed for ease of use as it 
allows loading of the total 25 mL buffer in one go. 2.5 mL of protein solution 
containing supernatant was then loaded into the column, and the flow-through 
discarded once the solution had completely entered the packed bed. For sample 
volumes less than 2.5 mL, 50 mM HEPES buffer was added to adjust the volume to 
2.5 mL.  Elution was carried out with 3.5 mL 50 mM HEPES buffer containing 4 mM 
PLP added to the column. The eluate of purified enzyme was analysed by SDS-PAGE 
as described in Section 2.6.5. The purified enzyme solution was stored in the fridge at 
4 °C for a period of up to 2 weeks before use.  
 
2.3.3. Alcohol Dehydrogenase (ADH) 
 
Commercially available alcohol dehydrogenases from Lactobacillus kefir (0.44 U.mg
-
1
 protein where 1 U corresponds to the amount of enzyme which reduces 1 μmol 
acetophenone to phenylethanol per minute at pH 7.0 and 25 °C) and 
Thermoanaerobium brockii (0.5 U.mg
-1
, 1 U will oxidize 1.0 μmol of 2-propanol to 
acetone per minute at pH 7.8 at 40 °C in the presence of NADP
+
) were dissolved in 
HEPES buffer (pH 7.5) with concentrations depending on the required reaction 
concentrations (i.e 0.5 M, 1.0 M and 1.5 M) as discussed in Sections 4.5 and 5.6. 
Magnesium ions (Mg
2+
) form an essential part of the active enzyme which prevents 
enzyme deactivation (Hummel, 1990) and so 10 mM MgCl2 was added to each 
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solution to help stabilize the enzyme activity. The enzyme solutions were either used 
immediately in bioconversion reactions, or stored in the fridge at 4 °C and used within 
24 hours. Meanwhile, the ADHs in powder form were stored at -20 °C for up to 12 
months.  
 
2.3.4. Glucose Dehydrogenase (GDH) 
 
Commercially available Glucose dehydrogenase from Pseudomonas sp. (260 U.mg
-1
, 
where 1 U corresponds to the amount of enzyme which will oxidizes 1 μmol β-D-
glucose to D-glucono-δ-lactone per minute at pH 8.0 and 37 °C) was dissolved in 
HEPES buffer (pH 7.5) with concentrations depending on the reaction concentrations 
(i.e 0.5 M, 1.0 M and 1.5 M) as discussed in Sections 4.5 and 5.6. The enzyme 
solutions were either used immediately in bioconversion reactions or stored in the 
fridge at 4 °C and used within 24 hours. Meanwhile, the GDH in powder form was 
stored at -20  °C for up to 12 months.  
 
 
2.4. SYNTHESIS OF PRODUCT AND DERIVATIZING REAGENT 
 
2.4.1. Chemical Synthesis of ABT Product Standard 
The chemical synthesis of ABT was performed as described by Ingram et al. (2007). 
Briefly L-erythrulose (4 g, 33 mmol), was suspended in acetone:dimethoxypropane 
9:1 v/v  (30 mL) and p-toluenesulfonic acid (catalyst) was added.  The mixture was 
stirred at room temperature under N2 for 3 hours during which time the reaction 
mixture became homogeneous. The reaction was monitored by TLC (Thin layer 
chromatography) using a 2:1 v/v, ethyl acetate: hexane running solvent.  
 
Sodium acetate (0.5 g) was then added, and the reaction solution was stirred for a 
further hour before the mixture was filtered and concentrated to dryness. The residue 
was purified by flash chromatography on silica gel (ethyl acetate/hexane 1:2 v/v) to 
yield the desired 3,4-O-isopropylidene acetal. 
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To an aliquot of the produced acetal (487 mg, 3.02 mmol) in methanol (10 mL) was 
added benzylamine (660 L, 6.04 mmol) and then sodium cyanoborohydride (570 
mg, 9.06 mmol).  The pH was adjusted to pH 6.0 using acetic acid and the reaction 
was stirred at room temperature for 6 hours. The reaction was monitored by TLC (1:1, 
ethyl acetate:hexane).  The mixture was concentrated under vacuum, and the residue 
partitioned between dichloromethane (100 mL) and sodium hydrogen carbonate (aq, 
sat) (100 mL) with vigorous stirring.  
 
Solid sodium carbonate was added to the suspension in small portions to ensure that 
the final pH of the aqueous layer was 9. The layers were then separated, the aqueous 
phase was extracted with further dichloromethane (two times 100 mL) and the organic 
phases combined and concentrated to dryness. The residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexane 1:1 v/v then neat ethyl acetate) to 
yield the desired amine as a 1:1 mixture of diastereomers.  
 
To a solution of the previously produced amine (200 mg, 0.80 mmol) in MeOH (5 
mL) was added 1 M HCl (aq) drop wise to give a mixture that gave a dark red colour 
to moist litmus paper. The reaction was stirred at room temperature and was 
monitored by TLC (1:1 v/v, ethyl acetate: hexane). After 2 hours, the reaction was 
completed, and the mixture concentrated to dryness to yield the crude amine as the 
hydrochloride salt. This residue was re-dissolved in MeOH (5 mL) and hydrogenated 
(balloon pressure) in the presence of palladium on carbon (10 % wt/wt, 100 mg) at 
room temperature overnight.  The catalyst was removed by filtration, and the solvent 
was removed under vacuum to yield 2-amino-1,3,4-butanetriol (ABT) as a 1:1 
mixture of threo and erythro diastereomers.  
 
2.4.2. Enzymatic Synthesis of ABT 
 
The enzymatic synthesis of ABT was performed in a 100 mL scale bioconversion 
with 200 mM ERY, 0.2 mM PLP and 30 % v/v of CV2025 ω-TAm lysate (final 
enzyme concentration of 0.3 g.L
-1
). To this mixture, a solution of 300 mM 
isopropylamine (pH 7.5) was added in a fed batch mode using a P-1 peristaltic pump 
(Pharmacia Fine Chemicals, Uppsala, Sweden) with a flow rate of 2.1 mL.hr
-1
 for 48 
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hours until the total volume of the reaction was approximately 200 mL.  The 
temperature of the CV2025 ω-TAm catalyzed reaction was maintained at 30 oC using 
a circulating water bath (Grant Instruments, Cambridge, UK), and the pH was kept at 
7.5 by the automatic addition of 1 M NaOH using a 718 STAT Titrino pH controller 
(Metrohm Ion Analysis, Switzerland).  
 
After the bioconversion, the enzyme was spun down (5000 rpm, at 4 °C for 15 min), 
and the mixture was additionally filtered through a 0.2 μm sterile filter (ParadiscTM 25 
AS, Whatman plc. Kent, UK). 50 g of Amberlite IRA-410 resin (Sigma-Aldrich, 
Gillingham, UK) was added to the reaction mixture for 1 hour, and the resin was then 
removed by filtration. The remaining aqueous mixture was then passed through 80 g 
of an Isolute SCX-2 ion exchange column (Biotage, Uppsala, Sweden), and the 
column was washed with 400 mL of methanol.  The column was then eluted with 500 
mL 4 M NH3 and the eluent was evaporated to yield 2-amino-1,3,4-butanetriol (ABT). 
 
2.4.3. Synthesis of Derivatizing Reagent 
 
The derivatizing agent 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) 
was synthesized ‘in house’ according to a previously published protocol (Cohen and 
Michaud, 1993). Di (N-succinimidyl) carbamate (3 g, 6 mmol), was refluxed in 25 mL 
of dry acetonitrile. Dropwise addition of a 6-aminoquinoline (1.5 g, 5 mmol) solution 
in dry acetonitrile was carried out over 45 min. Following a further 30 min reflux, 
concentration was carried out to half the original volume. The solution was stored at –
4 
o
C overnight. The crystals were then filtered off and stored in vacuo until used for 
derivatization step as described in Section 2.6.6.  
 
2.5. BIOCONVERSION REACTIONS 
 
2.5.1.  Microscale Experimental Platform 
 
Microscale bioconversions were performed either in a glass 96-well, flat-bottomed 
microtiter plate with individual wells having a diameter of 7.6 mm and height of 12 
mm (Radleys Discovery Technologies, Essex, UK) or in 2 mL flat bottom standard 
glass vials (Chromacol, UK) of dimension of 12 x 32 mm with 8 mm screw neck.  
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The microplate was covered with a thermoplastic elastomer cap (Figure 2.1) designed 
to work with automated equipment (Micronic, Lelystad, Netherlands) while glass 
vials were well-sealed with 11 mm snap caps, PTFE / silicone (Chromacol,UK). 
 
 
 
Figure 2.1. Cap for 96-microwell plate used for ω-TAm bioconversions. (A) Diagram of 
thermoplastic elastomer cap (B) Cap specifications (http://www.micronic.com/products/98/tpe-
capcluster-96). 
 
 
All the bioconversions were performed using 300 µL total volume at 30 
o
C unless 
noted otherwise, and orbital shaking was provided at 300 rpm with a Thermomixer 
Comfort shaker (shaking diameter of 6 mm, Eppendorf, Cambridge, UK). Reactions 
were carried out in 50 mM HEPES buffer pH 7.5 unless noted otherwise, and the 
concentration of ω-TAm co-factor pyridoxal-5-phosphate (PLP) was 0.2 mM in all 
cases. Biocatalyst, either as a whole cell suspension, lysate or purified together with 
the co-factor solutions were always added first to the reaction vessel. They were then 
left to incubate for 20 min at 30 
o
C, prior to initiation of the reaction by the addition of 
the substrate solutions.  
 
Aliquots of 20 μL were taken at various time intervals, and quenched with 180 or 380 
μL of a 0.1 % (v/v) trifluoroacetic acid (TFA) solution. They were then centrifuged 
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for 5 min at 5000 rpm and transferred into an HPLC vials for further analysis. The 
specific activities were determined as the amount of Ery, AP and ABT formed per 
unit of time normalized by the amount of enzyme used in the reaction. The specific 
activity was based on the measured mass of the ω-TAm present in each 
bioconversion. For whole cell experiments, this was calculated based on 50 % of the 
dry cell weight being protein (Watson, 1972), combined with data on the percentage 
of total protein that was determined to be ω-TAm by SDS-PAGE analysis described 
in Section 2.6.5. 
 
2.5.2. Preparative Scale Bioconversions 
 
Bioconversions at preparative scale (volumes of 30 mL) were performed in a 50 mL 
titration vessel with a thermostated jacket (Metrohm Ion Analysis, Switzerland) 
(Figure 2.2). Temperature was maintained at 30 
o
C using a circulating water bath 
(Grant Instruments, Cambridge, UK), mixing was achieved using a magnetic stirrer at 
300 rpm, and the pH was maintained at pH 7.5 by automated addition of 1 M NaOH 
using a 902 STAT Titrino pH controller (Metrohm Ion Analysis, Switzerland) with 
Tiamo 2.2 Workplace software. Sampling procedures were performed in the same 
way as in Section 2.5.1.  
 
2.5.3. Second Enzyme Reaction 
 
Bioconversions involving a second enzyme reaction were performed similarly as in 
Section 2.5.1. Reactions were carried out in HEPES buffer of various concentrations 
as discussed in Sections 4.5 and 5.6., pH 7.5. 0.5 g.L
-1
 CV2025 ω-TAm lysate with 
0.2 mM PLP co-factor solutions added first and left incubated for 20 min at 30 
o
C, 
prior to initiation of the reaction by the addition of 1.5 g.L
-1
 ADH, 0.025 g.L
-1
 GDH, 1 
mM NADPH, 50 mM MBA, 50 or 70 mM Ery and 70 mM glucose unless otherwise 
stated. All enzymes, co-factors and substrates concentrations were as specified, unless 
noted otherwise. Again, sampling procedures were performed in the same way as in 
Section 2.5.1.  The pH of the reaction solutions were measured using pH indicator 
papers (Universalindikator pH indicator pH 1 - 14, Merck Chemical Ltd., UK) at the 
end of each reaction period. 
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Figure 2.2. Preparative scale worktable layout used for ω-TAm bioconversions with second 
enzyme system (Section 6.3) and L-α-serine alternative amino donors (Section 6.4). The units 
operation involves the utilization of the reaction solution titration vessel placed on a magnetic 
stirrer for mixing purpose and connected to 902 STAT titrino pH controller and circulating 
water bath for pH and temperature control respectively. The 902 STAT titrino pH controller was 
controlled online by Tiamo 2.2 Workplace Software. 
 
 
2.5.4. Reduced Pressure Reaction 
 
Reduced pressure reactions carried out at 5 torr were performed using the same 300 
μL total reaction volume with 50 mM MBA, 50 or 70 mM Ery, 1 g.L-1 CV2025 ω-
TAm, 0.2 mM PLP and 50 mM HEPES buffer (pH 7.5) at 30 °C. For applying the 5 
torr reduced pressure conditions, a glass 96-microwell plate was placed in an 
automation compatibility 96-well vacuum manifold (Supelco, Sigma-Aldrich, 
Gillingham, UK) which was connected to the vacuum/ pressure pump (Millipore, 
Durham, UK) and placed in incubator (Gallenkamp Economy Size 2 Fan Incubator, 
Severn Sales, Bristol, UK) for temperature control as shown in Figure 2.3. Sampling 
procedures were performed in the same way as in Section 2.5.1.  The rate of water 
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evaporation was determined at this reduced pressure by measuring the weight loss 
over time.  The evaporation study was carried out under similar conditions as the 
bioconversion reaction described.  
 
 
 
Figure 2.3. Diagram of system used for bioconversion at reduced pressure. 
 
 
2.5.5. ISPR Resin Adsorption Isotherms and Bioconversions 
 
Prior to adsorption and bioconversion experiments the commercial adsorbents (Table 
2.5) used in this work as shown in Table 2.5 were conditioned as per the 
manufacturer’s guidelines. In order to first wet the particles dry adsorbent was 
transferred to a 250 mL beaker and methanol was added to fully cover the adsorbent 
bed. The adsorbent was stirred gently and then left to stand for 30 min. The methanol 
was then decanted off and RO water was added, again completely covering the 
adsorbent bed. The adsorbent was stirred again and left to stand for a further 30 min. 
The wash water was decanted off, and fresh RO water added. The adsorbent was left 
to stand in this condition until use. Before use, the adsorbent slurry was filtered, 
washed with several bed volumes of RO water and filtered again until the adsorbent 
was dry to touch. Wetted adsorbents were used throughout this research.  
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Table 2.5. The chemical and physical properties of commercially available absorbents 
investigated in this work. 
 
Adsorbent Chemical 
nature 
Mesh 
size 
Surface area 
(m
2
g
-1
) 
Wet density 
(g.mL
-1
) 
Pore volume 
(mL.g
-1
) 
XAD 7 Acrylic ester 20 - 60 450 1.05 1.14 
 
XAD 1180 polyaromatic 20 - 60 600 1.01 1.68 
 
XAD 16 polyaromatic 20 - 60 800 1.02 1.82 
 
 
Adsorption isotherms of each adsorbent were determined by weighing different 
amounts of adsorbent into a 96-microwell plate. The adsorbent in each well was then 
contacted with 300 µL of each substrate and product solution which were prepared in 
50 mM HEPES buffer, pH 7.5. The well-closed microwell plate was agitated at 500 
rpm at 30 ºC. In order to determine when equilibrium had been reached, several wells 
were prepared to contain equal amounts of adsorbent. Each well was sampled every 
30 min and analyzed by HPLC as stated in Section 2.6.6. Equation 2.1 was used to 
calculate q, the equilibrium solid phase concentration (ggads
-1
) of the solute in each 
sample. Ci and C are respectively the initial liquid phase concentration and the liquid 
phase concentration at equilibrium (g.l
-1
). V is the volume of the liquid phase (l) and 
M is the mass of wetted adsorbent in the experiment (g). 
                      
 
 
Bioconversions involving ISPR resin adsorption were performed as described in 
Section 2.5.1 but with the additional of wetted adsorbent resins at various mass 
loading (30 mg ,60 mg, 100 mg, 200 mg, 1000 mg) and were shaken at 500 rpm. In 
order to obtain kinetic profiles, reactions were conducted using a sacrificial well 
procedure, where for each reaction several identical reaction wells were prepared and 
the entire content of a single well was used for sampling at each time interval. At 
every sampling point, a portion of the reaction solution was quenched as described in 
Section 2.5.1 and kept for HPLC analysis. Any solution left in the well was discarded 
(filtered with 0.2 µm filter (Pall, MI, USA)), and the well was refilled with isopropyl 
alcohol (IPA) to desorb bound compounds. The adsorbent in isopropylalcohol 
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solution was left shaking on a thermomixer shaker for an hour prior to sampling for 
determination of concentrations of absorbed compounds onto resins by HPLC as 
described in Section 2.6.6. 
 
2.5.6. Automated Microscale Bioconversion Processes 
 
A Tecan platform (Tecan Genesis, Tecan UK Ltd, Berkshire, UK), equipped with an 
eight channel pipette arm and a Roma arm for plate manipulation was used for 
automated microscale process studies as shown in Figure 2.4. This was controlled 
using Gemini software. Disposable tips (200 µL and 1000 µL MBP
®
-BioRobotix
TM
 
Tips, VWR International Ltd., Magna Park, UK) was used for reagent addition.  
 
 
Figure 2.4. Tecan Genesis robotic platform. General views from (A) left side (B) right side. 
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The accuracy and precision of pipetting was checked before each experiment for the 
low viscosity liquids, and the dispense volumes used in this work and the error was 
less than 5 % in all cases (Chen et al., 2008; Micheletti et al., 2006). All the 
experiments were carried out in glass 96-well microtiter plates with reaction 
conditions as previously described in Sections 2.5.1, 2.5.3 and 2.5.4 unless otherwise 
stated. The microwell plate was covered with 5 layers of pre-cut pierceable films for 
robotics (X-Pierce
TM
, Excel Scientific Inc., Sigma, UK). Reaction temperature and 
shaking were likewise controlled by the Thermomixer Comfort shaker placed in a 
Class II robotic containment cabinet. The reduced pressure reaction which was 
performed using a Tecan vacuum separator (Te-VacS
TM
, Tecan UK Ltd, Berkshire, 
UK), was conducted at room temperature (23 ºC). Te-VacS
TM
 specification details are 
displays in Table 2.6. 
 
 
Table 2.6. Specifications of Te-VacS (http://www.tecan.com) used in Section 5.7. 
 
Compatibility Genesis Series and Freedom EVO®  
Integration onto Tecan 
platforms 
Vacuum block can be accessed by robotic manipulator and liquid 
handling arms 
Software control Gemini™, FACTS™, Freedom EVOware®  
Performance characteristics 
Capacity per Unit Te-VacS Two 96-well plates/cartridges 
Vacuum Max. pressure difference 700 mbar Max. effective flow rate 
22 l/min 
Waste container control Liquid level sensor 
Dimensions (L x W x H) 
Vacuum block 255 mm x 155 mm x 50 mm 
Waste bottle 160 mm x 160 mm x 530 mm 
Te-VacS tower for Te-VacS 300 mm x 700 mm x 340 mm 
Weight 
Vacuum block 3.3 kg 
Waste bottle 2 kg 
Te-VacS tower 12 kg 
Supply ratings 24V DC max. 192 W  
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For the bioconversion reactions 20 μL aliquots were taken at various time intervals 
and quenched with 380 μL of a 0.1 % (v/v) trifluoroacetic acid (TFA) solution. They 
were then sampled into another 96-deep well storage plate with capacity 2.2 mL 
(Anachem Ltd., Bedfordshire, UK). The plate was then centrifuged using Tecan 
automated centrifuge (Tecan UK Ltd, Berkshire, UK) integrated with the robotic 
platform for 10 min at 5000 rpm, and transferred into HPLC vials for further analysis. 
All HPLC analyses were conducted manually (off-line) as described in Section 2.6.6. 
The Tecan scripts for automated microscale processes can be found in Appendix IV. 
 
2.6. ANALYTICAL METHODS 
 
2.6.1. Dry Cell Weight (DCW) Measurement 
 
1.5 mL aliquots of cell suspension were added to pre-dried and pre-weighed 2.2 mL 
Eppendorf tubes which were then centrifuged at 13,000 rpm for 5 minutes (Eppendorf 
AG, Germany).  The supernatant was discarded, and the tubes were left to dry at 90 
o
C for 24 hours until they reached a constant weight. The biomass concentration in 
gdcw.L
-1
 of the culture could then be calculated. All analyses were performed in 
triplicate. 
 
2.6.2. Optical Density Measurements for Biomass Quantification 
 
Optical density measurements were performed at a wavelength of 600 nm (OD600) 
using an Ultraspec 4000 variable wavelength spectrophotometer (Pharmacia Biotech, 
USA). A small aliquot of E. coli BL21 culture medium was taken from the 
appropriate culture and diluted with RO water when needed so that the optical density 
measurement was between 0.1 - 0.8 absorbance units. A calibration curve relating the 
OD600 measurement (Section 2.6.1) from a serial dilution of broth sample to the 
corresponding gdcw.L
-1
 measurement was constructed and is shown in Appendix I. The 
calibration relationship determined was that 1 unit of (OD600) was equal to 0.4 gdcw.L
-
1
. 
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2.6.3. Bradford Assay Total Protein Quantification 
 
Protein concentrations of the lysates were obtained using the Bradford assay 
(Bradford, 1976) following the instructions of a commercial protein assay kit (Bio-
Rad Laboratories Inc., Hemel Hempstead, UK). The method is based on the 
proportional binding of the dye Coomassie blue to proteins. Within the linear range of 
the assay (~5 - 25 µg.mL
-1
), the more protein present, the more Coomassie binds. 
Furthermore, the assay is colorimetric, as the protein concentration increases, the 
color of the test sample becomes darker. The protein concentration was calibrated 
against the most widely used protein, bovine serum albumin (BSA) standard curve 
which was generated for each assay (Appendix II).  Absorbance measurements at 595 
nm were carried out on an ATI Unicam UV/VIS spectrophotometer (Spectronic, 
Leeds, United Kingdom).  
 
2.6.4. Purified Enzyme Quantification by UV Absorbance. 
 
The quantification of pure enzyme concentration was performed by UV absorbance at 
280 nm using an ATI Unicam UV/VIS spectrophotometer (Spectronic, Leeds, UK). 
Readings were blanked with the appropriate buffer solution. Absorbance 
measurements were converted to protein concentration using the Beer-Lambert law: 
 
A = ελc                Equation 2.2 
 
Where A was the absorbance at 280 nm, ε is the extinction coefficient previously 
determined as 78,000 M.cm
-1
 for ω-TAm  (Matosevic, 2009), λ was the path length 
equal to 1 cm, and c  was the protein concentration in mol.L
-1
.  
 
2.6.5. SDS-PAGE Electrophoresis 
 
SDS-PAGE for protein analysis was carried out on a Mini-Protean II system (Bio-Rad 
Laboratories Inc., Hemel Hempstead, UK) using 8 % (w/v) Tris-Glycine commercial 
gels (1.5 mm, 10 well, Invitrogen, Paisley, UK). TEO buffer was used as SDS PAGE 
sample buffer and the contents of which are described in Table 2.7. The different 
components were measured out and dissolved in RO water to 1 L. The prepared 1x 
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TEO buffer pH was 8.4 - 8.5 at 25 ºC and was diluted 20 times for use in SDS-page 
analysis.  
 
Table 2.7. Composition of 1 x TEO buffer used in Section 2.6.5. 
 
Component Concentration (g. L
-1
) 
Tricine  (free acid)          143.4 
Tris (free base) 145.4 
Sodium dodecyl sulphate (SDS) 20.0 
Sodium meta-bisulphate 5.2 
 
 
Clarified lysate or pure enzyme solutions were mixed (1:1) with Lamelli 2x 
concentrated protein sample buffer (Sigma-Aldrich, UK) and heated to 99 
o
C in a 
PCR machine (Techne LTD, Cambridge, UK) for 10 min. Samples were subsequently 
loaded onto the gel using 20 µL per well. A range of 15 to 20 µg of total protein was 
applied per lane to avoid saturation of the bands. 5µL of EZ-Run Prestained Rec 
Protein Ladder (Thermo Fisher Scientific Inc, UK) was always loaded in the first lane 
of the gel as protein molecular weight marker. 
 
The gel was stained with 50 mL of Coomassie Blue staining solution containing 0.1 % 
(w/v) Coomassie Blue R-250, 40 % (v/v) methanol and 10 % (v/v) acetic acid and it 
was microwaved for 1 min and left on orbital shaker (Luckham 4RT Rocking Table, 
Genetic Research Instrumentation Ltd., Essex, UK) for 15 - 30 min. After washing the 
Coomassie Blue solution, the gel was de-stained overnight on orbital shaker with a 
solution 10 % acetic acid and 40 % (v/v) methanol. All gels were visualized and 
quantified (where appropriate) on a Gel–Doc–it bioimaging system with Labworks 
4.5 software (Bioimaging systems, Cambridge) (Hierro et al., 2007). The software 
automatically detected and edited the splayed lanes, faint bands and tight doublets, 
and quantitate with a standard calibration curve from known amounts or individual 
lane lane loading using 1D Gel Analysis Tool. The software was also quickly 
measured the band instensities from uniform areas with accurate background 
substraction for expression analysis using Area Density Analysis Tool. 
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2.6.6. HPLC Methods 
 
A Dionex (Camberly, UK) microbore HPLC system controlled by Chromeleon client 
6.80 software was employed for all RP-HPLC analysis. This system is comprised of a 
P680 gradient pump, ASI-100 automated sampler injector, STH 585 column oven and 
UVD170U UV detector. 
 
MBA, AP and (R)-1-phenylethanol were analyzed using an ACE 5 C18 reverse phase 
column (150 mm x 4.6 mm, 5µm particle size, Advance Chromatography 
Technologies, Aberdeen, UK). A gradient was run from 15 % acetonitrile/ 85 % 0.1 
% (v/v) TFA to 72 % acetonitrile/ 28 % TFA over 8 min, followed by a re-equilibrium 
step for 2 min (oven temperature, 30 C, flow rate 1 mL.min-1). Detection was 
performed by UV absorption at 210 nm (MBA) and 250 nm (AP). The retention times 
(in min) under these conditions were MBA, 3.4 min, AP, 7.28 min and (R)-1-
phenylethanol 6.45 min.  
 
Ery and pyruvate were analysed with an Aminex HPX-87H Ion exchange column 
(300 mm x 7.8 mm, Biorad, Hemel Hampstead, UK). 0.1 % (v/v) TFA was used as 
mobile phase for isocratic elution with an oven temperature of 65 C and a flow rate 
of 0.6 mL.min
-1
. Detection was via electrochemical detection using a standard triple 
protection, after raising the pH to 11 - 12 by post column addition of 0.5 N NaOH 
(final flow rate of 1.2 mL.min
-1
).  The retention times of Ery and pyruvate are 11.63 
min and 10.43 min respectively. 
 
2−amino−1,3,4−butanetriol (ABT) and L-α-serine were analyzed using an ACE 5 
C18 reverse phase column with UV detection at 254 nm and oven temperature of 37 
C. Mobile phases used were A = 140 mM sodium acetate, pH 5.05 and B = 100 % 
acetonitrile. A gradient was run from 85 % A to 100 % A over 10 min, flow rate 0.5 
mL.min
-1
, followed by a column wash phase and re-equilibrium step at 1 mL.min
-1
. 
Samples for analysis were first derivatized using AQC as the derivatizing agent. This 
derivatezing agent was synthesized “in house" as previously described in Section 
2.4.3. Samples were mixed with borate buffer and briefly vortexed. A clean tip was 
used to reconstitute AQC reagent, which was first prepared prior to use by mixing 
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AQC reagent powder with dried acetonitrile as reagent diluent and heated at 55 C 
until the powder dissolves. The solution was then immediately vortexed 
(WhirliMixer
TM
, Fisons Scientific Equipment, Leicestershire, UK) for a few seconds 
and incubated at room temperature for 1 min prior to transfer to HPLC vial. The 
retention times of derivatized ABT and L-α-Serine were 8.9 min and 7.3 min 
respectively. Example chromatograms for each method and calibration curves for 
each of the above analysed compounds can be found in Appendix III. 
 
2.6.7. Mass Spectrometry 
 
Chemical ionisation (CI) mass spectrometry (Section 6.5) analyses were performed on 
a Thermo Finnigan MAT900xp.  Methane was used as carrier gas. Operating 
conditions: capillary temperature 300◦C, capillary voltage 9V, spray voltage 4.5 kV, 
sheath gas 80, auxiliary gas 30, and sweep gas 0 arbitrary units. Results are shown in 
Appendix V. 
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3. MICROSCALE QUANTIFICATION 
OF 
ω-TRANSAMINASE KINETICS 
 
 
 
 
 
 
 
3.1. INTRODUCTION 
 
As described in Section 1.4.4, the -TAm from C. violaceum DSM30191 (CV2025 
-TAm) is a Vibrio fluvialis-like amine transaminase that shows high 
enantioselectivity for chiral amines, such as S-α-methylbenzylamine, and 
demonstrated the highest activity with pyruvate as amine acceptor (Kaulmann et al., 
2007). While the CV2025 ω-TAm has been comprehensively studied with respect to 
substrate spectrum and its potential for ketodiol conversion (Kaulmann et al., 2007), 
there  are little kinetic data in the literature on its use for industrial bioconversions. 
Only the recent work of Rios et al. (2011), has begun to characterise the 
bioconversion kinetics, but with an emphasis on establishing two-step bioconversions 
rather than optimisation of the CV2025 ω-TAm reaction yield. 
 
To date most of the conventional, laboratory scale studies on the CV2025 ω-TAm 
have employed sealed glass vials of around 2 mL total volume and 1 mL working 
volume (Ingram et al., 2006). Conversion of these methods into microplate formats is 
worth further investigation as these would enable a further reduction in scale and the 
introduction of parallel operation. Adoption of microplate formats also facilitates the 
ready automation of ω-TAm experiments (Lye et al., 2003) and take advantage of the 
large commercial investment in laboratory robotics. The ability to relate 
bioconversion kinetics from conventional scales to the microscale would then 
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facilitate high throughput investigation and improve understanding of the key 
engineering parameters of ω-TAm bioconversion to aid efficient bioprocess design. 
 
The choice of a particular type of reaction to study between asymmetric synthesis 
from prochiral compounds and kinetic resolution from racemic compounds depends 
on the enantioselectivity of the enzyme and the economics of the reaction process 
(Section 1.4.8). -TAms which have sufficiently high enatioselectivity could lead to a 
useful asymmetric synthesis permitting the production of highly enantiopure chiral 
amines. The asymmetric synthesis of chiral amines with ω-TAm may also offer many 
potential advantages over kinetic resolution as described in Section 1.4.8.  
 
An accurate understanding of enzyme kinetic properties is a prerequisite for the 
effective optimisation of ω-TAm catalysed bioconversions. Here, the CV2025 ω-TAm 
catalysed bioconversion between MBA and pyruvate (Figure 3.1) was selected as an 
initial model reaction for study with the CV2025 ω-TAm. This is known to have a fast 
reaction rate with these substrates (Section 1.4.5) and is easily quantified by HPLC, 
(Section 2.6.6.) therefore, making it a good model for microscale evaluation of 
CV2025 ω-TAm reaction conditions, parameters and behaviours.  
 
 
 
 
 
Figure 3.1. Reaction yield scheme of the CV2025 ω-TAm catalyzed transamination between (S)-
-methylbenzylamine (MBA) and pyruvate to acetophenone (AP) and L-Alanine in the presence 
of co-factor, pyridoxal-5-phosphate (PLP).  
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3.2. AIM AND OBJECTIVES  
 
The aim of this Chapter was to develop microwell experimental methods for 
evaluation of the basic kinetic properties of the CV2025 ω-TAm from C. violaceum 
DSM30191 at the mircolitre scale (< 1 mL). The preliminary approach will involve 
investigations of a model reaction of MBA and pyruvate each at a relatively low 
substrate concentration of 50 mM each. Validated microwell scale methods for 
quantitative data generation could enable further investigation of enzyme mechanisms 
with different substrates under optimum reaction conditions to help overcome the low 
ω-TAm reaction yields. The key objectives of this Chapter are thus: 
 
 To initially increase CV2025 ω-TAm production in E. coli by optimisation of 
fermentation conditions for enzyme expression and to scale-up production of 
the biocatalyst from shake flask to 7.5 L stirred bioreactor scales. 
 
 Use of the published model of ω-TAm bioconversions to establish base-line 
bioconversion kinetics for conventional lab scale reactions. 
 
 To establish equivalent microscale experimental methods in 96-microwell 
plate formats for CV2025 ω-TAm bioconversions at the 300 µL scale and to 
compare these with the standard laboratory scale bioconversion kinetics. 
 
 To identify a suitable reaction system with readily analyzed substrates that 
displays typical, equilibrium controlled bioconversion kinetics that might be 
further developed or enhanced by microscale process design for overcoming 
unfavorable reaction equilibrium 
 
 
3.3. ω-TRANSAMINASE PRODUCTION AND LYSATE PREPARATION 
  
3.3.1. CV2025 ω-TAm Production at Shake Flask and 7.5 L Bioreactor Scales 
 
The growth and production studies of E.coli BL21 (DE3) Gold cells with plasmid 
pQR801 for expressing the CV2025 ω-TAm were accomplished in shake flask and 
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bioreactor scale fermentations. The shake flask fermentation was performed in a 2 L 
shake flask with a working volume of 200 mL. The fermentation procedure was 
detailed in Section 2.2.1 while the media used (LB-glycerol) was defined in Table 2.1. 
The shake flask scale fermentation was shown to reach typical final biomass 
concentration of 1.4 gdcw L
-1
. As observed in the growth curves (Figure 3.2), cells 
grew exponentially and the induction of CV2025 ω-TAm expression was achieved by 
the addition of 1 mM IPTG when an OD600nm of ~ 0.6 was reached. The cell growth 
reached a plateau once the stationary phase was reached after a period of 
approximately 7 hours. The fermentation was stopped and harvested 3 hours later. 
 
In order to increase the total volume of fermentation and the overall amount of 
CV2025 ω-TAm produced, the fermentation was scaled up to a 7.5 L stirred tank 
fermenter with a working volume of 5 L which was operated in a fed-batch mode 
(Section 2.2.3).  Fed-batch is the most common mode of fermentation operation in 
industry because it allows for control of the environment conditions and particularly 
maintenance of the glucose concentration at defined levels (Lemuth et al., 2008). 
Parameters like DOT, pH, temperature and impeller speed were logged throughout the 
fermentation. 
 
As shown in Figure 3.2, cells grew exponentially during the initial batch phase with a 
specific growth rate of 0.365 hr
-1
. Cell growth reached a plateau after 4 hours 
indicating limitation of a key nutrient. At this point feeding was started with pre-
sterilized medium containing 5 g.L
-1
 glycerol to promote further cell growth and 
hence a higher final cell density (Section 2.2.3). The detection of a sharp rise in the 
DOT profile at approximately 4 hours was also an indication of reduced oxygen 
consumption suggesting glycerol limitation in the growth medium. 
 
Following feed addition cells resumed growth almost instantaneously as indicated by 
both the increase in biomass dcw (Figure 3.2) and the reciprocal decrease DOT level 
(Figure 3.3).  1.0 mM IPTG was added to induce CV2025 ω-TAm synthesis after 7 
hours of fermentation when the OD600 of the broth reached 6.0 (3.4 gdcw.L
-1
). 0.2 mM 
PLP was also added to the broth at this point in order to study the effects of co-factor 
on CV2025  ω-TAm  expression  and  catalytic  activity. Cell  growth  continued  after 
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Figure 3.2. Growth kinetic profiles for E.coli BL21 (DE3) Gold cells containing plasmid 
pQR801 in a 2 L shake flask (■) and a 7.5 L bioreactor (♦) cell cultivation  scales with the fed-
batch operation. The temperature for both scales was set at 37 
o
C. Cell cultivation  conditions for 
the 7.5 L bioreactor were pH 7.5, 800 rpm and air flow of 1.4 L min
-1
. Cell cultivation  carried out 
as described in Sections 2.2.1 (Shake flask scale) and 2.2.3 (bioreactor scale). 
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Figure 3.3. Online measurement of pH (▲), temperature (x), DOT(■) and agitation rate (♦) for 
the 7.5 L fed-batch bioreactor fed-batch fermentation shown in Figure 3.2. Operating conditions 
and experimental procedure as described in Section 2.2.3.  
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feeding at a growth rate of 0.240 hr
-1
. As observed in the initial batch culture phase, 
the cell growth reached a stationary phase plateau after a further 4 hours, and hence a 
second batch of feed addition glycerol was supplied. The fermentation was continued 
for an hour and then stopped as decreases in agitation speed (which was controlled in 
a cascade manner by stirrer speed) as well as DOT level were observed. 
 
The maximum biomass concentration obtained in the first 7.5 L fermenter run was 6.9 
gdcw.L
-1
 which was about 6-fold higher than the corresponding shake flask culture 
described earlier. As expected, the improvement of cell growth rate was due to the 
improvement of oxygen transfer rates and better controlled environmental conditions 
in the stirred bioreactor. Above all, the fed-batch mode used for the addition of 
nutrient feeding as cell experienced nutrients shortage have proof to greatly enhance 
the growth rate. The effect of PLP addition on CV2025 ω-TAm catalytic activity is 
further discussed in Section 3.3.3. 
 
 
3.3.2. Characterization of CV2025 -TAm Synthesis 
 
At the end of the cultures, cells were lysed and total intracellular proteins were 
analysed using the Bradford assay (Section 2.6.3). Using a BSA standard curve 
(Appendix II), the total protein concentrations measured at the end of the shake flask 
and 7.5 L bioreactor cultures were 2.6 g.L
-1
 and 5.2 g.L
-1
 respectively indicating a 2-
fold increase in the stirred bioreactor. 
 
SDS-PAGE analysis of the soluble intracellular protein showed that the recombinant 
CV2025 -TAm migrated as a single band of approximately 47.5 kDa (Kaulmann et 
al., 2007). The CV2025 -TAm was seen to be expressed at a high level (Figure 3.4) 
making up some 40 % w/w (1.04 g.L
-1
) and 43 % w/w (2.22 g.L
-1
) of the protein in 
the clarified soluble fraction for the shake flask and 7.5 L bioreactor cultures 
respectively. All the bioconversion reactions with CV2025 ω-TAm in this research 
were carried out either using lysates from shake flask or 7.5 L bioreactor 
fermentations unless otherwise stated.  
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Figure 3.4. SDS-PAGE gels showing intracellular expression of CV2025 -TAm in cellular 
extracts of E. coli BL21 (DE3)-Gold cells. Lane 1 is protein marker, Lane 2 is protein expression 
from shake flask culture, Lane 3 is protein expression from 7.5 L bioreactor culture and Lane 4 
is protein expression from uninduced plasmid of E.coli BL21 (DE3)-Gold cells. Molecular weight 
of CV2025 ω-TAm is 47.5 kDa and for both culture scales it appears highlighted in the box. 
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3.3.3. Influence of Pyridoxal 5’ Phosphate (PLP) Addition 
 
Like other classes of transaminases (Section 1.4.2), -TAm requires PLP as a firmly 
bound prosthetic group. The addition of low concentrations of PLP to the enzyme 
solution enhances formation of E-PLP, resulting in enhancement of enzyme stability 
(Shin et al., 2003). Enzyme stability in the reaction mixture is a very important factor 
affecting bioconversion yield and productivity (Ingram et al., 2007; Shin et al., 2003). 
This is especially true in bioconversions lasting over 24 hours, which can be the case 
for the CV2025 ω-TAm with the majority of amino donors and amino acceptors 
(Smith et al., 2010; Ingram et al., 2007).   
 
The effect of PLP on enzyme stability was studied by comparison of CV2025 -TAm 
bioconversion kinetics using lysates produced from either the 7.5 L bioreactor or the 
shake flasks. CV2025 ω-TAm obtained from shake flask culture was added with 0.2 
mM PLP during centrifugation step in cell free lysate preparations (Section 2.3.1) and 
was incubated with the same concentration of PLP in bioconversion reactions prior to 
substrate addition (Section 2.5.1). 
 
In contrast, CV2025 ω-TAm produced from the bioreactor was synthesised in the 
presence of 0.2 mM PLP added from the start of the fermentation process (Section 
3.3.1). After harvesting, the process was followed by cell free lysate preparation 
(Section 2.3.1) in which PLP was again added prior to sonication and in centrifugation 
steps, and finally the lysate was incubated with PLP in the bioconversion reaction 
(Section 2.5.1). 
 
Figure 3.5 shows the experimental progress curves for the CV2025 ω-TAm catalysed 
bioconversion of 50 mM MBA and 50 mM pyruvate using biocatalyst produced in 
both the shake flasks and the 7.5 L fermenter with concentrations of 0.6 g.L
-1
 and 0.3 
g.L
-1
 CV2025 ω-TAm respectively. Good agreement was found between the 
experimental data, where the conversion was only much faster using the shake flask 
biocatalyst as expected due to its 2 times higher concentration of CV2025 ω-TAm 
(Section 3.3.2). Nevertheless, the specific initial rates of bioconversions with CV2025 
ω-TAm obtained from the fermenter were marginally higher than the shake flask 
scales  which  were  2.88  and  2.1  µmol.min
-1
.mg
-1
  respectively. The bioconversions  
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Figure 3.5. Bioconversion kinetics of CV2025 ω-TAm clarified lysates obtained from 2 L shake 
flask (where 0.3 mM PLP was added only during centrifugation step) and 7.5 L bioreactor 
fermentation (where 0.3 mM PLP was added during the fermentation process and during cell 
free lysate preparation) (Section 3.3.1): MBA consumption (■) and AP production (●) for 2 L 
shake flask cell culture and MBA consumption (♦) and AP production (▲) for 7.5 L bioreactor 
cell culture. Reaction conditions: 0.6 g.L
-1
  CV2025 ω-TAm for 2 L shake flask culture and 0.3 
g.L
-1
 CV2025 ω-TAm for 7.5 L bioreactor cells culture; 0.2 mM PLP; [MBA] and [pyruvate] 
were 50 mM each; 30 
º
C; pH 7.5; 300 rpm in 50 mM HEPES buffer; total volume of 300 µL in 
glass vials. Bioconversions performed as described in Section 2.5.1.  
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from both scales shown a comparable optimum conversion of approximately 60 % 
(mol.mol
-1
) reached at 16 min for biocatalyst from shake flask scale and 40 min for 
biocatalyst from bioreactor scale. This observation indicates the extra addition of PLP 
to the fermentation process and lysate preparation steps significantly improves the 
CV2025 -TAm catalytic activity. Therefore, the CV2025 ω-TAm concentration of 
0.3 g.L
-1
 was chosen as a standard parameter for investigating the CV2025 ω-TAm 
bioconversions further throughout the study. 
  
3.3.4. Stability of Stored and Fresh Cells Lysate  
 
CV2025 ω-TAm bioconversions using fresh lysate and stored lysate frozen at -80 C 
were performed to examine their effect on enzyme stability. Hence, both types of 
clarified lysates were used to catalyse the bioconversion of 50 mM MBA and 50 mM 
pyruvate. As shown in Figure 3.6, the frozen lysate was stable for at least 6 months as 
the reaction kinetics showed no significant difference to those using freshly prepared 
CV2025 ω-TAm lysate. The stored lysate used here was obtained from the 7.5 L 
bioreactor fermentation (Section 3.3.1). Accordingly, the addition of an excess PLP 
during the fermentation (Section 3.3.3) may be one of the factors responsible for 
ensuring the long-term stability of CV2025 ω-TAm activity during storage.  
 
As a consequent of these results, either fresh or stored lysate were used throughout 
this study interchangeably. In general, the storage stability can vary from a few weeks 
to more than a year and is dependent on the nature of the protein and the storage 
conditions used. Freeze-thaw cycles are known to compromise protein stability. 
Repeated freeze-thaw cycles will cause protein damage due to ice crystal formation 
during freezing that can lead to protein denaturation and also cause a loss of 
phosphate groups (Cao et al., 2003). Therefore, the lysates prepared here for frozen 
storage were initially dispensed and prepared in single-use aliquots so that repeated 
freeze-thaw cycles were avoided. 
 
The same practice was applied in preparing frozen stock solutions of substrates, 
products and others compounds used in this research. In these cases, the compounds 
were prepared in the desired type and concentration of buffer and were adjusted to the  
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Figure 3.6. Bioconversion kinetics using either fresh or stored clarified CV2025 ω-TAm lysates 
(6 months at – 80 ºC): MBA consumption (♦) and AP production (■) for fresh clarified lysate and 
MBA consumption (▲) and AP production (●) for stored clarified lysate. Reaction conditions: 
0.3 g.L
-1
 CV2025 ω-TAm; 0.2 mM PLP; [MBA] and [pyruvate] were 50 mM; 30 ºC; pH 7.5; 300 
rpm in 50 mM HEPES buffer; total volume of 300 µL in glass vials. Stored lysate obtained from 
7.5 L bioreactor fermentation (Section 3.3.1) and bioconversions performed as described in 
Section 2.5.1. Error bars represent one standard deviation about the mean (n=3). 
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desired pH prior to storage at -20 C. Control experiments showed that freezing of 
these stock solutions for up to 6 months had no significant impact on the CV2025 ω-
TAm bioconversion kinetics. 
 
3.4. IDENTIFICATION OF LEAD ω-TRANSAMINASE AND INITIAL 
BIOCONVERSION CONDITIONS 
 
3.4.1. Activity of His-tagged (PQR801) and non His-tagged (PQR800) CV2025 
ω-TAm 
 
Labelling of recombinant proteins with polypeptide fusion partners or affinity tags is a 
useful method to facilitate subsequent protein purification and detection. Poly-
histidine tags (His-tags) are among the most commonly used affinity tags (Heijbel, 
2003). Plasmid pQR801 expressing the CV2025 ω-TAm enzyme was therefore 
constructed with a His6-tag at the enzyme’s N-terminus to facilitate rapid single-step 
purification using His-Select Nickel Affinity Gel, an immobilized metal-ion affinity 
chromatography (IMAC) product. The use of IMAC to rapidly purify His-tagged 
proteins is widely used as a tool for simple and inexpensive production of large 
quantities of pure industrial enzymes (Benevides et at., 2003; Bastida, et al., 1998; 
Crowe et al., 1994; Porath et al., 1975).  
 
CV2025 ω-TAm clarified lysates obtained from two different plasmids pQR800 (non 
His-tagged protein) and pQR801 (His-tagged protein) were used in a comparative 
study to check that there were no detrimental effects of adding the His-tag on CV2025 
ω-TAm activity and stability. As shown in Figure 3.7, both enzyme preparations 
showed similar bioconversion kinetics with 50 mM MBA and 50 mM pyruvate as 
substrates. The non His-tagged CV2025 ω-TAm showed marginally higher AP 
production rates while the MBA consumption rates were similar. The slightly higher 
AP production measured for the non His-tagged enzyme (CV2025 ω-TAm with 
plasmid pQR800) is most probably due to experimental errors caused by the way in 
which reaction samples were treated particularly regarding AP evaporation during 
sample storage and HPLC analysis. Overall, the results suggest that the poly-His tag 
fusion did not affect the activity and stability of the CV2025 ω-TAm  and  so enzymes  
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Figure 3.7. Bioconversion kinetics of CV2025 ω-TAm clarified lysates prepared using plasmids 
pQR 800 (non His-tagged) and pQR801 (His-tagged): MBA consumption (▲) and AP production 
(♦) for non His-tagged lysate and MBA consumption (●) and AP production (■) for His-tagged 
lysate. Reaction conditions: 0.3 g.L
-1
 CV2025 ω-TAm; 0.2 mM PLP; [MBA] and [pyruvate] were 
50 mM; 30 
º
C; pH 7.5; 300 rpm in 50 mM HEPES buffer; total volume of 300 µL in glass vials. 
Bioconversions performed as described in Section 2.5.1. Error bars represent one standard 
deviation about the mean (n=3). 
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preparations used during the remainder of this research were prepared from His-
tagged plasmids. 
 
3.4.2.  Activity Determination at Laboratory and Microwell Scales 
 
Previous laboratory studies on CV2025 ω-TAm bioconversions were performed using 
conventional 2 mL, flat bottom, snap-cap vials (Section 2.5.1). These come with a 
wide selection of sealing caps appropriate for an excellent seal preventing 
evaporation. The vials are Class 1 hydrolytic extraction neutral borosilicate glass to 
give assurance of sample stability and low extraction of compounds in liquid samples 
making them appropriate when dealing with compounds such as MBA which is 
known to degrade plastic vials. In developing an equivalent high-throughput 
microscale approach, microwell plate formats will be employed. These are typically 
manufactured in a range of well densities (6 – 1536 wells) and materials. The 
advantages include the available range of microtitre plates and associated equipment 
such as multi-channel pipettes, laboratory robotic platforms, microplate readers and 
HPLC autosamplers. 
 
Consequently, a comparative study to translate the conventional CV2025 ω-TAm 
bioconversion method into an effective 96-microwell plate format was performed. 
Choices of plate type, material and options for sealing individual wells were among 
the major factors for consideration. The material used for sealing individual wells 
within the plate can have a significant effect on the overall performance of the 
reaction system. Without an effective seal, loss of volatile components such as AP, 
from the reaction mixture will impact on reaction kinetics, equilibrium and analysis. 
As mentioned in Section 2.5.1, a glass, 96-microwell plate was used which shows the 
good compatibility with most type of solvents and resistance to chemical attack. Wells 
were sealed using a thermo plastic elastomer cap to prevent evaporation.  
 
The CV2025 ω-TAm is more stable as a lysate instead of purified enzyme hence this 
form of the biocatalyst was used (Ingram et al., 2007). Similarly to the previous 
extensive studied ω-TAm from Vibrio fluvialis (Shin and Kim, 2001), substrate 
inhibition of the CV2025 ω-TAm by MBA and pyruvate was not observed below 100 
mM. Reaction solutions containing 50 mM each of MBA and pyruvate were thus used 
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to examine bioconversion kinetics in the microwell format and standard vials. Again, 
both reactions were performed as previously described in Section 2.5.1. 
 
In experiments with both formats containers were sealed throughout the reaction and 
the covers were only peeled off at each sampling point. Overall CV2025 ω-TAm 
bioconversions performed using either conventional standard glass vials or 96-well 
plates showed suitably comparable results. The initial rates determined in both 
reaction formats were maximised up to 30 to 40 min of reaction (Figure 3.8). After 
approximately 60 % (mol.mol
-1
) conversion, the product concentrations peaked and 
then decreased slightly in the last 3 time points. This is most probably because some 
AP had evaporated out of the system during sample preparation and analysis.  
 
In previous work, it was found that the bioconversion of 50 mM MBA and 50 mM 
pyruvate catalysed by the ω-TAm from Bacillus thuringiensis JS64 gave almost 
quantitative bioconversion since the equilibrium completely favours product 
formation in the forward direction producing L-alanine (Shin and Kim, 1998; 
Kaulmann et al., 2007). This was not the case using the CV2025 ω-TAm. The product 
inhibition exerted by AP could be the major cause for the incomplete conversion 
attained (Shin and Kim, 1998). This assumption is confirmed later in Section 4.3 and 
methods to remove AP during the reaction so as to increase yield are explored in 
Chapters 4 and 5.  
 
3.4.3. Influence of pH 
 
The effect of pH on CV2025 ω-TAm activity in both clarified lysate and whole cell 
forms were investigated as shown in Figure 3.9.  The optimum pH for activity of the 
CV2025 ω-TAm lysate appears to be about pH 7.5. This is in agreement with the 
previous work using CV2025 ω-TAm for the synthesis of (2S, 3S)-2-aminopentane-1, 
3-diol from (3)-1,3-dihydroxypentane-2-one and isopropylamine substrates (Smith et 
al., 2010). In contrast, for the whole cell CV2025 ω-TAm, the enzyme activity 
remained almost unaffected at all pH values tested apart from at pH 8 where a 
significantly lower activity was measured. This is because the internal environment of 
the cell is still much closer to neutral and is usually fairly insensitive to the external 
environment (Guo et al., 2009b). 
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Figure 3.8. Bioconversion kinetics for CV2025 ω-TAm clarified lysate performed in glass vials 
and 96-well glass microplate formats: MBA consumption (♦) and AP production (▲) for vial 
format and MBA consumption (■) and AP production (●) for 96-micowell plate format. Reaction 
conditions: 0.3 g.L
-1
 CV2025 ω-TAm; 0.2 mM PLP; [MBA] and [pyruvate] were 50 mM; 30 ºC; 
pH 7.5; 300 rpm in 50 mM HEPES buffer; total volume of 300 µL, CV2025 ω-TAm obtained 
from 7.5 L bioreactor fermentation (Section 3.3.1) and bioconversions performed as described in 
Section 2.5.1. Error bars represent one standard deviation about the mean (n=3). 
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Figure 3.9. Effect of pH on the initial rate of AP production by clarified CV2025 ω-TAm lysate 
(▲) and whole cells (■) of E. coli with plasmid pQR801 expressing CV2025 ω-TAm. Reaction 
conditions: [MBA] and [pyruvate] were 50 mM; 30 
o
C; 300 rpm in 50 mM HEPES buffer; total 
volume of 300 µL in 96-glass microwell plate. Bioconversions performed as described in Section 
2.5.1. Error bars represent one standard deviation about the mean (n=3). 
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3.5. L-ERYTHRULOSE (ERY) BIOCONVERSION KINETICS 
 
3.5.1. Kinetic Profile of CV2025 ω-TAm Bioconversion  
 
In the previous sections pyruvate was used as substrate in order to develop the 
microscale experimental methods to be used throughput this thesis. However, most 
industrially relevant substrates tend to show poor equilibrium conversions (Tufvesson 
et al., 2011; Buchholz et al., 2005). Since the major aim of this thesis is to explore 
microscale methods to increase ω-TAm bioconversion yields, a new reaction model 
was chosen for investigation.  
 
The particular bioconversion investigated will use Ery as amino acceptor (Figure 
3.10). Among various amino acceptors tested in a previous study (Kaulmann et al., 
2007), Ery shows a low conversion yield of just 14 - 22 % at reaction equilibrium 
(Table 1.2 (Chapter 1.4.7)).  
 
 
Figure 3.10. Reaction yield scheme of the CV2025 ω-TAm catalyzed transamination between 
(S)--methylbenzylamine (MBA) and L-erythrulose (Ery) to acetophenone (AP) and 2-amino-
1,3,4-butanetriol (ABT) in the presence of co-factor pyridoxal-5-phosphate (PLP).  
 
 
As discussed in Section 3.4.2, experiments will be performed in a 96-well glass 
microtitre plate covered with a thermo plastic elastomer cap for closed environment 
conditions. In addition, based on all the previous studies, the reaction conditions 
selected for this preliminary reaction evaluation were 30 
o
C, pH 7.5 in 50 mM HEPES 
  
 114 
 
buffer using a clarified CV2025 ω-TAm lysate produced from plasmid pQR801 (His-
tagged). The biocatalyst was produced in a single 7.5 L fermentation (Section 3.3.1) 
so as to provide a continuous and stable source of CV2025 ω-TAm for use in all 
subsequent studies.  
 
The CV2025 ω-TAm bioconversion was conducted as detailed in Section 2.5.1. A 
complete kinetic profile comprising depletion of both substrates and formation of both 
products were plotted here for more precise analysis of the actual data attained (Figure 
3.11). In order to quantify the ABT product a derivitization method using AQC 
reagent (Section 2.4.3) was used prior to HPLC analysis (Section 2.6.6).  
 
As shown in Figure 3.11, after 15 hours, the final reaction yield was only 26 % 
(mol.mol
-1
). This is about half that obtained in the previous reactions with pyruvate as 
amino acceptor. The low conversion observed here underlines the unfavourable 
equilibrium seen with many ω-TAm substrates which may also be influenced by 
strong by-product (AP) inhibition (Section 1.4.9). This reaction therefore provides a 
useful and relevant model system by which to investigate methods for increasing the 
bioconversion yield.   
 
 
3.5.2. Influence of Biocatalyst Form: Clarified Lysate and Whole Cells 
 
The kinetics of the Ery bioconversion using the CV2025 ω-TAm were further studied 
to evaluate both isolated enzyme and whole cell forms of the biocatalyst. Whole cell 
biocatalysts are easier to prepare, but in developing whole-cell biocatalytic processes, 
it is becoming important to consider the effects of medium, process conditions, 
substrates, and products, on cell physiology, enzyme activity, and cofactor 
regeneration (Held et al., 2000).  
 
As shown in Figure 3.12 the whole cell CV2025 ω-TAm biocatalyst showed a better 
performance than the clarified lysates for bioconversion of 50 mM MBA and 50 mM 
Ery. Typical reactions kinetic profiles of CV2025 ω-TAm bioconversions in the case 
of whole cell  and clarified  lysate forms are  preceded with optimum product yield of 
40 % (mol.mol
-1
) and 26 % (mol.mol
-1
) respectively.  
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Figure 3.11. Bioconversion kinetics using CV2025 ω-TAm clarified lysate with Ery as amino 
acceptor: MBA consumption (●); Ery consumption (-); ABT production (▲) and AP production 
(■). Reaction conditions: 0.3 g.L-1  CV2025 ω-TAm; 0.2 mM PLP; [MBA] and [Ery] were 50 
mM; 30 
º
C; pH 7.5; 300 rpm in 50 mM HEPES buffer; total volume of 300 µL in 96-glass 
microwell plate. Biocatalyst obtained from 7.5 L bioreactor fermentation (Section 3.3.1) and 
bioconversions performed as described in Section 2.5.1. Error bars represent one standard 
deviation about the mean (n=3). 
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Figure 3.12. Bioconversion kinetics of CV2025 ω-TAm in whole cell and clarified lysate forms: 
Ery consumption (▲) and ABT production (●) for clarified lysate and Ery consumption (■) and 
ABT production (♦) for 96-micowell plate format. Reaction conditions: 0.3 g.L-1  CV2025 ω-
TAm; 0.2 mM PLP; [MBA] and [Ery] were 50 mM; 30 
º
C; pH 7.5; 300 rpm in 50 mM HEPES 
buffer; total volume of 300 µL in 96-glass microwell plate. Bioconversions performed as 
described in Section 2.5.1. Error bars represent one standard deviation about the mean (n=3). 
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Previous ω-transaminases bioconversions studies also reported the same outcome 40 
% (mol.mol
-1
) and 26 % (mol.mol
-1
) respectively. Previous ω-transaminases 
bioconversions studies also reported the same outcome attributed to an increase in 
stability of the enzyme inside the cell (Shin and Kim, 1997), metabolism consumption 
of inhibitory compounds (Shin and Kim, 1999) and the effect of the cell membrane in 
partitioning inhibitory components between the inside and outside of the cell (Yun et 
al., 2004).  
 
The high cell yield, the low production costs (i.e cheap biomass), and the processes 
are usually robust would appear to favour the application of whole cell biocatalyst 
industrially.  However, the organisms have to be cultivated, side reactions are 
common, and purification steps involve cell removal and product extraction from a 
possibly complex medium (Sanchez and Demain, 2011). Further, in developing high 
throughput rapid screening processes, the whole cell versus clarified lysate form 
might appear inconsequential as the processes are more complicated and hence time 
consuming. Thus, CV2025 ω-TAm in clarified lysate form has more potential of 
achieving true preparative relevance for this project enables quicker, simpler and 
rapid microscale technique processes for identification of ω-TAm catalytic activity 
and its subsequent improvement.  
 
 
3.6. SUMMARY 
 
The work performed in this initial chapter demonstrated the utility of microscale 
reaction formats for the quantitative study of CV2025 ω-TAm bioconversion kinetics. 
This now provides a basis for studies in subsequent chapters of the thesis.  
 
For biocatalyst production, fed-batch fermentation is advantageous for providing a 
large and constant source of biocatalyst (Section 3.3.1). In comparison to shake flask 
culture, CV2025 ω-TAm expressed in bioreactor with the fed-batch supply of PLP 
(Section 3.3.2) was benefited as it helped tremendously to increase CV2025 ω-TAm  
 
catalytic activity (Section 3.3.3). Moreover, the CV2025 ω-TAm expressed from his-
tagged labelled plasmid (pQR801) shown an equivalent activity to non his-tagged 
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CV2025 ω-TAm (pQR800) (Section 3.4.1). CV2025 ω-TAm bioconversions of MBA 
with Ery as amino acceptor (Section 3.5.1) showed more typical unfavourable 
equilibrium control than with pyruvate as verified by its relatively lesser reaction 
yield observed. Beside chemical equilibrium, the incomplete transamination might 
also be due to acceptor reactivity, poor substrate / product solubility and inhibition 
effects.  
 
In summary, the validated method and technique of the reaction in the conventional 
vial format was successfully mimicked into 96-glass microwell plate format. The 
comparable CV2025 ω-TAm bioconversion reactions presented by both formats 
(Section 3.4.2) suggest that the microwell plate format can be developed as a 
promising method for further exploring ω-TAm biocatalysts potentials in manual 
conventional method as well as automation platform. 
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4. MICROSCALE PROCESS OPTIONS 
TO INCREASE ω-TAm 
BIOCONVERSION YIELDS 
 
 
 
 
4.1. INTRODUCTION 
 
Biocatalytic processes (Section 1.2) are becoming increasingly competitive with 
conventional organic syntheses and have been used in industry for preparing optically 
pure amine enantiomers (Section 1.3) showing various pharmacological properties 
(Sutin, 2007; Koszelewski et al., 2008). Enantioenriched amines can be produced by 
either asymmetric synthesis (Shin and Kim, 1999) using an achiral ketone (i.e 
amination of the ketone) or via kinetic resolution of a racemic amine (i.e 
stereoselective deamination of the unwanted isomer) (Shin and Kim, 1997).  
 
The direct asymmetric synthesis of chiral amines using an ω-transaminase potentially 
offers significant advantages over chemical syntheses or kinetic resolution (Section 
1.4.8).  Nevertheless, certain challenges must be addressed (Section 1.4.9). These 
relate to the speed of biocatalytic process development (relative to chemical 
processes) and the need to (i) shift the reaction equilibrium to product formation and 
(ii) overcome issues of product inhibition (Shin and Kim, 1997; Shin and Kim, 1999). 
These challenges currently hinder attainment of high substrate conversion yields and 
the attainment of high product concentrations (Shin and Kim, 1998). 
 
A number of recent publications have begun to address the issues of shifting the 
equilibrium towards product formation for ω-TAm catalysed bioconversions (Truppo 
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and Turner, 2010; Truppo et al., 2009; Hohne et al., 2008; Yun et al., 2003). 
Examples include the use of a second enzyme system and auto degradation of bi-
product (Section 1.4.10). While benefits have been reported in each case the 
implementation of such methods requires considerable further experimentation to 
optimise bioconversion conditions. Figure 4.1 summarises some of the potential 
process options available to overcome low yielding, equilibrium-controlled ω-TAm 
reactions or those with inhibitory substrates or products. The focus in this chapter will 
be the creation of novel microscale experimental methods to enable the rapid and 
parallel evaluation of the different process options. Such approaches would provide 
the data necessary for early stage process design and economic evaluation. 
 
 
 
Figure 4.1. Overview of potential process options to increase the yield of equilibrium-controlled 
ω-TAm bioconversions. 
 
 
4.2. AIM AND OBJECTIVES 
 
The aim of this chapter is to establish a series of novel microscale methods to enable 
experimental evaluation of the different process options identified in Figure 4.1. The 
feasibility of these approaches will be investigated for the CV2025 ω-TAm catalyzed 
asymmetric synthesis of chiral amines using Ery as substrate and MBA as the initial 
amine donor. The methods to be established here will enable selective removal of 
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inhibitory by-products and evaluation of different amine donors. The key objectives 
of this chapter are thus: 
 
 To confirm by-product inhibition to the CV2025 ω-TAm bioconversion by 
AP.  
 
 To identify alternative amino donors and establish microscale methods to 
evaluate their impact of overall bioconversions yields.  
 
 To develop micorscale methods for enzymatic in-situ product removal of 
inhibitory by-products such as AP, in this case by applying a second enzyme, 
ADH to catalyze AP reduction into (R)-1-phenylethanol and hence shift the 
reaction towards product formation. 
 
 To develop microscale physical in-situ product removal methods for volatile 
products or by-products by promoting evaporation under reduced pressure.  
 
 To develop microscale physical in-situ product removal methods based on the 
introduction of adsorbent resins for selective binding of unwanted by-product 
overcoming inhibitory of equilibrium limitations.  
 
 
4.3. STANDARD CV2025 ω-TAM BIOCONVERSION KINETICS AND 
YIELD 
 
In order to illustrate the problem of low yielding, equilibrium-controlled reactions 
initial experiments with CV2025 ω-TAm were performed at equilmolar substrate 
concentrations as described in Section 3.5.1. In this case, only 26 % (mol.mol
-1
) 
conversions were achieved when 50 mM of each substrate MBA and Ery were used.  
 
The inhibition of CV2025 ω-TAm by the amine by-product (AP) is believed to be one 
of the reasons why the conversion does not progress to completion as shown in Figure 
4.3. This inhibition study was performed by exogenously adding increasing amounts 
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of AP into the reaction mixture before the biotransformation reaction proceed. 
Product inhibition (Section 1.4.9) results from the formation of a Michaelis complex 
between AP and the ω-transaminase enzyme. This is due to the reversibility of 
enzyme reaction, where product can bind to the enzyme and thus reduces the chances 
of substrate binding to the enzyme active site. In similar experiments with exogenous 
addition of increasing amounts of MBA or Ery, inhibitory effects on reaction kinetics 
were not observed at concentrations below 100mM (Rios et al., 2011) and so these 
can be considered negligible relative to AP by-product inhibition.  
 
To increase the product yield, four approaches were subsequently evaluated: 
evaluation of alternative amino donors, use of a second enzyme system, and physical 
ISPR methods via reaction under reduced pressure and the use of adsorbent resins. 
These are illustrated in Figure 4.2. The aim is to selectively remove AP from the 
reaction system, thereby overcoming the inhibition effects and also shifting the 
reaction equilibrium to the right increasing the final yield of the desired product, 
ABT. These method approaches will each be developed to operate at 300 µL scale in 
96-glass microwell scale as described earlier in Chapter 3. The conversion yield (26% 
(mol.mol
-1
)) attained from equimolar bioconversion of MBA and Ery at 50 mM will 
be considered the baseline against which potential improvements in bioconversion 
yield can be evaluated. 
  
 
4.4. EVALUATION OF ALTERNATIVE AMINO DONORS 
 
Kaulmann and co-workers (2007) have previously reported on the specificities of 
CV2025 ω-TAm towards various amino donors (Section 1.4.7). Their study was 
based on relative initial rates using 10 mM Pyruvate as amino acceptor (Table 1.1) 
instead of Ery. Their work nevertheless provides insight into the selection of potential 
alternative amino donors for use with ERY.  
 
Five amino donors were investigated, as an alternative to MBA as used in the standard 
CV2025 ω-TAm bioconversion. The main aim was to identify amino donors leading 
to reduced by-product inhibition. Furthermore, in industrial asymmetric synthesis the 
choice  of  amino  donor  is  important  as  this  will impact on the overall process cost  
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Figure 4.2. Process options investigated in this work at microwell scale to overcome thermodynamic and equilibrium limitations of the CV2025 ω-TAm 
bioconversion. 
 
  
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Quantification of product inhibition effects by AP.  Reactions were carried out 
with equilmolar MBA and Ery at 50 mM by the addition of specified concentration of AP (0, 10, 
20, 30, 40 mM) prior to start of the CV2025 ω-TAm bioconversion.  Reaction conditions: 0.3 g.L-
1
 CV2025 ω-TAm in lysate form; 0.2 mM PLP; 30 ºC; pH 7.5; 300 rpm in 50 mM HEPES buffer; 
total volume of 300 µL in 96-glass microwell plate. Bioconversions performed as described in 
Section 2.5.1.  
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(Shin and Kim, 1999). Table 4.1 summarises the properties of the alternative amino 
donors selected. These were investigated for the transamination of Ery at equilmolar 
concentrations of 50 mM of each substrate. As depicted in Figure 4.4 the results from 
CV2025 ω-TAm bioconversions with Ery as the amino acceptor, showed higher 
conversion yields towards all tested alternative compounds with the exception the 
aromatic amino donor Benzylamine. 
 
Table 4.1.  Amino donors selected for study on the equilibrium yield of Ery transamination by 
CV2025 ω-TAm. 
 
Amino donor Chemical Formula  Chemical 
Structure 
 
Amines 
 
S-(+)-α-metylbenzylamine 
(MBA) 
 
C8H11N 
 
 
 
 
 
 
Isopropylamine  
 
 
(CH3)2CH2NH2 
 
 
 
 
Benzylamine 
 
C6H5CH2NH2 
 
 
 
 
 
S-(+)-sec-butylamine 
 
C2H5CH(NH2)CH3 
 
 
 
 
 
S-(+)-1-aminoindan 
 
C9H11N 
 
 
 
 
 
Amino 
acid 
 
L-α-serine 
 
 
C3H7NO3 
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Figure 4.4. Effect of alternative amino donors on ABT product formation kinetics for the 
profile of CV2025 ω-TAm clarified lysate bioconversions of Ery with alternative amino donors 
(Section 4.4) which were: MBA (♦); isopropylamine (■); benzylamine (●); S-(+)-sec-butylamine 
(- - -); S-(+)-1-aminoindane ( ) and L-α-serine (▲). Reaction conditions: 0.3 g.L-1 CV2025 ω-
TAm in lysate form; 0.2 mM PLP; [amino donor] and [Ery] were 50 mM; 30 
º
C; pH 7.5; 300 
rpm in 50 mM HEPES buffer; total volume of 300 µL in 96-glass microwell plate. 
Bioconversions performed as described in Section 2.5.1. Error bars represent one standard 
deviation about the mean (n=3). 
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When MBA was substituted with the much cheaper, more volatile, and more water-
soluble substrate, isopropylamine, a nearly 3-fold increase in final bioconversion yield 
was attained. This is most probably because the by-product in this case (acetone) is 
less inhibitory and more volatile than AP. Nevertheless the reaction required a longer 
time, more or less double the period of the standard reaction, to reach completion. It is 
anticipated that a similar reaction yield can be obtained in a shorter period by using a 
more concentrated CV2025 ω-TAm lysate. Different substrate ratios, for instance an 
increased concentration of amino donor, could also be expected to promote higher 
reaction rates (Smith et al., 2010; Rios et al., 2011). Additionally isopropylamine and 
its by-product, acetone, could be more easily removed downstream owing to their 
high volatilities compared to aromatic amine donors (Smith et al., 2010). 
 
A final product concentration of 20 mM ABT was detected when another aliphatic 
amine, S-(+)-1-sec-butylamine was used as an alternative amino donor. This 
represents a 14 % (mol.mol
-1
) increase in the reaction yield compared to the standard 
reaction. This result however contradicts the earlier works based on initial rates, 
which indicated a lower rate than with MBA as amino donor (Kaulmann et al., 2007; 
Shin et al., 2003). 
 
MBA was next substituted with two other aromatic amino donors; S-(+)-1-
aminoindan and benzylamine. CV2025 ω-TAm bioconversion with S-(+)-1-
aminoindane showed nearly an equal conversion yield to the reaction with S-(+)-1-
sec-butylamine. These observations once again confirm the good reactivity of 
CV2025 ω-TAm towards a broad range of (S)-amines that could be potentially useful 
(Section 1.4.7) for the production of enantiopure amines and amino alcohols 
(Kaulmann et al., 2007; Yun et al., 2005; Yun et al., 2003; Shin et al., 2001; Shin and 
Kim, 1999). Using benzylamine as amine donor for transamination of Ery yielded a 
yield of approximately 8 % (mol.mol
-1
) considerably lower than with MBA.  
 
Finally, using L-α-Serine, a naturally occurring amino acid, an increased reaction 
yield of 46 % (mol.mol
-1
) was obtained. The use of amino acids as an amine donor is 
noteworthy considering their availability at relatively low cost and the strategies 
available for their selective extraction (Kaulmann et al., 2007). Therefore, the 
transamination of Ery could be further examined with other amino acids and their 
  
 128 
 
derivatives such as L-α-alanine, 6-aminohexanoic acid and γ-aminobutyric acid which 
were previously tested (Kaulmann et al., 2007) and gave promising results based on 
initial reaction rates.  
 
In summary, of the five alternative amine donors tested, four of them showed good 
conversion with Ery to ABT. Some proved to be very effective being both cheaper 
than MBA (isopropylamine and L-α-Serine) and giving significantly enhanced 
reaction yields. These positive results suggest screening of alternative amino donors is 
likely to be a simple, quick and reliable option for helping to optimise ω-TAm 
bioconversion yields.   
 
 
4.5. SECOND ENZYME SYSTEM 
 
For in-situ removal of the inhibitory AP, one option is to reduce it to the chiral 
alcohol, (R)-1-phenylethanol by applying a second enzyme, ADH (Figure 4.2). 
Coupling ADH with ω-TAm has previously been shown to help alleviate reaction 
inhibition and also provide access to the synthesis of chiral alcohols (Yun et al., 
2003). ADHs is biocatalysts that been previously used for the synthesis of optically 
pure compounds by reduction of prostereogenic ketones to the corresponding 
optically active alcohol (Yun et al., 2003; Koeller and Wong, 2001; Hummel, 1999). 
However, in this study the aim is to utilise ADH to establish an efficient micro-scale 
solution for in situ removal of an inhibitory by-product by conversion into a non-
inhibitory compound and hence to shift the reaction equilibrium towards completion.   
 
The commercially available ADH from Lactobacillus kefir selected for this study is a 
NADPH-dependent enzyme (Bradshaw et al., 1992). As this co-factor is expensive, an 
effective and economically viable co-factor regeneration system also needs to be 
implemented.  In general, there are two methods to recycle the co-factor, which are a 
coupled-enzyme process or a coupled-substrate approach (Faber, 2004; Peters, 1998).  
 
In the coupled-substrate process, a second substrate (i.e 2-propanol, isopropanol) is 
added to the reaction system and is oxidised by the same enzyme for NADPH 
regeneration. However, the maximum conversion of this option is usually limited by 
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the thermodynamics of the system as there is  competition between substrate, product, 
co-substrate and co-product. There is also the potential for inhibition or deactivation 
of ω-TAm by the newly added. For instance, the previous study by Yun et al. (2003) 
examining the use of 2-propanal coupled to the ADH revealed a critical decrease in 
both activity and stability of the ω-TAm JS17 from Vibrio fluvialis. 
 
In the coupled-enzyme process, an independent enzyme such as glucose 
dehydrogenase (Truppo and Turner, 2010; Koszelewski et al., 2009; Yun et al., 2003), 
formate dehydrogenase (Rissom et al., 1999) or glucose-6-phosphate dehydrogenase 
(Hummel, 1990) is also added into the reaction medium. In this work, glucose 
dehydrogenase from Pseudomonas sp. (GDH) has been selected to couple with ADH 
in order to recycle the co-factor NADPH. This enzyme was chosen as it has high 
specific activity (Yun et al., 2003), a favourable equilibrium for NADPH (Hummel, 
1999), no inhibitory effect of the glucose co-substrate on ω-TAm activity (Yun et al., 
2003) and is also commercially available.  
 
A further consideration when implementing the NADPH recycling system is that good 
control of pH is needed because the gluconolactone product formed from glucose 
(Figure 4.2) is spontaneously hydrolysed to gluconic acid causing a decrease in pH. 
As shown previously, the optimum pH for CV2025 ω-TAm activity in lysate form is 
about pH 7.5 with activity decreasing rapidly at lower pH values (Section 3.4.3).  
 
As presented in Figure 4.5, when the second enzyme bioconversion was carried out in 
50 mM HEPES buffer (pH 7.5), the reaction reached completion after 5 hours based 
on production of (R)-1-phenylethanol (which also attributed to the conversion of AP) 
by ADH, which was 13 mM and at the level where AP become inhibitory to the 
CV2025 ω-TAm (Figure 4.3). This is equivalent to the optimum AP conversion 
achieved in the standard CV2025 ω-TAm bioconversion at 16 hours (Figure 4.5). 
However, the pH of the second enzyme bioconversion solution measured at this time 
had declined to 4.5 where the activity of the CV2025 ω-TAm was likely to decrease 
or deactivate thus prevented the reaction to progressing any further. Nevertheless, the 
comparable resulted in a yield of CV2025 ω-TAm bioconversion with the second 
enzyme system assimilation was accomplished at 3 times earlier (at 6 hours) than the 
standard CV2025 ω-TAm reaction (at 16 hours).  This  confirms  the  second  enzyme  
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Figure 4.5. Influence of second enzyme system on CV2025 ω-TAm bioconversion kinetics: (R)-
1-Phenylethanol production from the preliminary study with second enzyme system (Section 4.5) 
(▲) and AP production from standard CV2025 ω-TAm reaction (Section 4.3) (●). Reaction 
conditions: 0.3 g.L
-1 CV2025 ω-TAm in lysate form; 0.2 mM PLP; [MBA] and [Ery] were 50 
mM; 1 mM NADPH; 70 mM glucose; ADH (1.2 g.L
-1
); GDH (0.02 g.L
-1
); 30 
º
C; pH 7.5; 300 rpm 
in 50 mM HEPES buffer; total volume of 300 µL in 96-glass microwell plate. Bioconversions 
performed as described in Section 2.5.3.  
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system behaved as anticipated, but points to the need to more tightly control pH in the 
reactions.  
 
For preparative scale bioconversions and above pH-stat devices can easily be used for 
control of pH and maintenance of the optimum value during bioconversions (Truppo 
et al., 2010). However, such an approach is not yet possible for the high throughput, 
microwell scale methods being developed here. In order to achieve effective pH 
control, in this case higher buffer concentrations will be investigated realising that if 
enhancements in bioconversion yield are seen during high throughput studies the 
optimum reaction conditions can later be verified by a pH stat study at a larger scale. 
Consequently, second enzyme bioconversions were operated with stronger buffer 
solutions of 0.5 M, 1.0 M and 1.5 M HEPES (pH 7.5). All the substrates, co-factors 
and substituted ADH and GDH enzymes (Section 2.3.3 and 2.3.4) apart from CV2025 
ω-TAm were hence prepared in these targeted HEPES concentrations and were 
adjusted to pH 7.5 when necessary (Section 2.5.3). 
 
Figure 4.6 displays the measured CV2025 ω-TAm bioconversion kinetics using the 
second enzyme system at the various HEPES buffer concentrations. The reaction with 
the lowest HEPES concentration of 0.5 M proceeded to only 50 % (mol.mol
-1
) 
conversion and the pH value at the end of reaction was decreased to 7.0. Meanwhile, 
an ABT production of 36 mM, corresponding to 72 % (mol.mol
-1
) reaction 
conversion, was obtained in 1.0 M HEPES where the final pH value was 7.2. Finally 
for the reaction with the highest HEPES concentration of 1.5 M the product yield 
increased to 43 mM ABT (86 % (mol.mol
-1
)) and the pH only decreased to 7.4. In this 
case, the time needed to achieve this maximum yield was also quicker by 8 hours in 
comparison to the reactions at lower HEPES concentrations.  
 
As the substrate inhibition exerted by amino acceptor (Ery) was nearly negligible 
(Rios et al., 2011), the effect of using higher initial concentrations of Ery to drive the 
equilibrium further towards completion was also examined. This would also increase 
conversion of amino donor (i.e MBA) as well as increasing the final product 
concentration (i.e ABT). When the reaction in 1.5 M HEPES was repeated with 70 
mM Ery, there was almost complete conversion of 50 mM MBA and a final product 
concentration of 49 mM ABT was obtained in 20 hours as also shown in Figure 4.6.  
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Figure 4.6. CV2025 ω-TAm bioconversion kinetics using the second enzyme system at 
increased buffer concentrations: (A) Ery consumption and (B) ABT production. The reaction 
mixture contained 50 mM MBA, 50 mM  Ery in different HEPES (pH 7.5) concentrations of 0.5 
M (■) 1.0 M (●) or 1.5 M (▲) and 70 mM Ery in 1.5 M HEPES (♦). Reaction conditions: 0.3 g.L -1 
CV2025
 ω-TAm; 0.2 mM PLP; [MBA] and [Ery] were 50 mM; 1 mM NADPH; 70 mM glucose; 
ADH (1.2 g.L
-1
); GDH (0.02 g.L
-1
); 30 
º
C; pH 7.5; 300 rpm in various concentrations HEPES 
buffer; total volume of 300 µL in 96-glass microwell plate. Bioconversions performed as 
described in Section 2.5.3. 
 
 
  
 133 
 
The 40 % (mol.mol
-1
) excess of Ery added at the start of the reaction helped further 
increase the initial reaction rate to nearly 2-fold over that when the substrates were 
initially present at equal molar ratio. 
 
 
4.6. PHYSICAL ISPR METHOD: OPERATION AT REDUCED PRESSURE  
 
Other potential methods for overcoming unfavourable thermodynamic equilibria and 
ketone product inhibition are by operating the bioconversion at reduced pressure or 
higher temperatures in order to encourage evaporation of unwanted compounds (Yun 
et al., 2004). These options, however, are only applicable when the unwanted 
compound (i.e by-product) is more volatile than the other substrates and the target 
product. This is the case here for the AP by-product (Yun et al., 2004). The option of 
studies at higher temperatures is not explored as this may lead to decreased ω-TAm 
activity and denaturation (unless interest’s thermophiles enzyme is used). 
 
Various options for operation of parallel experiments at reduced pressure were 
therefore studied to develop parallelization reactions application at microscale format. 
300 μL scale reactions were performed in an un-covered 96-glass microwell plate 
integrated with a commercially available 96-well vacuum manifold as depicted in 
Figure 4.2. The 96-well vacuum manifold requires a different vacuum source that was 
originally designed for 96-well filter plates and solid phase extraction (SPE). Instead 
of operating in normal SPE mode, in the reduced pressure system, the reaction plate 
was placed inside the vacuum manifold whilst a fresh cleaned plate was placed at the 
top to serve as the cover and to provide a closed environment system. Considering the 
total bioconversion volume, a very mild vacuum was initially used of 5 torr (~6.67 
mbar) controlled by a vacuum / pressure pump was applied to this novel reaction 
system to avoid rapid evaporation of the reaction solution (i.e water).  
 
In micro-scale bioprocesses, it is very important to determine the evaporation rate of 
reaction media (i.e water) for accurate quantification of substrate and product 
concentrations. Here, the average rate of evaporation across a plate was determined 
based on gravimetric analysis. In short, evaporation experiments were carried out in a 
microwell plate containing 300 μL RO water comprising 50 mM HEPES buffer. At 
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each sampling point, the weight of water left inside the well was measured. Likewise, 
bioconversion kinetics were subsequently measured at a constant evaporation rate and 
for operation at 5 torr pressure and 30 ºC. As shown in Figure 4.7, the water 
evaporation kinetics followed the first-order rate law and was constant at 6.8 μL.hr-1 
during the course of the bioconversions.   
 
The evaporation rates of ABT, MBA and Ery were determined by carrying out a 
control reaction using 300 µL 50 mM HEPES buffer containing 50 mM of each 
compound at pH 7.5. In the same way as described in Section 2.5.4, these control 
reactions were carried out at 5 torr vacuum pressure in a 96-microwell plate placed in 
the vacuum manifold. Solutions were sampled at specific times and analysed by 
HPLC (Section 2.6.6).  The AP evaporation rate was carried out likewise, but with 40 
mM AP as that is its maximum water solubility.  
 
The ABT, MBA and Ery did not show any selective evaporation and their 
concentrations increased equally during this control reaction. After correction for the 
amount of water evaporated (Figure 4.7) the concentrations were the same as the 
starting conditions and so any substrate evaporation effects are considered (data not 
shown). In contrast, the evaporation rate of AP was quantified to be 1.22 mM.hr
-1
. 
 
For operation under reduced pressure condition, the evaporation behaviour of 
ionisable compounds involved will change according to the reaction pH since this 
affects their ionization states. The CV2025 ω-TAm bioconversion reaction performed 
here was carried out at pH 7.5 which is close to neutral pH, therefore the ionisable 
compounds MBA, Ery and ABT evaporation rates were less affected by pH at the 
reduced pressure environment. The AP however is not an ionisable compound 
therefore its evaporation rate does not change regardless the pH.  
  
Nevertheless, it might be important to determine the evaporation rates of ionisable 
compounds involved if the optimum reaction under normal atmospheric pressure is far 
from neutral pH. This is because, losing of substrates and / or targeted product are 
expected as reaction progress relative to their strong evaporation rates under the 
reduced pressure condition.  
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Figure 4.7. Average water evaporation kinetics across a 300 µL plate operated at 30 °C under 
reduced pressure and 5 torr pressure.  The water evaporation constant is 6.8 μL.hr-1. Experiment 
conditions: 5 torr vacuum pressure;  30 
º
C; RO water contained 50 mM HEPES buffer (pH 7.5); 
total volume of 300 µL in 96-glass microwell plate placed in 96-well vacuum manifold connected 
to vacuum / pressure pump for pressure source. Reaction performed as described in Section 
2.5.4. Error bars represent one standard deviation about the mean (n=6). 
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And when this is the case, we might expect the optimal pH of the reaction will be no 
longer equivalent to the reaction conducted at atmospheric pressure. In understanding 
the evaporation behaviour of an ionisable compound at different pH under reduced 
pressure, Yun and co-workers (2004) have derived mathematical equations that allow 
prediction of the evaporation rate constants (Figure 4.8).  
 
Kinetic profiles of the CV2025 ω-TAm reaction carried out at 5 torr applied pressure 
are shown in Figure 4.9.  As water evaporation will likely affect the outcome of 
reactions over long time periods a high CV2025 ω-TAm concentration (i.e 1.0 g.L-1) 
was used to ensure the reaction could reach equilibrium 24 hours or less where the 
maximum level of water evaporation would be 50 % (vol.vol
-1
). When equivalent 
concentrations (i.e 50 mM) of both substrates were used, the optimum ABT yield was 
28 mM in 12 hours. This is equivalent to a 30 % (mol.mol
-1
) increase over the yield of 
the standard CV2025 ω-TAm reactions (Figure 4.9).  
 
When the initial Ery concentration was increased to 70 mM, as previously observed 
with the second enzyme reaction system (Section 4.5), the product concentration 
increased slightly further to 33 mM ABT, some 40 % (mol.mol
-1
) higher than the 
standard CV2025 ω-TAm bioconversion (Section 3.5.1). 
 
By comparison with results from the second enzyme system (Section 4.5), it can be 
concluded that the relatively small increases in conversion at reduced pressure are 
most probably due to the fact that only a proportion of the inhibitory AP is being 
evaporated. While more AP could be removed by operation at lower pressures, this 
would lead to further problems with water evaporation. While the microscale methods 
for operation at reduced pressure has been shown to work, the benefits of physical in-
situ product removal by evaporation will only be found in cases where the by-
products are considerably more volatile than the AP studied here. 
 
4.7. PHYSICAL ISPR METHOD: APPLICATION OF ADSORBENT 
RESINS  
 
The fourth approach to alleviate the problems of product inhibition and an 
unfavourable equilibrium constant problem is in situ product removal using adsorbent  
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Figure 4.8. Mathematical equations for prediction of evaporation rate constant. The ratio of 
protonated to deprotonated form is governed by the pH of solvating media as Equations (1) and 
(2), where [BA]total, [BA] and [BAH
+
] are the concentrations of ionised amine, deprotonated 
ionised amine and protonated ionised amine respectively. To accurately predict the evaporation 
rate constant of the ionised amine, the overall evaporation rate constant (koverall,e) and evaporation 
rate constant (ke) of free amine are defined as in Equations (3) and (4) respectively. Combining 
Equations (1) - (4) yields Equation (5). While (koverall,e) is sensitive to pH, the (ke) of non-ionised 
amine form is constant. The linear regression between 1/Koverall,e and 10
-pH
 gives the values of pKa 
and ke of the ionised amine, and consequently yields the calculation of Koverall,e at a given pH. 
(Yun et al., 2004). 
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Figure 4.9. CV2025 ω-TAm bioconversion kinetics for operation at reduced pressure: (A) 
MBA (-- --) consumptions and AP (—) productions; (B) ABT productions (values plotted are 
corrected for evaporation). The reaction mixture (300 μL) contained 50 mM MBA; Ery of either 
50 mM (●) or 70 mM (▲); 1 g.L-1 CV2025 ω-TAm in lysate form; 0.2 mM PLP and 50 mM 
HEPES buffer. Reaction conditions: 30 
º
C; pH 7.5;  5 torr vacuum pressure; total volume of 300 
µL in 96-glass microwell plate placed in 96-well vacuum manifold connected to vacuum / 
pressure pump for pressure source. Bioconversions performed as described in Section 2.5.4. 
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resins to selectively binding the unwanted by-product (Lye and Woodley, 1999). 
Three commercially available hydrophobic polymeric resins called Amberlite
TM
 XAD 
7, XAD 1180 and XAD 16 were investigated. Further details on the resins are listed in 
Table 2.5.  These were chosen particularly because they have been previously shown 
to absorb AP from the reaction solution (Yang et al., 2008; Nakamura et al., 2000). To 
desorb bound products from the resins isopropyl alcohol was used. 
 
4.7.1. Equilibrium Adsorption Isotherms 
 
Adsorption isotherm studies were initially conducted to measure the capacity and 
selectivity of each resin towards the various solutes present in the bioconversions. The 
adsorption capacity depends on the properties of the adsorbant and adsorbate, 
temperature, solution pH and amount of impurities presence (Yang et al., 2003). 
Nevertheless, the molecular basis of adsorption is poorly understood, and it is not 
currently possible to predict performance based solely on chemical and physical 
properties alone. Experimental adsorption isotherms are therefore used to obtain 
information on  the equilibrium adsorption relationships. The experimental isotherms 
data were correlated to three well-known isotherm models namely Langmuir, 
Fruendlich and Linear (Du et al., 2008; Yang et al., 2003). The mathematical 
relationships for each data set is shown in Table 4.2.  The adsorption isotherm 
experiments were carried out as described in Section 2.5.5. 
 
For ISPR application with the CV2025 ω-TAm bioconversion studied here, it is 
desirable that the adsorbent should have high capacity and affinity for the by-product 
AP whilst demonstrating minimal binding of the substrates MBA and Ery.  Based on 
initial adsorption equilibrium experiments the ability of all the adsorbents to bind AP 
was considerably greater than Ery (Figures 4.10, 4.11, 4.12) and MBA (results for 
MBA showed similar binding affinity as seen for Ery). Meanwhile, the initial 
experiment on the binding of ABT showed less than 2 % (mol.mol
-1
) was adsorbed by 
resins. Of the tested resins, XAD-16 demonstrated the highest adsorption capacity for 
AP with XAD 7 and XAD 1180 showing marginally less binding. These results 
confirm the adsorption ability of these resins for AP as previously reported by Yang et 
al. (2008) and also show that AP will out compete Ery for binding sites on the resin. 
This is confirmed by the binding constants calculated for each component in Table 4.3 
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and 4.4. Theoretically, the use of these resins in the bioconversion should be able to 
bind any produced AP driving the reaction towards completion. 
 
Table 4.2. Isotherms expression for single component solutions.  
Model name                                   Model Equation                                     
Langmuir                                         
                                  
 
Freundlich                                                                            
Linear                                                                        
 
Where,  
C = concentration (g.L
-1
) 
 K = equilibrium constant 
 B = constant for each adsorbent 
qmax = saturation concentration of the adsorbent phase at equilibrium (g) 
 
 
 
Figure 4.10. Equilibrium adsorption isotherms on XAD 7 resin: AP as sole solute (●); AP in 
the presence of equilmolar Ery (▲); Ery as sole solute (■); Ery in the presence of equilmolar AP 
(♦) prepared in 50 mM HEPES buffer (Section 4.7.1). Experiment conditions: 30 ºC; pH 7.5; 50 
mM HEPES buffer; 500 rpm; total volume of 300 µL in 96-glass microwell plate. Experiments 
performed as described in Section 2.5.5. The solid lines represent mathematical relationships 
fitted to the data as presented in Tables 4.3 and 4.4.  
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Figure 4.11. Equilibrium adsorption isotherms on XAD 1180 resin: AP as sole solute (●); AP in 
the presence of equilmolar Ery (▲); Ery as sole solute (■); Ery in the presence of equilmolar AP 
(♦) prepared in 50 mM HEPES buffer (Section 4.7.1). Experiment conditions: 30 ºC; pH 7.5; 50 
mM HEPES buffer; 500 rpm; total volume of 300 µL in 96-glass microwell plate. Experiments 
performed as described in Section 2.5.5. The solid lines represent mathematical relationships 
fitted to the data as presented in Tables 4.3 and 4.4.  
 
 
Figure 4.12. Equilibrium adsorption isotherms on XAD 16 resin: AP as sole solute (●); AP in 
the presence of equilmolar Ery (▲); Ery as sole solute (■); Ery in the presence of equilmolar AP 
(♦) prepared in 50 mM HEPES buffer (Section 4.7.1). Experiment conditions: 30 ºC; pH 7.5; 50 
mM HEPES buffer; 500 rpm; total volume of 300 µL in 96-glass microwell plate. Experiments 
performed as described in Section 2.5.5. The solid lines represent mathematical relationships 
fitted to the data as presented in Tables 4.3 and 4.4.  
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Table 4.3. The mathematical relationships fitted to the adsorption isotherm data for adsorption 
of AP (in a mixed solution with Ery) and AP alone. y represents the adsorbed phase 
concentration at equilibrium (ggads
-1
) and C represents the liquid phase concentration at 
equilibrium (g.L
-1
).  Each mathematical relationship is visualized as a solid line in Figures 4.10, 
4.11, and 4.12. 
 
Adsorbent Fitted adsorption isotherm 
AP (mixed with Ery) R
2
 AP R
2
 
 
XAD 7 
 
 
 
0.997 
 
 
 
0.997 
 
XAD 1180 
 
 
 
0.932 
 
 
 
0.985 
 
XAD 16 
 
 
 
0.835 
 
 
 
0.990 
 
 
 
Table 4.4. The mathematical relationships fitted to the adsorption isotherm data for adsorption 
of Ery (in a mixed solution with AP) and Ery alone. y represents the adsorbed phase 
concentration at equilibrium (ggads
-1
) and C represents the liquid phase concentration at 
equilibrium (g.L
-1
).  The best fitting isotherms equation is indicating by the solid line in Figures 
4.10, 4.11 and 4.12. 
 
Adsorbent Fitted adsorption isotherm 
Ery (mixed with AP) R
2
 Ery R
2
 
 
XAD 7 
 
 
 
0.983 
 
 
 
0.970 
 
XAD 1180 
 
 
 
0.920 
 
 
 
0.956 
 
XAD 16 
 
 
 
0.923 
 
 
 
0.990 
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4.7.2. CV2025 ω-TAm Bioconversions with ISPR by Adsorptive Resins 
 
Bioconversion reactions were carried out at 300 µL scale using equilmolar MBA and 
Ery at 50 mM. ISPR adsorbent resins as described in Section 2.5.5. In order to obtain 
a complete reaction profile for the total amount of compound absorbed from the resin, 
a ‘sacrifice well’ approach was used. At each interval time, all the liquid in the well 
was carefully aspirated off and isopropyl alcohol immediately added and then left 
shaken for 5 hours to ensure all solute was fully desorbed. Full details of the reaction 
procedure are described in Section 2.5.5. Besides isopropyl alcohol, nearly any water-
miscible organic solvent can be used to desorb the absorbed absorbate from resins 
Amberlite
TM
 XADs (Vicenzi et al., 1997).  
 
The preliminary bioconversion reactions with CV2025 ω-TAm in clarified lysate in 
the presence of 20 % (w.w
-1
) adsorbent resins were found to only proceeded to 
between 5 % to 10 % (mol.mol
-1
) conversions (data not shown). These are far less 
than the standard lysate reaction which achieved 26 % (mol.mol
-1
) conversion 
(Section 3.5.1). The reason for this is unclear since the concentration of total protein 
in the supernatant remained constant. One possibility then is that there is selective 
binding of the PLP co-factor but this was not explored further.  
 
Consequently experiments were also performed using whole cell CV2025 ω-TAm 
biocatalyst as previously described in Section 3.5.2. The whole cell biocatalyst has a 
typical size of 0.2 - 0.5 microns which should be larger than the pore size of the resin 
particles which are approximately 0.03 microns or less (Table 2.5).  Figure 4.13 
presents the bioconversions with the ISPR resins method mediated by whole cell ω-
TAm biocatalyst. The CV2025 ω-TAm bioconversions accompanied by use of 20 % 
(w/w) of the adsorbents XAD 7 and XAD 16 accomplished 50 % (mol.mol
-1
) 
conversion whilst a marginally lower conversion of 46 % (mol.mol
-1
) was attained 
with XAD 1180.  These yields are equivalent to 12 % and 8 % (mol.mol
-1
) 
improvements over the standard CV2025 ω-TAm whole cell bioconversion without 
the resin adsorption.  
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Figure 4.13. Influence of ISPR adsorbent resin selection on CV2025 ω-TAm bioconversion 
kinetic profiles performed with three ISPR adsorption resins (XAD 7 (●); XAD 1180 (▲); XAD 
16 (■) system (Section 4.7.2) and CV2025 ω-TAm whole cell standard reaction (♦) (Section 3.5.2). 
(A) ABT production (total concentrations in both aqueous and resins phases); (B) AP production 
(in the aqueous phase); (C) MBA productions: (---) MBA total concentrations in aqueous and 
resins phases; (- - -) MBA concentrations in resins phase only. Reaction conditions: 0.3 g.L
-1
 
CV2025 ω-TAm in whole cell form; 0.2 mM PLP; [MBA] and [Ery] were 50 mM, 60 mg (wetted) 
adsorption resin; 30
º
C; pH 7.5; 500 rpm in 50 mM HEPES buffer; total volume of 300 µL in 96-
glass microwell plate. Bioconversions performed as described in Section 2.5.5. Error bars 
represent one standard deviation about the mean (n=3). 
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AP was totally removed from the aqueous reaction solution owing to the presence of 
the resins. This showed that all resins behaved as anticipated based on the single and 
multiple component studies described in Section 4.7.1 As soon as the solute phase 
equilibrium reached, MBA was being adsorbed onto each adsorbent in the 
concentrations of 13 mM (XAD 7), 11 mM (XAD 16) and 17 mM (XAD 1180) 
(Figure 4.13c). Thus, theoretically 37 mM, 39 mM, 33 mM MBA respectively were 
left in aqueous solutions. Likewise, about the same amount of Ery was being absorbed 
onto each adsorbents resin leaving about 40 mM (XAD 7), 42 mM (XAD 16) and 38 
mM (XAD 1180) of Ery in the aqueous solutions during the reaction courses (Data 
not shown). As shows in Figure 4.13c, the concentrations of MBA adsorbed onto 
resins were almost from the start of the reactions were nearly remained persistent till 
the termination courses. This indicated the binding affinities of all resins towards 
MBA were very strong. However, about 20 to 30 % (mol.mol
-1
) of MBA were still 
left detected in the aqueous solutions at the end of reaction courses. 
 
Further bioconversions were performed at various resins mass loading. The study 
indicated the reactions with 20 % (w.w
-1
) resins (as described above) were the best 
overall. Reactions attempted with 33.3 % and 66.7 % (w.w
-1
) loaded resins failed to 
increase the reactions conversion higher than the standard bioconversion (data not 
shown). The equilibrium between adsorbent and the aqueous phase at certain 
concentration may pose an inhibition effect to enzyme (Rudroff et al., 2006). Besides, 
most of the remarkable ISPR resin applications were reported with simple and 
straightforward bioconversion mechanism of biocatalyst catalysed single substrate to 
alleviate inhibitions of substrate / product and cell toxicity (Guo et al., 2009a; Yang et 
al., 2008; Rudroff et al., 2006; Nakamura et al., 2000).   
 
Despite the initially promising behaviour seen in the single and two-component 
studies, it is clear that the potential benefits to the bioconversion reaction are less easy 
to predict. Further complications include protein adsorption onto the resin and the 
potential for lysis of whole cells due to shaking in the presence of 20 % (w.w
-1
) resin. 
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4.8. SUMMARY 
 
The aim of this chapter was to establish a series of novel microscale methods to 
enable  experimental  evaluation  of  the  different process options for overcoming low  
equilibrium constant as well as selectively removing an inhibitory product (AP) in the 
micro-scale processing technique. The experimental studies performed have shown 
the benefit (or otherwise) of each of the four systems developed.  
 
The benefits seen with each method for CV2025 ω-TAm bioconversions carried out at 
equilmolar substrate concentration are summarized in Table 4.5. In comparison, the 
second enzyme reaction (Section 4.5), a system applying ADH Bacillus kefir as a 
second enzyme and coupling with GDH Pseudomonas sp. for co-factor NADPH 
regeneration has the highest product yield than the other three investigated options. 
The excellent result of 86 % (mol.mol
-1
) conversions obtained from second enzyme 
system with 1.5 M HEPES buffer shown that CV2025 ω-TAm is very stable in a very 
strong buffer solution. The evaluation of alternative amino donors (Section 4.4) 
however still represents the simplest and fastest option meanwhile reduced pressure 
system (Section 4.6), is an efficient method for overcoming inhibition or suppresses 
the unfavourable equilibrium constant cause by a compound having high volatilities 
property. The ISPR resin adsorptions method (Section 4.7) only applicable for whole-
cell biocatalyst utilisation. The highest optimum yield of 12 % (mol.mol
-1
) attained 
from this method is still low and thus should be further examined for significant yield 
improvement. Employing second enzyme and reduced pressure systems with a higher 
ratio of amino acceptor to amino donor had also further increased the reactions 
conversion to 98 % (mol.mol
-1
) for second enzyme system and 66 % (mol.mol
-1
) for 
reduced pressure system.  
 
In more general terms, the best method for increasing bioconversion yield will depend 
on the particular enzyme and reactants being studied. In this case, the methods 
developed here are generic and can be applied to any bioconversion having 
established. 
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Table 4.5.  List of productivity of the investigated process options and number of fold increases 
as a comparison to standard CV2025 ω-TAm reaction. 
 
Option Optimum ABT product concentration  
(equilmolar substrates reaction) 
 
Fold 
increase 
in yield 
Evaluation of alternative 
amino donors 
(bioconversion by CV2025 ω-
TAm in lysate form) 
 
 
36 mM 
(Isopropylamine as the amino donor) 
 
2.8 
Second enzyme system  
(bioconversion by CV2025  ω-
TAm in lysate form) 
 
 
43 mM 
 
3.3 
Reduced pressure 
(bioconversion by CV2025 ω-
TAm in lysate form) 
 
 
28 mM 
 
2.2 
Adsorbent resins 
(bioconversion by CV2025 ω-
TAm in whole cells form) 
 
 
25 mM 
 
1.3 
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5. AUTOMATION AND PARALLEL 
OPERATION OF MICROSCALE 
PROCESS OPTIONS 
 
 
 
 
 
5.1. INTRODUCTION 
 
The rapid kinetic evaluation of novel biocatalysts such as TAm is important given 
their potential for diverse industrial application. Nevertheless, TAm biocatalysts are 
known to have low conversion yields due to the reversible equilibrium between 
products and substrates (Shin and Kim, 1996; Christen and Metzler, 1985). In this 
work, the microscale methods developed in Chapter 4 are systematically applied in 
order to increase the product yield of an ω-TAm bioconversion known to be 
equilibrium-controlled (Section 4.3).   
 
In general one of the main criticisms of biocatalytic systems is that they are relatively 
slow to implement (Pedro, 2010; Lye et al., 2003). Therefore, the automation of the 
approaches developed in Chapter 4 holds the possibility to efficiently examine the 
activity of a large number of biocatalysts acting on a wide range of substrates. In 
addition, this would also allow options to decrease production costs to be explored 
through a variety of improvements leading to potentially high space-time yields using 
biological and engineering principles (Ghisalba et al., 2010). 
 
Over the past decade, the drive to identify new drug compounds had led to intensive 
development of high throughput screening techniques. As described in Section 1.5.2 
much of the automation technology is based on microwell formats to reduce sample 
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volume and enable the application of laboratory robotics to increase throughput (Lye 
et al., 2003). A range of innovative methods is now being used to accelerate process 
development in both academia and industry, with automated approaches playing an 
increasing role over the conventional manual platform as well as larger scale trials 
approaches. The advantages of such automated microscale methods include the 
following: higher sample throughput and potentially increased assay precision, 
reduced cost of bioprocess development and speed up the development process of 
bioconversion system (Lye et al., 2009).  
 
5.2. AIM AND OBJECTIVES 
 
The aim of this chapter is to integrate the microscale methods established in Chapter 
4, for overcoming low yield, equilibrium controlled ω-TAm bioconversions, into an 
integrated and automated microscale process sequence. The research here was mainly 
focussed on comparison of both conventional and automated microscale processes 
techniques and the potential benefits of increased processing speed and reduced 
experimental costs. The key objectives of this chapter are thus: 
 
 To characterize a novel ω-TAm library for parallel evaluation with a view to 
identifying a better ω-TAm than currently used CV2025 ω-TAm in term of 
catalytic activity, selectivity and stability. 
 
 To establish automated microscale process sequences to facilitate rapid 
process characterization and evaluation of the ω-TAm library to identify those 
capable of giving industrially relevant space-time yields at pilot scale. They 
will be tested on the standard reaction of MBA and Ery at 50 mM and also 
with a range of alternative amino donor substrates on the established 
automated microscale platform. 
 
 To demonstrate the benefits of the automated microwell method to further 
evaluate performance of the second enzyme reaction. The method is developed 
to enable rapid evaluation and optimization of broaden range of reaction 
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parameters and conditions for increase production yield and significantly 
reduce the production cost prior scaling up productions.  
 
 To establish microscale automated approaches of reduced pressure system 
using integrated robot system and equipment of a vacuum manifold (Te-VacS) 
for advance modification and implementation for efficient parallel 
investigation of the in-situ product removal process option.  
 
5.3. CHARACTERISATION OF ω-TRANSAMINASE LIBRARY 
 
5.3.1. Parallel E.coli BL21 (DE3) Gold Batch Growth Kinetics 
 
A focussed library of ten different ω-TAm enzymes each expressed in the same E.coli 
host was evaluated in this work. This diverse library of enzyme sources was 
established with the intent to evaluate it for better catalytic activity, selectivity and 
stability. The initial production of the ω-TAm library was carried out in 2 L shake 
flasks with a working volume of 200 mL as previously described in Section 2.2.2.  
Each fermentation was carried out in duplicate.  
 
Instead of LB media, the library was grown using another complex medium 2xTY 
(Ferreira Vaz et al., 2011). This is also commonly used for E.coli growth and was 
used here for higher biomass production and evaluate the influence of the culture 
medium on the expression of ω-TAm. 0.2 mM PLP additions were supplied to the 
fermentation and lysate preparation steps to enhance the ω-TAm stability and boost its 
catalytic activity as discussed earlier in Section 3.3.3. The composition of the media 
used (2xTY) was defined in Table 2.2. As observed in the growth curves (Figure 5.1), 
the cell growth kinetics were similar and reached a stationary phase after a 
fermentation period of approximately 7 hours. This is similar to that observed when 
the CV2025 ω-TAm was grown with LB medium (Section 3.3.1).  
 
Most of the E.coli cultures carrying the alternative ω-TAm plasmids grown using the 
2xTY medium obtained higher growth cells density than previously obtained with 
E.coli expressing the CV2025 ω-TAm with LB medium. The only exceptions were  
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Figure 5.1. Batch growth kinetics for E.coli BL21 (DE3) Gold strains each expressing different 
ω-TAm plasmids cultured in 2xTY media: pQR1017 (♦); pQR956 (■); pQR1019 (▲); pQR985 
(■); pQR960 (●); pQR811 (●); pQR813 (■); pQR1011 (♦); pQR1014 (-); pQR978 (♦). The 
CV2025 ω-TAm expressed from pQR801 (■) was grown using LB media as previously discussed 
in Section 3.3.1. The fermentations temperature of the novel ω-TAm strains were set at 37 oC 
initially but after IPTG induction (OD600 reached a value of 1.8 - 2.0) the temperature was then 
lowered to 30 C prior harvested the next 5 hours. Cell cultivation was  performed in 2L shake 
flask using pH 7.5 and 250 rpm. The cultivation  procedure details were as described in Section 
2.2.2. 
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the E.coli with Rru_A1254 ω-TAm (pQR1017) and BSU09260_1971 ω-TAm 
(pQR960). Both these recombinant E.coli strains only reached a final biomass 
concentration of 1.4 gdcwL
-1
 similar to the E.coli with CV2025. The increased biomass 
density obtained with the new medium may also be due to the difference in 
fermentation temperature. As mentioned in Section 2.2.2, instead of applying a 
constant temperature of 37 ºC, the temperature was lowered to 30 ºC once induced 
with IPTG. As shown in Figure 5.1, the shake flask scale fermentations of the E.coli 
with the rest of alternative ω-TAms were grown to final biomass concentrations 
between 2 to 2.2 gdcwL
-1.  ω-TAm biocatalysts were used either in lysate (Section 
2.3.1) or purified form (Section 2.3.2) as specified for each particular reaction. 
 
5.3.2. Quantification of ω-TAm and Host Cell Protein Production 
 
The concentrations of proteins produced by the ω-TAm library strains were analysed 
by the Bradford assay using absorbance measurements, A595 (Section 2.6.3). The total 
protein concentrations of shake flask were again determined using a BSA standard 
curve (Appendix II) and were as detailed in Table 5.1. 
 
SDS-PAGE assays were subsequently conducted using equal concentrations of total 
protein loaded onto the gel based on the Bradford assay measurements. The un-
purified recombinant -TAms migrated on the SDS-PAGE as a single band of in the 
size range between 46 to 51 kDa as displayed in Figure 5.2.  
 
Despite the higher growth cells density, most of new -TAms were expressed at a 
high level approximately comparable to the CV2025 ω-TAm at 1.0 g.L-1 with the 
exceptioned to BLi00474 ω-TAm, Krad_4078 ω-TAm and Rru_A1254 ω-TAm which 
made up to only 0.19, 0.32 and 0.36 g.L
-1
 of the ω-TAm from the clarified soluble 
fraction respectively. In addition, despite growing to the same cell density (Figure 5.1) 
as the other strains, the BLi00474 ω-TAm from Bacillus licheniformis only had a low 
total protein expression of 2.35 g.L
-1
 hence the very low ω-TAm concentration.  
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Figure 5.2. SDS-PAGE analysis showing expression of the library of novel ω-TAm enzymes 
compared to the CV2025 ω-TAm (pQR801). Results are from clarified cellular extracts produced 
from the fermentations showing in Figure 5.1:  Lane 1 is protein marker; lane 2 is pQR801 lane 
23 is pQR811; lane 4 is pQR813; lane 5 is pQR985; lane 6 is pQR1011; lane 7 is pQR960; lane 8 
is pQR978; lane 9 is pQR956; lane 10 is pQR1014; lane 11 is pQR1017;  lane 12 is pQR1019; and 
lane 13 is a null strain of E.coli BL21 (DE3). Molecular weights of ω-TAm varied between 46 to 
51 kDa as specified in Table 5.1.  The ω-TAm expressions are  highlighted in the box. 
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Table 5.1. Properties of the cloned ω-TAm library and expression levels. The construct gene ID 
is the external link to National Center for Biotechnology Information (NCBI)'s record for the 
gene or the organism-specific ID relevant to the clone. The total protein concentrations were 
analysed by Bradford assay (Section 2.6.3) and ω-TAm concentrations were calculated from 
SDS-PAGE gel (Figure 5.2). 
 
Microorganism Construct  
Gene ID 
Plasmid Molecular 
Weight 
(kDa) 
Total protein 
concentration  
(g.L
-1
) 
ω-TAm 
concentration  
(g.L
-1
) 
 
Chromobacterium 
violaceum 
DSM30191 
CV2025 pQR801 47.5 7.5 1.0 
Pseudomonas 
putida KT 2440 
PP2799 pQR811 49.7 6.9 1.2 
Pseudomonas 
aeruginosa PAO2 
PAO0221 pQR813 51.1 8.5 1.6 
Bacillus 
licheniformis 
BLi00474 pQR985 50.3 2.4 0.2 
Klebsiella 
pneumoniae 
KPN_03745 pQR1011 50.1 7.4 1.0 
Bacillus subtillis BSU09260_ 
1971 
pQR960 49.9 4.5 0.6 
Deinococcus 
geothermalis 
Dgeo_1177 pQR978 46.7 7.4 0.7 
Kineococcus 
radiotolerans 
Krad_4078 pQR956 50.9 5.9 0.3 
Microccocus  
luteus 
Mlut_00920 pQR1014 50.2 7.0 1.2 
Rhodospirillum 
rubrum 
Rru_A1254 pQR1017 50.4 5.2 0.4 
Rhodobacter 
sphaeroides 
Rsph17025_ 
2835 
pQR1019 50.1 6.3 1.4 
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5.4. BIOCONVERSION AUTOMATION PLATFORM DESIGN AND 
DEVELOPMENT   
 
5.4.1. Overview of the Tecan Platform 
  
The commercially available Tecan Genesis (http://www.tecan.com) laboratory robotic 
platforms (Figure 2.4) enable integration with associated equipments such as 
spectrophotometric plate readers, centrifuges, HPLC autosamplers and vacuum 
manifolds. The Tecan robot used here features 8 separate pipetting tips mounted on a 
single liquid handling arm (LiHa). The LiHa system has liquid level sensing on each 
tip. The system is based on measurement of electrical resistance which enable 
tracking of the liquid level during aspiration and dispense, to prevent air uptake and 
can be used to ensure minimal tip contamination. Additionally the LiHa system also 
comes with variable liquid handling parameters (liquid classes such as water, Gemini 
predefined liquid, and custom define liquid for any reagent intended to use which 
specifies speeds, air gaps and detection modes) to increase accuracy and precision. 
The LiHa system is able to move in XYZ directions over the entire platform, the 
pipetting head can spread between 9 and 20 mm to cope with different microwell 
plates or other laboratory vessel used such as reagent troughs, vials and Eppendorf 
tubes. The pipette tips can either be disposable (DiTi) or fixed. DiTi are available in a 
variety of sizes for ranges of volumes capacity and are also offered with and without 
filter. Meanwhile, the fixed tips require sufficient wash steps present between aspirate 
of different reagents.  
 
With the Tecan platform, the contents of wells were mixed by specifying the number 
of mix cycles of simultaneous aspirate and dispense steps using an appropriate 
volume of liquid. The pipette calibration was done by measuring the weight of water 
dispensed in pre-weighed Eppendorfs tubes assuming a density of 998 kg.m
-3
. The 
pipetting precision used in the study was usually allowed between 0 to 5 % (v/v). The 
system was also equipped with a gripper tool known as a robotic manipulator arm 
(RoMa). Likewise, robotic arm also can move in XYZ axes with rotation angle 270° 
over the entire platform. The gripper spaces range 58 to 140 mm and comprise gripper 
force of up to 10 N. These features make the robot a very convenient platform to 
transport the equipment such as microplates from one rack / carrier to another rack / 
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carrier as well as to the integrated equipment. All the equipment racks and carriers 
such as microwell plate carrier, vials rack and Eppendorfs rack can be custom 
programmed into the Gemini software provided that is does not exceed the travel 
heights of the pipette tips (110 mm) and the RoMa. Moreover, when aseptic operation 
is needed, the entire workstation can be sterilized with Ultraviolet (UV) light and then 
operated within the available Class-2 robotic safety cabinet.  
 
5.4.2. Preliminary Bioconversion Automation Platform Evaluation    
 
To obtain a precise and uniform distribution of the materials in robotic platform 
designed, the required methods and integrate necessary associated equipment are to be 
primarily developed. Similarly to the established manually microwell scale 
bioconversions (Chapter 3), there are several significant challenges and constraints 
that emerged in order to transform it into an efficient automation platform. This 
includes solutions to evaporation and correct choice of pipette tips. Most importantly, 
it also need to first compare the data from manual experiments to those obtained using 
the automation platform. 
 
The microwell plates used for bioconversions were the same as those used in the 
manual process i.e glass 96-well, flat-bottomed microtiter plate (Section 2.5.1). 
Again, the issue of plate cover that provide well closed system in order to prevent 
compounds and water evaporation was the first to be resolved. This was a major 
challenge as in manual platform, we can easily apply the cover which easily peels off 
at each sample time interval, but in automation we need to choose the best plate cover 
that compatible with the LiHa.  
 
The glass 96-well reaction plate was placed on the Thermomixer Comfort shaker for 
temperature and shaking control. Another plate was needed for sampling the reaction 
at each time interval which was placed in an adjacent plate carrier available with the 
Tecan platform. The plates were initially sealed with Thermo plastic elastomer cap 
that was previously used in manual platform (Section 2.5.1). Unfortunately, the cap 
did not perform well with either fixed tips or disposable tips. This issue was resolved 
by replacing the seal with pre-cut pierceable films from Excel Scientific that support 
automation and robotic applications. Instead of 1 adhesive layer the plates were sealed 
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with 5 layers of films for a better assurance to prevent samples evaporation and 
contamination. Disposable tips were used to perform liquid aspirating and dispensing 
by penetrated through the pre-cut over each well. The pre-cut hairline "X" pattern 
created four flaps that bend easily when pushed by disposable tips, and returned to 
their original position after each pipetting for continued protection. 
 
The RoMa was used to move plates to the integrated centrifuge (Section 2.5.6) 
controlled by Gemini software and placed underneath the Tecan workstation for 
samples clarification. The clarified samples were then dispended into HPLC vials 
placed on the HPLC rack. Here, they were first derivatized using AQC reagent as 
described in Section 2.6.6. Finally, each vial was manually capped and transferred for 
off-line HPLC analysis of substrate and product concentrations (Section 2.6.6.) The 
use of automation has accelerated the sample preparation for analysis while offered 
significant time savings by reducing preparation time by an order of magnitude 
compared with manual preparation. Figure 5.3 shows the layout of the deck of the 
entire platform. 
 
The sensitivity of the automated method established was determined by comparing the 
original method with that modified conditions to allow the design of an efficient 
automated platform. As shown in Figure 5.4, the result obtained using the automated 
platform was comparable to those obtained by manual determination (Chapter 3). 
Moreover, the comparable AP concentrations measured from both automated and 
manual platforms highlighted the credibility of the established platform in ensuring 
well closed system protecting evaporation whilst maintained its overall efficiency and 
effectiveness.  
 
5.5. PARALLEL EVALUATION OF ALTERNATIVE AMINO DONORS   
 
As described in Section 4.4, the simplest and most easily implemented option for 
overcoming low yielding equilibrium controlled reaction was the evaluation of 
alternative amino donors. Using the manual approach it was possible to address five 
alternative co-substrates (isopropylamine, benzylamine, s-(+)-sec-butylamine, s-(+)-1-
aminoindane and L-α-serine) to MBA solely with the CV2025 ω-TAm expressed 
from plasmid pQR801.  
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Figure 5.3. Detail of the robotic platform used for ω-TAm bioconversions with alternative 
amino donors (Section 5.5) and second enzyme system (Section 5.6). (A) Platform side view and 
(B) platform top view. Both images show the worktable layout of integrated equipment involved 
on the Tecan Genesis robot. Abbreviations: RoMa is robotic manipulator arm; LiHa is liquid 
handling arm / liquid handler; DiTi is disposable pipette tips. 
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Figure 5.4. Comparison of automated and manual microwell methods for bioconversion 
kinetics of CV2025 ω-TAm (pQR801). Automated experiments performed using 96-microwell 
plate covered with 5 layers pre-cut pierceable films (Section 5.4) and manual experiments performed 
using 96-microwell plate covered with thermo plastic elastomer cap (Section 3.5): MBA 
consumption (♦) and AP production (■) for the automation experiments and MBA consumption 
(▲) and AP production (●) for the manual experiments. Reaction conditions: 0.3 g.L-1 CV2025 
ω-TAm; 0.2 mM PLP; [MBA] and [Ery] were 50 mM; 30 ºC; pH 7.5; 300 rpm in 50 mM HEPES 
buffer; total volume of 300 µL. Bioconversions performed as described in Sections 2.5.6 
(automated experiments) and 2.5.1 (manual experiments). Error bars represent one standard 
deviation about the mean (n=3). 
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The further development of this approach into an automated methodology now 
facilitates a wider range of parallel experimentation involving six amino donors to be 
evaluated with each of the enzymes in the novel ω-TAm library (Section 5.3). In this 
way, it is possible to simultaneously characterise each enzyme’s substrate range and 
the potential benefits for better ketodiol conversion with a range of amino donors. The 
individual reactions were again performed using equilmolar concentrations of amino 
donor and Ery (amino acceptor) at 50 mM. All reactions were performed of at 
equivalent ω-TAms concentrations of 0.3 g.L-1. The unit operations performed here 
on the automated platform were similar to those defined in Section 5.4.2 and mainly 
corresponded to the disposable tips utilization approach. 
 
The effectiveness of the automated approach was first established by the excellent 
agreement seen between the automated (Figure 5.5) and manual (Figure 4.4) 
experimental result for the standard bioconversion (50 mM MBA and 50 mM Ery) 
using CV2025 ω-TAm. In this case, the final conversion yields of the automated and 
manual processes were 12 mM and 13 mM ABT respectively. As shown in Figure 
5.5, under these standard reaction conditions, none of the novel ω-TAms evaluated 
achieved greater performance than the CV2025 ω-TAm (pQR801). Only the PA00221 
ω-TAms (pQR813) and PP2799 ω-TAms (pQR811) showed reasonable conversion 
about 16 % (mol.mol
-1) lower than CV2025 ω-TAms. Meanwhile, the remaining 
TAms achieved 50 % (mol.mol
-1
) or less of the conversion reached by CV2025 ω-
TAms (Graph A of Figure 5.5). 
 
When MBA was replaced with the aliphatic amine compounds isopropylamine and 
sec-butylamine of the ten novel ω-TAms tested, only two showed significant activity 
towards isopropylamine whereas lower reactivity were detected from the remaining 
eight TAms tested. The PA00221 ω-TAm  (pQR813) and PP2799 ω-TAm (pQR811) 
accomplished conversions of 20 mM and 16 mM of ABT respectively which were 
still much lower than with the CV2025 ω-TAm (pQR801) which was 35 mM. When 
sec-butylamine was used as an alternative amino donor, none of the novel ω-TAms 
reached an improved reaction conversion over CV2025 ω-TAm (pQR801). 
Bioconversion using sec-butylamine with PA00221 ω-TAm (pQR813) produced a 
similar conversion to CV2025 ω-TAm (pQR801) which were 14 mM and 15 mM 
ABT respectively. However, with this amine donor it would be feasible to increase the  
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Figure 5.5. Summary of measured bioconversion kinetics of the ω-TAm library on the 
microscale automation platform (Section 5.5) using alternative amino donors: (A) MBA; (B) 
isopropylamine; (C) L-α-serine; (D) benzylamine; (E) s- (+)-1-aminoindane; (F) s-(+)-1-sec-
butylamine. The reactions were sampled at 0 hr (■); 6 hr (■); 20 hr (■) and 30 hr (■). Reaction 
conditions: 0.3 g.L
-1
 ω-TAm; 0.2 mM PLP; [Amino Donor] and [Ery] were 50 mM; 30 ºC; pH 
7.5; 300 rpm in 50 mM HEPES buffer; total volume of 300 µL in 96-glass microwell plate 
covered with 5 layers pre-cut pierceable films (Section5.4). Bioconversions performed as 
described in Sections 2.5.1 and 2.5.6. Error bars represent one standard deviation about the 
mean (n=3). 
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product yield by applying reduced pressure operation (Sections 4.6 and 5.7) to 
encourage evaporation of its resulting volatile ketone product, 2-butanone. The 
performances of all the ω-TAms evaluated with these alternative amino donors are 
detailed in Graphs B (isopropylamine) and F (sec-butylamine) of Figure 5.5. 
 
MBA was next substituted with the aromatic amino donors, benzylamine and S-1-
aminoindane. It was formerly reported that ω-TAm from Vibrio fluvaris (Shin and 
Kim, 2001) and CV2025 (Kaulmann et al., 2007) showed high activities towards 
amino donor of aromatic (S)-amines such as MBA and (S)-aminoindane. Nonetheless, 
only PA00221 ω-TAm (pQR813) and Rsph17025_2835 ω-TAm (pQR1019) using 
benzylamine and PA00221 ω-TAm (pQR813) using s-1-aminoindane showed 
equivalent activities to the CV2025 ω-TAm. Their resulted product formations were 
12 mM and 21 mM respectively. Yet again, as shown in Graphs D (benzylamine) and 
E (s-1-aminoindane) of Figure 5.5, the remaining ω-TAms displayed low conversions 
of 5 mM ABT or less. 
 
In the case of BSU09260_1971 ω-TAm (pQR960), enzyme was identified that had a 
better catalytic activity than CV2025 (pQR801) when an amino acid, L-α-serine was 
used as amino donor. As presented in Graph C (Figure 5.5) BSU09260_1971 ω-TAm 
(pQR960) catalysed the conversion of 50 mM L-α-serine and 50 mM Ery yielded 25 
mM ABT equivalent to a 23 % (mol.mol
-1) higher conversion than CV2025 ω-TAm.  
 
L-α-Serine is a compound naturally occurring in E.coli cells and is also available 
commercially at a considerably cheap price than many other amino donors tested. 
Therefore, this novel ω-TAm bioconversion was selected for subsequent scale-up 
studies (Section 6.4). Comparable data obtain at a larger scale will help confirm the 
novel ω-TAm biocatalytic activity for the transamination of Ery using the relatively 
cheap donor, L-α-serine. The identification of this reaction also indirectly proves the 
effectiveness of these microscale studies as a rapid tool for quantitative evaluation of 
various biocatalysts and reaction conditions. 
 
Overall the results indicate the relatively narrow substrate range of most ω-TAms 
apart from PP2799 ω-TAm (pQR811), PAO0221 ω-TAm (pQR813) and 
Rsph17025_2835 ω-TAm (pQR1019) which each showed relatively good activity 
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with a variety of amine donors.  These ω-TAms have significantly broader substrate 
specificities towards different amino donors than the CV2025 ω-TAm (pQR801). The 
asymmetric synthesis of the tested amino donors with all novel ω-TAms were no 
greater than 25 mM, which yet again signifying the extremely unfavourable 
thermodynamic equilibrium and products and / or substrates inhibitions. In general, 
most ω-TAms showed better and considerably higher reactivities towards aromatic 
amines than aliphatic amines and amino acids as witnessed in the previous reported 
work (Hwang and Kim, 2004).  
 
5.6. OPTIMIZATION OF SECOND ENZYME REACTION CONDITION 
 
5.6.1. Parallel CV2025 ω-TAm Bioconversions with Second Enzyme Reaction 
Using Alcohol Dehydrogenase (ADH) from Lactobacillus Kefir 
 
As presented in Section 4.5, the utilization of ADH, an NADP
+
 dependent enzyme, 
coupled with GDH for efficient NADPH co-factor regeneration is one potential option 
for in-situ AP removal. This led to a 3.3-fold increase in bioconversion yield, but 
under the conditions used is likely to be uneconomic due to the expense of the 
additional enzymes and co-factors involved. Obtaining enantiomerically pure 
intermediates and products efficiently and economically is of immense importance in 
the pharmaceutical and chemical industries (Sanchez and Demain, 2011). Hence, the 
work presented here aims to use the microscale process platform to evaluate the most 
economically feasible conditions. In practice, this will involve the study of reduced 
concentrations of enzymes at varying ratios and reduced reactant / co-factor 
concentrations. In addition, 1.5 M HEPES was used for all reactions performed here 
to ensure pH was well kept at about its optimum value as noted earlier in Section 4.5. 
The unit operations performed on the automated platform were as defined in Section 
5.4.2 and mainly corresponded to the disposable tips utilization approach. Table 5.2 
summarizes the variable parameters used for further investigation.  
 
The automated process conditions allowed for the evaluation of a much wider range 
of enzyme and reactant concentrations than the manual process. When the initial 
glucose concentration was maintained at a concentration of 70 mM, equal to the 
previous manual process, the concentration of ADH used could be decreased from 1.2  
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g.L
-1
 down to 0.03 g.L
-1 
while still obtained the same production producing 40 mM 
ABT at 21 hours (Figure 5.6 (A-1)). In terms of AP conversion into (R)-1-
phenylethanol by the second enzyme ADH coupled with GDH, it was observed that 
the AP produced was almost totally consumed (2 mM or less left in the reaction 
solution) when the ADH concentration reduced to 0.03 g.L
-1
 or less (Figure 5.6 (A-
2)). Further reduction of the ADH concentration to only 0.003 g.L
-1
 significantly 
reduced the bioconversion yield by more than 20 %  (mol.mol
-1
) while the 
concentration of AP left in the reaction was 8 mM (above the inhibitory 
concentration). When the same ADH concentration was used with reduction of the 
GDH concentration from 0.02 g.L
-1
 to 0.002 g.L
-1
, the reaction conversion further 
declined to 28 mM ABT, whereas only approximately half AP was succeeded to 
diminish from the reaction solution (Figure 5.6 (A-1 and A-2)). 
 
 
Table 5.2. Summary of parameters investigated for CV2025 ω-TAm bioconversions using the 
second enzyme system on the automated platform. 
 
 
 
 
 
  Glucose (mM) 
70, 50, 25 
Enzyme concentrations 
ADH 
(g.L
-1
) 
GDH 
(g.L
-1
) 
1.2 0.02 
0.3 0.02 
0.03 0.02 
0.003 0.02 
0.003 0.002 
 
 
It was also possible to achieve comparable ABT production when the glucose 
concentration was reduced to 50 mM. However, a consequence of this was that AP 
reduction by the second enzyme reaction was reduced, with 8 mM AP being left in 
solution (a concentration close to the inhibitory level (Section 4.3)) whereas only 2 
mM or less was left in solution at the higher 70 mM glucose concentration (Figure 5.6 
(B-2)).   
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Figure 5.6. Bioconversion kinetics of CV2025 ω-TAm (pQR801) using the second enzyme 
system with various ratios of ADH, GDH and glucose (as described in Table 5.2). Experiments 
performed using ADH from Lactobacillus kefir on the microscale automation platform (Section 
5.6.1): (A-1) ABT productions and (A-2) AP consumption of reaction using 70 mM Glucose; (B-1) 
ABT productions and (B-2) AP consumption of reaction using 50 mM Glucose and (C-1) ABT 
productions and (C-2) AP consumption of reaction using 25 mM Glucose. The reactions were 
sampled at 0 hr (■); 21 hr (■) and 25 hr (■). Reaction conditions: 0.3 g.L-1; CV2025 ω-TAm; 0.2 
mM PLP; [MBA] and [Ery] were 50 mM, 1 mM NADPH; 30 
º
C; pH 7.5; 300 rpm in 1500 mM 
HEPES buffer; total volume of 300 µL in 96-glass microwell plate covered with 5 layers pre-cut 
pierceable films (Section 5.4). The concentrations of ADH and GDH used in the reactions are as 
mentioned in the Enzyme Concentration (g.L
-1
) of each graph. Bioconversions performed as 
described in Sections 2.5.3 and 2.5.6. Error bars represent one standard deviation about the 
mean (n=3). 
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At the lowest glucose concentration (25 mM) evaluated, similar ABT production was 
observed for all the combination of ADH and GDH concentrations tested. As 
expected, as the glucose concentration was reduced beyond that of the starting 
substrate it reduced the rate of second enzyme reaction as displayed by increased in 
AP concentrations in the solutions (Figure 5.6 (C-2)). Theoretically, for every 1 mM 
glucose will convert 1 mM AP. Equally, for the first 3 reactions of ADH 
concentrations 1.2, 0.3 and 0.03 g.L
-1
, of about 40 mM ABT produced and as 
predicted about 15 mM or more AP was left unconverted in the reactions. 
Furthermore at this glucose concentration, we have it just enough to convert an 
amount of AP produced to lowered it down to below its inhibition concentration (Ki). 
Complete reactions observations were depicted in Figure 5.6.  
 
Confirmation that glucose was the limiting factor was obtained from a control 
reaction carried out at very low glucose of 5 mM is shown in Figure 5.7. It was 
observed at glucose limitation, the CV2025 ω-TAm bioconversion reaction 
conversion decreased to 25 mM from 40 mM of ABT as previously reached with 
excess glucose concentration under identical reaction conditions and parameters. 
 
 
5.6.2. Parallel CV2025 ω-TAm Bioconversions with a Second Enzyme Reaction 
Using Alcohol Dehydrogenase (ADH) from Thermoanaerobium Brockii 
 
An alternative ADH from Thermoanaerobium brockii (ADH-TB) was also used to 
catalyse the second enzyme reaction in order to provide an activity and cost 
comparison to the previously studied ADH from Lactobacillus kefir. Again, the 
experimental design involved the use of the automated platform to simultaneously 
explore and minimise the various enzyme and glucose concentrations. 
 
As presented in Figure 5.8, the CV2025 ω-TAm bioconversion reactions with 
application of the second enzyme reaction using ADH-TB and 70 mM glucose 
displayed an optimum conversion of 40 mM ABT as previously obtained using ADH 
from Lactobacillus kefir (Section 5.6.1). Nevertheless, the conversion rate observed 
was 4-fold slower with ADH–TB than earlier observed with the ADH Lactobacillus 
kefir. Furthermore, 20 % (mol.mol
-1
) of AP was detected as being unconverted to (R)-
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1-phenylethanol while the earlier bioconversions using ADH from Lactobacillus kefir 
showed complete depletion of AP from the reaction solution (Figure 5.6 (A-2)). Also, 
alongside the decreased rate of the ADH-TB only approximately 60 % (mol.mol
-1
) 
corresponding 30 mM ABT conversion (Figure 5.8 (A-1)) was achieved with 10 mM 
AP was quantified left in the reaction solution (Figure 5.8 (A-2)). 
 
Comparable results were found when glucose was present at initial concentrations of 
50 mM and 25 mM in the second enzyme reactions with ADH-TB (Figure 5.8 (B-1 
and C-1)). For both sets of reaction conditions, no yield improvement was 
accomplished as ADH–TB and GDH concentrations were decreased.  
 
 
 
 
Figure 5.7. Bioconversion kinetics of CV2025 ω-TAm (pQR801) using the second enzyme 
reaction with ADH from Lactobacillus kefir and Glucose limitation on the microscale automation 
platform (Section 5.6.1): (A) ABT productions and (B) AP consumption. The reactions were 
sampled at 0 hr (■); 20 hr (■) and 25 hr (■). Reaction conditions: 0.3 g.L-1 CV2025 ω-TAm; 1.2 
g.L
-1 
ADH; 0.02 g.L
-1 
GDH; 0.2 mM PLP; [MBA] and [Ery] were 50 mM, 5 mM Glucose; 1 mM 
NADPH; 30 
º
C; pH 7.5; 300 rpm in 1500 mM HEPES buffer; total volume of 300 µL in 96-glass 
microwell plate covered with 5 layers pre-cut pierceable films (Section 5.4). Bioconversions 
performed as described in Sections 2.5.3 and 2.5.6. Error bars represent one standard deviation 
about the mean (n=3). 
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Figure 5.8. Bioconversion kinetics of CV2025 ω-TAm (pQR801) using second enzyme reaction 
with various ratios of ADH, GDH and glucose (as described in Table 5.2). Experiments 
performed using ADH from Thermoanaerobium brockii on the microscale automation platform 
(Section 5.6.2): (A-1) ABT productions and (A-2) AP consumption of reaction using 70 mM 
Glucose; (B-1) ABT productions and (B-2) AP consumption of reaction using 50 mM Glucose and 
(C-1) ABT productions and (C-2) AP consumption of reaction using 25 mM Glucose. The 
reactions were sampled at 0 hr (■); 6 hr (■); 20 hr (■) and 25 hr (■). Reaction conditions: 0.3 g.L-
1
 CV2025 ω-TAm; 0.2 mM PLP; [MBA] and [Ery] were 50 mM; 1 mM NADPH; 30 ºC; pH 7.5; 
300 rpm in 1500 mM HEPES buffer; total volume of 300 µL in 96-glass microwell plate covered 
with 5 layers pre-cut pierceable films (Section 5.4). The concentrations of ADH and GDH used in 
the reactions are as mentioned in the Enzyme Concentration (g.L
-1
) of each graph. 
Bioconversions performed as described in Sections 2.5.3 and 2.5.6. Error bars represent one 
standard deviation about the mean (n=3) 
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Overall, the low product yield and the greater AP accumulation in the CV2025 ω-
TAm bioconversions when using ADH-TB as the second enzyme indicated a 
relatively slow reaction rate. This once again implies that the glucose excess amount 
plays a substantial role in driving the second enzyme reaction faster. Consequently, it 
will promote the reduction of interconversion (i.e AP to MBA) rate of the CV2025 ω-
TAm reaction whilst hinder the accumulation of AP concentration to reach Ki. This 
indeed verifies another possible candidate that accepted AP, however under the 
conditions applied, the AP reduction rate was substantially slower.  
 
Further, the practical use of the ADH-TB was also previously observed to be limited 
to substrates with bulky side chains such as AP despite its recognition for thermal 
stability and broad substrates range (Hummel, 1990). 
 
5.6.3. Economic Considerations of Second Enzyme Reactions 
 
Use of the automated microscale methods to study the second enzyme system has 
provided a better understanding of how changes in a reaction variable will affect the 
overall CV2025 ω-TAm bioconversion rate and yield.  As presented in Sections 5.6.1 
and 5.6.2, ADH from Lactobacillus kefir showed a better biocatalytic performance 
than ADH-TB. Although the concentration of the ADH from Lactobacillus kefir could 
be reduced to low levels (i.e 0.03 g.L
-1
), the dual enzyme reaction nevertheless 
performs efficiently under high substrate concentrations. In addition, the second 
enzyme reaction catalysed by ADH Lactobacillus kefir can perform reasonably well at 
glucose concentrations as low as 25 mM. However, the possibility of using lower 
glucose concentrations for bioconversions with ADH-TB was ruled out since 70 mM 
seem to be the most favourable concentration. This again proves the ADH 
Lactobacillus kefir performance which is most likely due to its good catalytic activity 
and stability (Table 5.3).  
 
In general, the main reason to choose a biocatalytic process is the cost advantage over 
other available process options including chemical synthesis (Ghisalba et al., 2010). If 
the cost issue is addressed particularly on a price per mg basis of ADH enzyme from 
both studied strains, ADH from Lactobacillus kefir is again shown to be the best 
enzyme as the market price is 4 times cheaper than ADH-TB (Table 5.3). Glucose as 
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the co-substrate, however, is considerable cheaper at £0.13 per gram and will have 
less impact on process economics. Therefore, it is best to use at least an equal 
concentration of glucose to the first reaction substrate concentration (i.e 50 mM) to 
promote higher recycling of co-factor NADPH and consequently drive the second 
enzyme reaction rate even faster or to completion. 
 
In summary, the automated evaluation of second enzyme reaction conditions has 
made this a more attractive process option since it was possible to explore a higher 
number of variables simultaneously. These identified significant opportunities for 
reducing the cost of operating the second enzyme system.  
 
Table 5.3. Activity and prices of the various ADHs used in Sections 5.6.1 and 5.6.2. 
 
Enzyme Activity (units mg
-1
) Market Price 
£ (per mg) 
 
ADH Lactobacillus kefir 
 
0.4 
 
(1 unit will reduce 1 µmol AP per min at 
pH 7 and 25 ºC to phenylethanol) 
 
1.16 
 
ADH Thermoanaerobium 
brokii 
 
3.82 
 
(1 unit will oxidize 1 µmol of 2-propanol 
to acetone per min at pH 7.8 and 40 ºC in 
the presence of NADP
+
) 
 
4.12 
 
 
 
5.7. PARALLEL EVALUATION OF REDUCED PRESSURE REACTION 
 
5.7.1. The Design of Reduced Pressure System Automation Platform  
 
The microscale technique designed for reduced pressure reactions in Section 4.6 used 
a customised vacuum manifold (Te-VacS) that could be located on the deck of the 
Tecan robotic workstation. Indeed, the vacuum manifold used in Section 4.6, the Te-
VacS module was originally designed for integration with a Tecan platform and its 
operation could be controlled by the Gemini software. The Te-VacS module provides 
two separate vacuum blocks positions connected to a high performance vacuum pump 
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and its specification details are displayed in Table 2.6 (Section 2.5.6). The combined 
use of the Te-VacS and the integrated robotic manipulator RoMa allows full 
automation of this biocatalytic process option in a 96-well format similar to the 
procedure already performed manually. 
 
The reduced pressure was applied by specifying the vacuum time and the applied 
pressure intended for each reaction studied. The Te-VacS vacuum block was 
configured to host the glass 96-microwell plate for this reduced pressure operation. 
Once the enzyme and substrates were dispensed using disposable tips into the reaction 
plate, this was placed inside the vacuum block. The automated sequence then 
continues with the RoMa placing another plate on the top of Te-VacS which acted as 
lid. The reaction begins once the vacuum is applied. Given the closed nature of the 
vacuum block the vacuum was released at defined time intervals to allow reaction 
sampling. Once again the RoMa arm was used to remove the plate lid to allow the 
disposable tips to aspirate the sample solution. Once this was done the RoMa arm 
placed the plate lid back on the vacuum block, and the pressure was again applied to 
continue the reaction.  The sample solution was clarified by centrifugation and sample 
aliquots were derivatized in HPLC vials as described in Section 5.4.2. Figure 5.9 
illustrates the layout of the Tecan platform set up for reduced pressure bioconversions. 
 
5.7.2. Parallel CV2025 ω-TAm Bioconversions at Reduced Pressure 
 
The work presented here aims to establish the feasibility of the automated vacuum 
manifold for performing reduced pressure bioconversions with robotic integration. 
Again considering the total volume of the reaction, it was intended to apply mild 
pressure to encourage the evaporation of AP as reaction progress (Section 4.6). It was 
found that the minimum pressure that can be effectively applied to the system was 30 
mbar (~22.5 torr). This pressure was about 4 times higher than what have been 
applied in manual system using vacuum/ pressure pump. Unlike the manual process, 
the Tecan workstation did not have independent temperature control.  Because it was 
not possible to control the temperature on the automated platform at 30 ºC, reactions 
were compared with / without the applied vacuum at ambient temperature, 23 ºC. 
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Figure 5.9.  Detail of the robotic platform used for CV2025 ω-TAm standard bioconversions 
with reduced pressure system using a Te-VacS vacuum separator (Section 5.7). The image shows 
the worktable layout of the integrated equipment involved on the Tecan Genesis robot. 
Abbreviations: RoMa is robotic manipulator arm; LiHa is liquid handling arm / liquid handler; 
DiTi is disposable pipette tips. 
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Before preceded with the reaction, yet again the evaporation rate of the reaction 
medium was first determined in order to facilitate accurate measurement of product  
and substrate concentrations. Again the water evaporation rate was measured based on 
gravimetric analysis. The water evaporation rate was found to be constant at 1.25 
µL.hr
-1
 (Figure 5.10) during the course of bioconversion. This was about 5 times 
slower than observed in the manual process (Figure 4.7) most likely due to the lower 
operating temperature. The quantification of all compound concentrations for reduced 
pressure reactions were subsequently corrected for evaporative losses. Again, CV2025 
ω-TAm in clarified lysate form was used to catalyse MBA and Ery bioconversions at 
equimolar concentrations of 50 mM.  
 
The CV2025 ω-TAm reaction under reduced pressure option was monitored only for 
a 19 hour period as the reaction was expected to be completed faster than previous 
studies. This was due to the use of 3 times the concentration of CV2025 ω-TAm (i.e. 
1.0 g.L
-1
) in the clarified lysate form to accelerate the reaction rate to ensure the 
reaction could reach equilibrium 24 hours or less where the maximum level of 
evaporation would be 10 % (vol.vol
-1
). The reaction profiles for automated reduced 
pressure reactions are shown in Figure 5.11. These can be compared to a control 
reaction at normal atmospheric pressure at room temperature.  
 
The substrate consumption rates and product yields are plotted together in Figure 
5.11.  The optimum product yield of CV2025 ω-TAm under reduced pressure method 
was 19 mM ABT in 16 hours.  When it is compared to the standard reaction 
conducted at the same room temperature (23 ºC instead of 30 ºC), the reduced 
pressure condition applied has proven to facilitate an improved production yield by 
approximately 2.3-fold. Moreover, the system also have successfully shown its 
substantial effect on the ability and purpose to encourage more than 80 % (mol.mol
-1
) 
AP evaporation during the course of reaction which was in an excellent agreement to 
the manual platform (Section 4.6).  
 
Despite the technical limitation of temperature control, we have demonstrated the 
capability of reduced pressure option on a robotic platform to be effective for the 
study  of  reduced  pressure  bioconversion  in  order to remove inhibitory and volatile  
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Figure 5.10. Microwell evaporation kinetics of water at 23 ºC in the automated reduced 
pressure system (Section 5.7). Experiments performed at 30 mbar from 96-glass microwell plates. 
The water evaporation rate was constant at 1.25 µL.hr
-1
. Error bars represent one standard 
deviation about the mean (n=3).  
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Figure 5.11. Bioconversion kinetics of CV2025 ω-TAm (pQR801) performed at reduced 
pressure on microscale automated platform and manual method. Experiments performed using 
96-microwell plate covered with 5 layers pre-cut pierceable films (Section 5.7) and manual 
experiments using 96-glass microwell plate covered with thermo plastic elastomer cap performed 
at room temperature (23 ºC): MBA consumption (- -■- -), ABT(- -▲- -) and AP productions (- -
●- -) for the CV2025 ω-TAm bioconversions under the reduced pressure automation format and 
MBA consumption (■), ABT (▲) and AP(●) productions for the CV2025 ω-TAm bioconversions 
at 23 ºC with manual experiments. Reaction conditions of both platforms: 1.0 g.L
-1
 CV2025 ω-
TAm; 0.2 mM PLP; [MBA] and [Ery] were 50 mM; 23 
º
C; pH 7.5; 300 rpm in 50 mM HEPES 
buffer; total volume of 300 µL in 96-glass microwell plate. Bioconversions performed as 
described in Sections 2.5.4 and 2.5.6. The data plotted for reduced pressure reactions were 
corrected for water evaporation rate (Figure 5.10). Error bars represent one standard deviation 
about the mean (n=3). 
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side products. In addition, the automation reaction system also developed as a fast and 
reliable as verified from the data achieved. One of the major features of the system is 
its flexibility, allowing examination of hundreds of samples using 2 parallel 96-well 
micro-plates reactions to be conduction on the couple vacuum blocks come with 
adaptation of the system online setup for intended applied pressure. In short, the 
automation platform successfully plays its role as one of the simplest and most cost 
effective routes to improved reaction yields of bioconversions encompassed 
unfavourable thermodynamic equilibrium with reduce bioprocess optimization times.  
 
 
5.8. SUMMARY 
 
In this chapter, the successful automation of the microscale bioprocess methods 
developed in Chapter 4 has been described. These have been applied to the detailed 
evaluation and optimisation of ω-TAm reaction conditions at the 96-well plate scale. 
The automated systems have facilitated a significant increase in parallel 
experimentation and the simultaneous evaluation of different process conditions and 
their optimization.   
 
Automated evaluation of a library of novel ω-TAm and a range of alternative amino 
donors showed most had specific activities equal or poorer than the CV2025 ω-TAm 
(Section 5.5). Therefore, this work shows that the CV2025 ω-TAm is still one of the 
most promising biocatalyst for asymmetric synthesis of broad substrates specificity. 
However, the experiments did identify one novel ω-TAm from Bacillus subtillis that 
have a high catalytic activity for transamination of Ery using L-α-serine as amino 
donor which resulted in a 23 % (mol.mol
-1
) improved conversion yield than CV2025.  
 
The work here also demonstrated the utility of the automation platform for the rapid 
evaluation and optimisation of reaction conditions when using more complication 
second enzyme reactions where multiple parameters must be evaluated 
simultaneously (Section 5.6). The optimised reaction could be performed at 40-fold 
reduction in the concentration of ADH from Lactobacillus kefir whilst maintaining 
comparable reaction conversion. This would lead to significant cost saving in terms of 
process economics. In contrast, evaluation of new ADH from Thermoanaerobium 
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brokii over a wide range of reaction conditions indicated little improvement over the 
first ADH studied.  
 
Finally, automation of bioconversions performed at reduced pressure was also 
achieved in a fully automated, hands-free manner (Section 5.7). The automated 
reduced pressure showed advantages over normal pressure CV2025 ω-TAm 
bioconversion as confirmed by 2.3-fold production yield improvement. 
  
Overall, this chapter has demonstrated automation of all the microscale unit 
operations developed in the previous chapter. Once again these have been shown to be 
able to increase the yield of equilibrium controlled CV2025 ω-TAm bioconversions 
by use of alternative amino donors or the in situ removal of inhibitory AP (Section 
3.5). Automation of the unit operations has enabled parallel and more detailed 
evaluation of reaction conditions than was possible with the manual methods. This has 
led to identification of one ω-TAm / amino donor combination that has increased rates 
and yields compared to the CV2025 ω-TAm. It has also demonstrated how the 
microscale methods can be used to optimise and reduce the costs of bioconversions 
such as those using co-factor recycling systems. In the next chapter, the important 
findings of this chapter will be validated at preparative scale. 
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6. PREPARATIVE SCALE 
VERIFICATION OF MICROSCALE 
BIOCONVERSION KINETICS 
 
 
 
 
 
6.1. INTRODUCTION 
 
As discussed in Section 1.5 microscale bioprocessing techniques can be used for to 
reduce costs and timescales of biocatalytic process development (Lye et al., 2003). 
Automation of these techniques can further accelerate the collection of bioconversion 
design data and the optimisation of reactions conditions (Chapter 5). However, one of 
the challenges of conducting early stage process studies at the microscale is the need 
for effectively translating the micro-scale process information into conventional 
laboratory or pilot plant scales (Zhang et al., 2008; Doig et al., 2002; Micheletti et al., 
2006; Smith et al., 2010).  
 
Experiments performed during early stage bioprocess development need to provide 
insights into the most suitable strategies for further process optimization and scale-up 
in order to maximize the yield of product on substrate and catalyst (Smith et al., 2010; 
Liddell, 2009). These issues are addressed in this final chapter. With the increase in 
scale reactions, conditions can frequently differ especially for industrial applications. 
Examples of changes include: use of  more concentrated solutions to improve space-
time yield, differences in mixing methods (overhead versus magnetic versus shaking), 
use of solvents that are more amenable to larger scale production and reductions in 
enzyme loading in order to improve process economics (Wells, 2006). 
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6.2. AIM AND OBJECTIVES 
 
The automation studies in the previous chapter helped identify microscale reaction 
conditions that enabled a 40-fold reduction in the concentration of ADH used for AP 
by-product removal (Section 5.6.1) and identification of novel ω-TAm from Bacillus 
subtillis that had a high catalytic activity for transamination of Ery using L-α-Serine 
as amino donor (Section 5.5). The aim of this chapter is to validate these important 
findings at preparative scale. Validation of the microscale results is important to the 
capacity for microscale automation tools to speed up biocatalytic process 
development and design. The key objectives of this chapter are thus: 
 
 To scale-up the CV2025 ω-TAm bioconversion using the optimised second 
enzyme reaction conditions and investigate the implementation of pH-stat 
control at the preparative scale. 
 
 To validate the novel bioconversion kinetics with BSU09260_1971 ω-TAm 
from Bacillus subtillis, using L-α-serine as amino donor. 
 
 To confirm ABT product synthesis from the above bioconversions using Mass 
spectrometry and bioconversions of L-α-serine and Ery perform using a null 
strain of E.coli BL21 (DE3) in clarified lysate form. 
 
6.3. VERIFICATION OF OPTIMISED SECOND ENZYME REACTION 
CONDITIONS 
 
In the preceding work, microscale experimentation  have been presented to explore 
the second enzyme reaction first using manual methods (Section 4.5) and 
subsequently to optimise reaction conditions using parallel, automated 
experimentation (Section 5.6). Despite the considerable reduction in enzyme 
requirements, the microscale methods relied on high buffer concentrations for 
microwell pH control given the stoichiometric production of gluconic acid. Here, the 
preparative scale up of the optimised bioconversion conditions is presented using a 
902 STAT Titrino pH controller device application (Section 2.5.2). This is important 
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for comparison and evaluation of the effectiveness of microscale reactions and also 
reduction of the amount of salts needed during the process in order to further 
minimize the production cost.  
 
The second enzyme reaction (Figure 4.2) was scaled-up from 300 µL parallel 
microwell studies to a 30 mL working volume laboratory scale stirred bioreactor. This 
represents a 100-fold increase in volume. The optimization conditions for this reaction 
were described in Section 5.6.1, and consisted of 0.03 g.L
-1
 ADH from Bacillus kefir, 
0.02 g.L
-1
 GDH and 50 mM Glucose. Further details of the preparative scale reaction 
conditions are displayed in Table 6.1. The transamination reaction was likewise 
performed using equilmolar concentrations of MBA and Ery at 50 mM each, and the 
CV2025 ω-TAm concentration was fixed at 0.3 g.L-1 in clarified lysate form (Section 
2.3.1). 
 
Results from the preparative scale process are depicted in Figure 6.1. The temperature 
was kept constant at 30 
o
C using a circulating water bath in contrast to an “under 
plate” heated platform used for the microscale experiments (Chapters 4 and 5). 
Instead of orbital shaking, the preparative scale bioreactor was mixed with a magnetic 
stirring bar in order to maintain adequate mixing and mass transfer rates. Changes in 
pH, temperature, and NaOH volume addition were monitored online using Tiamo 2.2 
Workplace software (Section 2.5.2). 
 
Initial experiments performed the reaction in pure water but, due to the absence of any 
buffering capacity in the solution, it was difficult to maintain the pH at an optimal 
value of pH 7.5 (Section 3.4.3). In particular, it was hard to stabilize the pH at a 
desired value due to rapid pH fluctuation as soon as the reaction was started and 
gluconic acid was formed by the second enzyme system (Figure 4.2). Subsequently 
the pH-STAT experiments began with 50 mM HEPES buffer present which 
significantly improved the stability of pH control.  The pH of the preparative scale 
bioconversion was maintained at 7.5 by the automated addition of 1.0 M NaOH in 
replacement of 1500 mM HEPES buffer used in the microscale reactions (Section 
5.6.1).  
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Table 6.1. Comparison of reaction conditions used for preparative scale verification of 
bioconversion kinetics optimised at the microscale. Verification involved scale-up of the selected 
second enzyme reaction conditions and use of an alternative amino donor previously optimised 
in automated, microscale experiments (Sections 5.6.1 and 5.5) and repeated here at preparative 
scale (Section 6.3 and 6.4).  
 
Bioconversion scale Microscale Preparative scale 
Temperature (
o
C) 30 30 
Temperature control Under plate heated platform Circulating water bath 
Mixing Speed (rpm) 300 300 
Mixing device 
Orbital Shaking platform 
(diameter= 6 mm) 
Magnetic stirrer 
Working reaction 
volume 
300 µL 30 mL 
Working volume and 
vessel 
550 µL glass microplate 
50 mL glass stirred 
bioreactor 
pH 7.5 7.5 
Buffer  
1500 mM HEPES buffer 
(Second Enzyme Reaction) 
50 mM HEPES buffer 
(Alternative Amino Donors 
Reaction) 
 
50 mM HEPES buffer 
 
pH controller - 
pH stat  with  1.0 M 
NaOH (aq) 
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In comparison to the microscale results in Section 5.6.1, the preparative scale reaction 
achieved a final ABT concentration of 27 mM, which represents a 26 % (mol.mol
-1
) 
decrease in reaction yield over 21 hours (Figure 6.1). A similar difference was seen in 
the initial rates of conversion respectively. This suggests that the CV2025 ω-TAm 
biocatalyst lost its activity more quickly in lysate form in the 30 mL bioreactor. This 
may be due to the use of the magnetic stirrer bar providing more vigorous mixing or 
the impact of the concentrated alkali additions used for pH control at the larger scale. 
Moreover, the discrepancies were further observed when the reaction was prolonged 
for another few hours. At the microlitre scale, the final conversion was constant at its 
optimum for the next few hours, whereas about 20 % (mol.mol
-1
) of the product was 
lost over a further 3 to 5 hours.  
 
In the preparative bioconversion, AP was almost completely removed from the 
reaction solution unlike what had been observed earlier in the microscale reaction, 
where approximately 20 % (mol.mol
-1
) AP was left unconverted to 1-PE and 
remained in solution. In the preparative scale bioconversion, the greater removal of 
AP is thought to be attributed to evaporation. Unlike the microscale format, where the 
reaction plate was covered with either thermo plastic elastomer cap (Chapters 3 and 4) 
or pre-cut pierceable films (Chapter 5), the glass vessel of the preparative scale 
(Figure 2.2) was not well covered and allowed further AP evaporation as the reaction 
progress. This was further exaggerated due to the high liquid surface area to volume 
ration in the glass vessel. 
 
Therefore, it can be concluded that the slightly difference in the final yield was mainly 
attributed to either the transamination reaction mechanism or the differences of 
reaction conditions between scales. Microscale, preparative and process scale 
bioreactors can present differences in fluid dynamics, solvent evaporation, shear 
stress, mass and heat transfer phenomena, and the methods used for pH control. These 
can cause significant and often unpredictable discrepancies in the bioconversion 
behaviour at the different scales (Doig et al., 2002; Micheletti et al., 2006; Nealon et 
al., 2006; Matosevic et al., 2008).  
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Figure 6.1. Comparison of preparative scale (Section 6.3) and automated microwell platform 
(Section 5.6.1) for bioconversion kinetics of CV2025 ω-TAm (pQR801) with second enzyme 
reaction using ADH from Lactobacillus kefir: ABT (♦) AP (■) productions of preparative scale 
and ABT (▲) AP (●) productions of automated microwell platform. Reaction conditions of 
preparative scale: 0.3 g.L
-1
 CV2025 ω-TAm; 0.03 g.L-1 ADH; 0.02 g.L-1 GDH; 0.2 mM PLP; 
[MBA] and [Ery] were 50 mM; 50 mM Glucose; 1 mM NADPH; 30 
º
C; pH 7.5; 300 rpm in 50 
mM HEPES buffer; total volume of 30 mL in the developed preparative scale bioreactor (Figure 
2.2). Section Bioconversions performed as described in Sections 2.5.2.  Reaction conditions of 
automated microwell platform as described in Figure 5.6. Error bars represent one standard 
deviation about the mean (n=3). 
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6.4. VERIFICATION OF THE USE OF ALTERNATIVE AMINO DONORS 
AND ω-TRANSAMINASES: L-α-SERINE AS AMINO DONOR 
 
6.4.1. Transamination of Ery Using L-α-serine by BSU09260_1971 ω-TAm in 
Clarified Lysate Form 
 
In Section 5.5, the automated microwell experiments allowed parallel evaluation of a 
library of novel ω-TAms and led to the discovery that the BSU09260_1971 ω-TAm 
from Bacillus subtillis (pQR960) could catalyse Ery conversion using L-α-serine as 
amino donor and at a better rate than the more widely studied CV2025 ω-TAm.  Here, 
the reaction kinetics will be verified at preparative scale, and the identity of the ABT 
product confirmed. The preparative scale reaction was performed using equilmolar 
concentrations of L-α-serine and Ery of 50 mM (Figure 6.2). The BSU09260_1971 ω-
TAm concentration was kept constant at 0.3 g.L
-1
 in clarified lysate form. The 
preparative scale process reaction conditions and equipment setup are as depicted in 
Table 6.1 and Figure 2.2 (Section 2.5.2) respectively. 
 
 
Figure 6.2. Reaction scheme of the BSU09260_1971 ω- TAm from Bacillus subtillis (pQR960) 
catalysed transamination between L--serine and L-erythrulose (Ery) to β-hydroxypyruvic acid 
and 2-amino-1,3,4-butanetriol (ABT) in the presence of co-factor pyridoxal-5-phosphate (PLP).  
 
 
The BSU09260_1971 ω-TAm catalysed L-α-serine and Ery to by-product β-
hydroxypyruvic acid and targeted product ABT showed similar reaction kinetics and 
conversions to the µL scale format up to around 15 hours with optimum conversion of 
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42 % (mol.mol
-1
) (Figure 6.3). At longer times, there was a rapid decrease in L-α-
serine and ABT concentrations. However, the reaction rate in the bioreactor was 
relatively faster as the optimum yield was reached 6 hours earlier than the µL scale 
reaction. This observation was consistent with the pH changes monitored online. The 
pH was maintained approximately constant over time at pH 7.5 as observed by the 
continuous addition of NaOH to the reaction solution.  However, no addition of   
NaOH was observed 5 hours before it reached the optimum point. This indicates that 
the transamination rate was decelerating due, most likely, to decreases in the activity 
of the enzyme. 
 
The degradation of the ABT product over prolonged reaction periods (> 5 hours) was 
again observed, as earlier detected in Section 6.3. Additionally a decrease of amino 
donor, L-α-serine was also observed. Prior the reaction termination, only about 6 mM 
of L-α-serine was quantified left in the reaction solution which may have led to the 
slightly lower ABT yield seen in the preparative scale bioconversion. The degradation 
of ABT and L-α-serine is again thought to be due to either NaOH concentration or 
competing reactions. 
 
Serine is a non-essential amino acid that can be synthesized and degraded in cell 
metabolism for maintenance and utilization in several pathways of serine catabolism 
(Hama et al., 1988). Therefore, the serine consumption by side reactions using the 
clarified lysate is not unexpected. However, the disappearance of L-α-serine was 
greater than observed in the microscale reactions presented earlier in Chapters 4 and 
5. Visual observations indicated that the reaction solution changed colour in the 
preparative scale bioconversion from an initial pale yellow, due to the presence of the 
co-factor PLP, into a bright yellow after 4 to 5 hours and finally a brownish colour at 
the termination point. This further suggests either non-specific side reactions using the 
lysate or degradation of the serine due to the NaOH used for pH control.  
 
In practice, to overcome the side reactions of the L-α-serine, it is possible to perform 
the bioconversion with a higher concentration of amino acceptor instead of equilmolar 
substrates. The CV2025 ω-TAm bioconversions of MBA and Ery as discussed in 
Chapter 4 shown that the 20 mM excess of amino acceptor did facilitate the 
acceleration  of  the  initial reaction rate faster and consequently increased the reaction  
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Figure 6.3. Comparison of preparative scale (Section 6.4.1) and automated microwell platform 
(Section 5.5) for bioconversion kinetics of BSU09260_1971 ω-TAm (pQR960) in clarified lysate 
form with L-α-serine as an alternative amino donor: L-α-serine consumptions (♦) ABT (■) 
productions for preparative scale and L-α-serine consumptions (●) ABT (▲) productions for 
automated microwell platform. Reaction conditions of preparative scale reactions: 0.3 g.L
-1
 
BSU09260_1971 ω-TAm clarified lysate; 0.2 mM PLP; [L-α-serine] and [Ery] were 50 mM; 30 
º
C; pH 7.5; 300 rpm in 50 mM HEPES buffer; total volume of 30 mL in the developed 
preparative scale bioreactor (Figure 2.2). Bioconversions performed as described in Sections 
2.5.2. Reaction conditions of automated microwell platform as described in Figure 5.5. Error 
bars represent one standard deviation about the mean (n=3). 
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yield by additional of 20 % (mol.mol
-1
). Previous reported work on the study of 
transamination also by CV2025 ω-TAm with varying substrate ratios of 
isopropylamine and 1,3-dihydroxypentan-2-one, also exposed an excess of 20 mM 
amine acceptor have driven the ω-TAm bioconversion yield give rise to an increase of 
25 % (mol.mol
-1
) targeted product (Smith et al., 2010).  
 
6.4.2. Transamination of Ery Using L-α-serine by BSU09260_1971 ω-TAm in 
Purified Form 
 
In order to prove that ABT synthesis from L-α-serine and Ery (Figure 6.3) was 
catalysed by the BSU09260_1971 ω-TAm from Bacillus subtillis, a preparative scale 
bioconversion was performed using purified enzyme. This would also enable a 
comparison of bioconversion kinetics between lysate and isolated enzyme forms. The 
BSU09260_1971 ω-TAm enzyme expressed from the pQR960 plasmid contains an 
N-terminal His-tag and hence was purified using a His- Select Nickel Affinity Gel as 
discussed in Section 2.3.2. Otherwise, bioconversion conditions and equipment setup 
were as previously depicted in Table 6.1 and Figure 2.2 (Section 2.5.2) respectively. 
 
The concentrations of lysate and purified proteins were analysed by Bradford assay 
(Section 2.6.3). The total protein concentration of shake flask culture used in this 
study was 4.53 g.L
-1. The recombinant BSU09260_1971 ω-TAm migrated on an 
SDS-PAGE gel as a single band of approximately 50 kDa. The BSU09260_1971 ω-
TAm was expressed at a significant level and ω-TAm concentrations in the lysate and 
purified preparations were 0.62 g.L
-1
 and 0.5 g.L
-1
 respectively as accessed by SDS-
PAGE analysis (Figure 6.4).  
 
As shown in Figure 6.5, the bioconversions with purified BSU09260_1971 ω-TAm 
revealed an almost 4-fold lower conversion rate than with the clarified lysate (Section 
6.4.1).  However, using the purified enzyme there is a stoichiometric relationship 
between L-α-serine utilisation and ABT formation as predicted by Figure 6.3. No 
additional decreases in substrate or product were observed during the course of 
reaction, owing to the elimination of unwanted side reactions by the use of purified 
enzyme.  
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Figure 6.4. SDS-PAGE gel showing expression of the BSU09260_1971 -transaminase in 
cellular extracts of E. coli BL21 (DE3)-Gold cells. Lane 1 is the protein molecular weight marker, 
Lane 2 shows protein composition of lysate form, Lane 3 shows purified ω-TAm form. Molecular 
weight of BSU09260_1971 ω-TAm is approximately 50 kDa as highlighted in the box. Cells 
produced as described in Section 2.2.2 and ω-TAm purified as described in Section 2.3.2. 
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Figure 6.5. Preparative scale bioconversion kinetics of purified BSU09260_1971 ω-TAm 
(pQR960) using L-α-serine as amino donor: L-α-serine (▲) consumption and ABT (■) 
production. Reaction conditions: 0.3 g.L
-1
 BSU09260_1971 ω-TAm in purified form; 0.2 mM 
PLP; [L-α-serine] and [Ery] were 50 mM; 30 ºC; pH 7.5; 300 rpm in 50 mM HEPES buffer; total 
volume of 30 mL in the developed preparative scale bioreactor (Figure 2.2). Bioconversions 
performed as described in Sections 2.5.2. Error bars represent one standard deviation about the 
mean (n=3). 
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This confirms that one of the major factors for both substrate and product losses 
discussed in Sections 6.3 and 6.4.1, is due to the high susceptibility of the reagents to 
side reactions catalysed by other enzymes in the lysate. Furthermore, no colour 
changes were observed in the reaction solution with the purified enzyme which 
remained pale yellow throughout.  
 
The low transamination rate of Ery using L-α-serine using purified BSU09260_1971 
ω-TAm was most probably due to the low stability of the enzyme in purified form. 
Previous work with CV2025 ω-TAm reported a 50 % decrease of transamination rate 
over long reaction period of 70 hours that was mainly due to enzyme inactivation 
rather than unfavourable thermodynamic equilibrium (Ingram et al., 2007). To date 
few reports exist in the literature of ω-TAms used in purified form. 
 
The structure of the closely related ω-amino acid pyruvate aminotransferase from 
pseudomonas sp. F-126 has been determined to be a tetramer comprised of two 
closely associated dimers (Watanabe et al., 1989). Ingram and co-workers (2007) also 
further suggested that the increased instability of purified β-alanine: pyruvate TAm 
from pseudomonas aeruginosa they used may probably due to the loss of the tetramic 
conformation during the purification step. Likewise, this could also be the same 
reason that has caused the instability and subsequently a remarkably low reactivity of 
the BSU09260_1971 ω-TAm.  
 
 
6.5. CONFIRMATION OF ABT PRODUCT SYNTHESIS  
 
The final objective of this work was to confirm the identity of the ABT product 
produced in the preparative scale bioconversions (Sections 6.3 and 6.4.1). ABT is not 
commercially available, therefore it was obtained by chemical and enzymatic 
syntheses as described in Sections 2.4.1 and 2.4.2. The ABT produced was derivatized 
by AQC reagent (Section 2.4.3) and then analysed by HPLC analysis (Section 2.6.6). 
The data obtained provided a calibration curve for ABT quantification from all 
bioconversions performed throughout the research. In order to confirm the identity of 
the ABT produced in the preparative scale bioconversions, it was purified and 
analysed by chemical ionization (CI) mass spectrometry (Section 2.6.7). The 
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fingerprints from the analysis can be found in Appendix V which confirms ABT 
synthesis.  
 
In addition, bioconversions of L-α-serine and Ery at 50 mM were performed using a 
null strain of E.coli BL21 (DE3) in clarified lysate form as a control. The null strain 
was grown under sterile condition using LB media in shake flask scale as described in 
Section 2.2 without the addition of antibiotic kanamycin, IPTG or PLP. The 
bioconversion was performed as described in Section 2.5.2 using 0.3 g.L
-1
 proteins in 
the clarified lysate form as quantified by Bradford assay (Section 2.6.3). HPLC 
analysis (Section 2.6.6) of the reaction samples obtained over extended time periods 
showed a detectable, but not quantifiable peak appearing at a retention time equivalent 
to ABT. This was most probably formed from naturally occurring transaminases 
present in E.coli. These results, therefore, confirm that the ABT synthesised in the 
reactions performed here was due to the activity of the heterologously expressed ω-
transaminases.  
  
 
6.6. SUMMARY 
 
On the basis of the optimized process design information obtained at the microwell 
scale (Chapter 5), selected bioconversions were verified here at the preparative scale. 
This work involved a 100-fold increase in reaction scale.  
 
The scale-up of CV2025 ω-TAm bioconversion using optimised conditions for use of 
the  second enzyme system  (Section 6.3) as a contrast to the microscale reaction 
(Section 5.6.1) shown 26 % (mol.mol
-1
) declined in reaction conversion due to 
enzyme inactivation. Meanwhile, the transamination of Ery using L-α-serine by the 
novel BSU09260_1971 ω-TAm in lysate form (Section 6.4.1) was 21 mM ABT yield 
corresponding 42 % (mol.mol
-1
) showed almost similar optimum yields and initial 
rates to the microscale reactions described in Section 5.5. The identity of the ABT 
product formed in the preparative scale bioconversions was confirmed by mass 
spectrometry and bioconversions of L-α-serine and Ery performed using a null strain 
of E.coli BL21 (DE3). 
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Overall these results show that optimised conditions from microscale experiments can 
be rapidly repeated at preparative scales. Small differences in the rates and yields 
measured can be attributed to changes in bioreactor design and reaction conditions, 
that will help guide further process optimisation and scale-up. The automated 
microwell scale platform developed here, therefore, provides a useful tool for the 
quantitative evaluation of larger numbers of biocatalyst and bioprocess options for 
enhancing the yields of equilibrium controlled bioconversions. 
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7. CONCLUSIONS AND FUTURE 
WORK 
 
 
 
 
 
 
 
7.1. SUMMARY OF PROJECT ACHIEVEMENTS 
 
In this thesis, a series of four microscale methodologies have been created to study 
process options for increasing the yield of equilibrium-controlled and product 
inhibited bioconversions with a particular emphasis on transaminase catalysed 
processes. The methods involved evaluation of alternative amino donors and selective 
removal of inhibitory by-products by either in-situ enzymatic conversion to non-
inhibitory compounds, continuous evaporation of volatile by-products or adsorption 
of inhibitory by-products onto polymeric resins. These methods were created 
specifically for micro-scale and parallel operation (Chapters 3 and 4) and were 
capable of automation on a robotic system (Chapter 5) to facilitate parallel, high 
throughput evaluation and ultimately process design and optimization.   
 
The first approach involving evaluation of alternative amino donors proved to be the 
simplest and most rapid to implement. Evaluation of a range of five alternative donors 
to the commonly used MBA, helped identify isopropylamine as a cheaper, less 
inhibitory donor of the CV2025 ω-TAm. For the transamination of Ery using 
isopropylamine, an almost 3-fold higher conversion yield than with the standard MBA 
was realised (Section 4.4). Automation of this approach allowed the simultaneous 
evaluation of a library of ten novel ω-TAms from various strains each with five 
alternative amino donors. The results of this worked showed that the CV2025 ω-TAm 
remains one of the most promising biocatalyst for optically pure amine synthesis 
(Figure 5.5). The results also led to the discovery of a novel ω-TAm from Bacillus 
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subtillis capable of the effective transamination of Ery using L-α-Serine as amino 
donor with a 23 % (mol.mol
-1) improvement on the conversion yield with CV2025 ω-
TAm (Section 5.5).  
 
The second approach involved a second enzyme system coupling in-situ the CV2025 
ω-TAm bioconversion with ADH from Lactoacillus kefir and GDH from 
Pseudomonas sp. for the rapid enzymatic conversion of the inhibitory AP by-product 
(Figure 4.2) to the non-inhibitory (R)-1-phenylethanol. These bioconversions showed 
the highest product yield of 86 % (mol.mol
-1
), more than with any of the other 
CV2025 ω-TAm bioconversions using the alternative process options (Section 4.5). 
Despite the largest increase in conversion yield, the second enzyme method is 
regarded as the most complicated and expensive to implement due to the cost of the 
available coupling enzymes and the need to match their activities. These issues were 
later resolved by further optimization studies using the automated experimental 
approach that allowed reaction kinetics to be evaluated over a wide range of enzyme 
and reactant concentrations (Section 5.6). Equivalent product yields were reached 
with a 40-fold decrease in the concentration of ADH and a 20 mM decrease in 
glucose. The optimised method hence represents a more cost effective option, and it 
was rapidly established from the automated and parallel experimentation. 
 
The third approach was the reduced pressure method that used a commercially 
available 96-well plate vacuum manifold and vacuum pump for established reduced 
pressure operating conditions. This is a simple and efficient approach for overcoming 
inhibition and suppresses the unfavourable equilibrium constant caused by 
compounds that are more volatile than others reactants and the desired product.  This 
method demonstrated a 2.2-fold increase of yield of the standard CV2025 ω-TAm 
reaction (Section 4.6). This approach could also be automated using the vacuum 
manifold (Te-VacS) controlled by the Tecan Gemini software as detailed in Section 
5.7. The current absence of temperature control on the automation platform meant that 
the same increases in yield could not be attained during automated operation, but the 
principle of the method was still successfully demonstrated. 
 
The fourth approach involved ISPR using adsorbent resins to selectively bind the by-
product AP to alleviate inhibition effects and shift the reaction equilibrium. Three 
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commercially available synthetic polymeric resins called AmberliteTM XADs (XAD 
7, XAD 1180, XAD 16) were evaluated. This method however, was only shown to be 
applicable for whole-cell ω-TAm bioconversion since in lysate form, the enzyme and 
co-factor PLP were absorbed onto resins. Nevertheless a 1.3-fold higher yield was 
obtained than with the standard CV2025 ω-TAm whole cell bioconversion (Section 
4.7). 
 
Finally, the optimised microscale reaction conditions involving the second enzyme 
reaction and use of the BSU09260_1971 ω-TAm from Bacillus subtillis for the 
bioconversion of L-α-serine and Ery were each scaled-up 100-fold for preparative 
scale investigations in a pH-stat. Both systems performed similarly at the larger scale 
although differences in mixing and the use of concentrated NaOH for pH control led 
to decreases in the rates and yields observed. For example, with the second enzyme 
reaction (Section 6.3) employing a 40-fold decrease in ADH concentration a 26 % 
(mol.mol
-1
) decline in the yield of conversion was measured compared to the 
microscale results (Section 5.6.1). Likewise, for the transamination of Ery using L-α-
serine by the novel BSU09260_1971 ω-TAm in lysate form (Section 6.4.1) there was 
a decrease in reaction yield by just 10 % (mol.mol
-1
). Nevertheless, these scale-up 
studies confirmed the utility of the microscale techniques for rapid identification of 
optimised process conditions applicable to at least preparative scale.  
 
In general, the best process option will depend on particular reaction being studied 
and the economical advantage. If the cost issue is addressed particularly on the main 
additional cost of material involved for each process option, the use of alternative 
amino donors is likely to be the best  in terms of ease and cost (i.e isopropylamine is 
available at only £ 0.02 per mL). The reduced pressure system is an efficient  and low 
cost method but only applicable when having high volatilities by-product. Meanwhile, 
the ISPR adsorption resin application is also a cost effective process option ( 
amberlite XAD resin is available at £0.02 per 100 mg) but in this case a further study 
is required for significant yield improvement. Despite have shown the best result, the 
second enzyme system is the most costly option due to  the expensive additional 
enzymes (ADH is available at £ 1.16 per mg and GDH is £ 9.11 per mg) and co-factor 
(NADPH is available at £100 per mg)  involved and thus will significantly have 
further economic impact at large scale. 
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Overall, this work has demonstrated the potential of different process options to shift 
unfavourable reaction equilibrium toward product formation and to overcome issues 
of product inhibition.  The research described here shows that microscale methods can 
be used to rapidly and effectively explore these process options using minimum 
quantities of material. Such approaches can be integrated on commercially available 
automation platforms for high throughput evaluation of different biocatalyst-
bioprocess options and the rapid optimisation of selected bioprocess conditions. 
 
 
7.2. FUTURE WORK 
 
Whilst the overall aim of this project was achieved, future work is required to expand 
these micro-scale methods to further increase reaction yields, and to enable better 
integration of these approaches with whole bioprocess studies and emerging high-
throughput analytical techniques. A detailed list of future work recommendations is 
given below. 
 
 For the second enzyme method, at least 80 % (mol.mol-1) conversion using a 
considerably reduced enzyme loading than was typically applied (Sections 4.5 
and 5.6) have been able to reach. However, for further system optimisation 
particularly from an economic point of view, an alternative way is to construct 
a recombinant E.coli, having all three heterologous genes of ω-TAm 
(Kahulmann et al., 2007; Shin and Kim, 2001), alcohol dehydrogenase (Chen, 
et al., 2008) and glucose dehdrohenase (Galkin et al., 1997) expressed.  
 
 Future studies are necessary to identify the crucial parameters that may affect 
the performance of the ISPR adsorbent resins in order to achieve higher 
bioconversion rates and yields. Studies could be performed with a wider range 
of absorbent resins or new ones could be synthesised with the required binding 
selectivity.  
 
 Automation of the ISPR experiments using adsorptive resins at 300 µL scale 
could be further developed. Full automation of the method is challenging 
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owing to unavailability of device for automatically weighing and transferring 
the small quantities of resin needed for study (Section 4.7). Development of 
such a device would be important in order to carry this aspect of the work 
forward. 
 
 An excess of amino acceptor substrate has been proven in literature to 
accelerate the initial reaction rate and yield (Sections 4.5 and 4.6). Such an 
approach could be further exploited by fed batch operation which it should be 
possible to implement on the automation platform.  
 
 The key parameters affecting scale up of the bioconversion to the preparative 
scale using the second enzyme method and alternative amino donor method 
were established in Sections 6.3 and 6.4. Future scale-up studies are necessary 
in order to get better quantitative agreement between the rates and yields 
achieved at the two different scales. Further scale-up to the >10L scale should 
also be investigated.  
 
 As was found in Section 6.4.2, the ω-TAm loss its activity and stability in the 
purified form. Further studies should be performed in immobilization 
techniques to improve the stability of the enzyme, while adding the benefit of 
allowing the enzyme to be recycled and used in a continuous flow bioprocess.  
 
 Finally, it would be beneficial to demonstrate ‘whole process’ automation 
linking sequences of individual unit operations including micro-well 
fermentation, induction, bioconversion, product recovery and analysis on a 
single robotic platform. These would enable the full potential of the high-
throughput nature of this work to be explored, for example, for studies on the 
interaction between fermentation and bioconversion conditions and for 
evaluation of larger biocatalyst libraries. 
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APPENDIX I 
CALIBRATION PLOT OF BIOMASS IN 
FUNCTION OF OD600 
 
 
 
 
 
Figure A.I. 1. Calibration graph of biomass in gdcw. L
-1
 as a function of OD600 (Section 2.6.2). 
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APPENDIX II 
BRADFORD ASSAY: CALIBRATION PLOT 
OF BSA CONCENTRATION IN FUNCTION OF 
OD595 
 
 
 
 
Figure A.II. 1. Standard graph for Bradford assay of BSA concentration as a function 
of OD595 (Section 2.6.3). 
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APPENDIX III 
HPLC STANDARD CALIBRATIONS AND 
CHROMATOGRAMS 
 
 
 
Figure A.III. 1. Calibration graph of L-Erythrulose (Ery) concentration as a function of 
HPLC area (Section 2.6.6). 
 
 
 
 
 
Figure A.III. 2.  HPLC chromatogram of Ery. The peak retention time is at 11.63 min. 
(Section 2.6.6). 
  
 218 
 
 
  
 
 
Figure A.III. 3.  Calibration graph of derivatized 2-amino-1,3,4-butanetriol (ABT) 
concentration as a function of HPLC area (Section 2.6.6). 
 
 
 
 
 
 
Figure A.III. 4.  HPLC chromatogram of derivatized ABT (Section 2.6.6). The peak 
retention time is at 8.9 min. 
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Figure A.III. 5.  Calibration graph of derivatized L-α-Serine concentration as a 
function of HPLC area (Section 2.6.6). 
 
 
 
 
 
 
Figure A.III. 6.  HPLC chromatogram of derivatized L-α-Serine (Section 2.6.6). The 
peak retention time is at 7.3 min. 
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Figure A.III. 7.  Calibration graph of Pyruvate concentration as a function of HPLC 
area (Section 2.6.6). 
 
 
 
 
 
 
 
Figure A.III. 8.  HPLC chromatogram of pyruvate (Section 2.6.6). The peak retention 
time is at 10.43 min. 
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Figure A.III. 9.  Calibration graph of Acetophenone (AP) concentration as a function of 
HPLC area (Section 2.6.6). 
 
 
 
 
 
 
Figure A.III. 10.  HPLC chromatogram of AP (Section 2.6.6). The peak retention time 
is at 7.28 min. 
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Figure A.III. 11.  Calibration graph of (R)-1-phenylethanol concentration as a function 
of HPLC area (Section 2.6.6). 
 
 
 
 
 
 
Figure A.III. 12.  HPLC chromatogram of (R)-1-phenylethanol (Section 2.6.6). The 
peak retention time is at 6.45 min. 
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Figure A.III. 13.  Calibration graph of (S)-α-Methylbenyzlamine (MBA) concentration 
as a function of HPLC area (Section 2.6.6). 
 
 
 
 
 
 
 
 
Figure A.III. 14.  HPLC chromatogram of MBA (Section 2.6.6). The peak retention 
time is at 3.4 min. 
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APPENDIX IV 
TECAN SCRIPTS 
Figure A.IV. 2. Parallel evaluation of alternative amino donors (Section 5.5) 
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TECAN SCRIPTS  
Figure A.IV. 2. Optimization of second enzyme reaction condition (Section 5.6) 
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TECAN SCRIPTS  
Figure A.IV. 3. Parallel evaluation of reduced pressure reactvion (Section 5.7). 
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TECAN SCRIPTS  
Figure A.IV. 4. Bioconversion reactions samples centrifugation step prior HPLC analysis 
(Sections 5.5, 5.6 and 5.7). 
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APPENDIX V 
MASS SPECTROMETRY 
CHROMATOGRAMS 
 
 
Chemical ionization (CI) mass spectrometry analyses were carried out on reaction 
mixture with ABT produced from CV2025 ω-TAm bioconversion of MBA and Ery 
with second enzyme reaction (Figure A.V.1), and BSU09260_1971 ω-TAm 
bioconversion of L-α-serine and ERY (Figure A.V.2). Results were compared with 
previous ABT MS-MS standards (Ingram, 2007). 
 
 
 
 
Appendix A.V.1. Chemical ionization (CI) mass spectrometry analysis for reaction 
mixture with ABT produced from CV2025 ω-TAm bioconversion of MBA and Ery with 
second enzyme reaction using ADH from Lactobacillus kefir (Section 6.3). 
 
 
  
 243 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix A.V.2. Chemical ionization (CI) mass spectrometry analysis for reaction mixture 
with ABT produced from BSU09260_1971 ω-TAm bioconversion of L-α-serine and ERY (Section 
6.4.1). 
 
 
 
 
